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ABSTRACT 
The continuous development and production of new chemicals to meet societal needs 
results in their increasing release and prevalence in the environment. These contaminants of 
emerging concern (CECs) are continuously discharged from wastewater treatment plants and 
other sources that are often not equipped to remove these classes of compounds. Thus, the 
pseudo-persistence of these CECs poses potential toxicological risks to aquatic organisms and, 
therefore, constitute a significant issue in many aquatic environments. However, current testing 
frameworks supporting chemical and environmental risk assessment (ERA) are falling short of 
the global need to rapidly test the increasing numbers of CECs because they rely on the 
extensive use of live animals, which is time-consuming, costly, and presents significant ethical 
concerns. Thus, there is an urgent need for the development and implementation of new 
approach methodologies (NAMs) aimed to replace, reduce, and refine (3Rs) live animal testing 
while increasing throughput and decreasing costs to improve hazard assessment strategies and 
support regulatory decision-making. This dissertation aimed to develop and evaluate a NAM 
system based on short-term embryonic exposure assays to (1) characterize the toxicity pathways 
of two priority CECs, 17α-ethinylestradiol (EE2) and fluoxetine (FLX) as model chemicals, 
through cross-organizational level assessments linking molecular mechanistic response patterns 
with physiological/apical outcomes; and (2) derive transcriptomics points-of-departure (tPODs) 
that can support quantitative hazard assessment across phylogenetically distant fish. 
Specifically, fathead minnow (FHM), rainbow trout (RBT), and white sturgeon (WS) were 
exposed to graded concentrations of each CEC from an early embryonic stage. At 4 days post-
hatch (dph), changes across the whole transcriptome and proteome were characterized, and 
higher organizational-level responses were evaluated at 28 dph (FHM) and 60 dph (RBT and 
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WS). Molecular alterations were then compared to downstream responses to build toxicity 
pathway models for each chemical. In addition, transcriptomic datasets from 4 dph were used 
to model dose-response for genes/transcripts and calculate benchmark concentrations 
(geneBMCs) of toxicant-responsive genes/transcripts. These geneBMCs were used to derive 
transcriptomics points-of-departure (tPODs) using a number of statistical strategies. These 
tPODs were then compared to chronic and physiological/apical PODs obtained in this study 
and from the literature. tPOD estimates were also compared across species. 
Results demonstrated that when exposed to EE2, transcriptomic and proteomic profiles 
of FHM at 4 dph were predictive of histological and apical outcomes at 28 dph. Similarly, 
transcriptomic profiles of RBT at 4 dph were predictive of histological and apical responses at 
60 dph, when exposed to EE2, although proteomic profiles at 4 dph did not correlate well with 
transcriptomics and apical outcomes. On the other hand, FLX-target genes and proteins were 
not significantly altered in FHM at 4 dph, but integrated functional analyses of transcriptomics 
and proteomics revealed molecular processes that were predictive of apical outcomes observed 
in this study and those reported in the literature. Overall, results showed that transcriptomic 
responses from whole-body early-life stage (ELS) fish were related to downstream and apical 
outcomes observed at more advanced life stages. Proteomic responses were limited in 
predicting relevant responses but added a valuable layer of biological information that enhanced 
the understanding of the connectivity between molecular events and apical outcomes. Hence, 
proteomics provided an additional line-of-evidence in support of enhancing our understanding 
of the mode of action of the tested CECs across biological levels.  
Estimated tPODs in all species closely approximated and were protective of chronic 
apical PODs observed in this study and in the literature, both for EE2 and FLX. tPODs derived 
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from the median of the 20 most sensitive active genes (omicBMC20) were the most protective 
among tPOD estimates within a species, with FLX tPOD values of 0.02, 0.02, and 0.56 μg/L, 
and with EE2 tPOD values of 0.06, 0.12, and 2.39 ng/L for WS, RBT, and FHM, respectively. 
These values were significantly more sensitive than pathway-level BMCs (pathBMC) and were 
independent of species annotations, which is one of the main limitations when working with 
non-model species for which no functionally annotated genomes or transcriptomes are 
available. In general, RBT appeared to be the most sensitive species in terms of tPOD estimates, 
closely followed by WS, with FHM being the least sensitive to exposure to both chemicals. 
Regardless, tPOD estimates from ELS fish were within a tight range of concentrations despite 
minor differences in exposure conditions and data analysis workflow. Overall, this dissertation 
demonstrated that the fish embryo assays established in this thesis project represent a promising 
approach to (1) characterize toxicity pathways for CECs that can inform cross-species and 
chemical hazard assessment, and (2) derive quantitative BMCs (tPODs) that are protective of 
apical PODs, and therefore show significant promise as a NAM to support chemical hazard 
assessment and regulatory decision making. Future studies should be directed towards the 
optimization and validation of this approach using more chemicals and other species that are 
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1. 1. Introduction  2 
The number of chemical substances for which toxicity data is required has been 3 
exponentially increasing over the past decades, with new compounds being introduced almost 4 
every day. These chemicals of emerging concern (CECs) typically end up in surface water systems, 5 
with effluents of municipal wastewater facilities that are not equipped to treat these compounds 6 
constituting one of their main sources (Petrie et al., 2015; Sauvé and Desrosiers, 2014; Templeton 7 
et al., 2009; USEPA OW/ORD Emerging Contaminants Workgroup, 2008; Vidal-Dorsch et al., 8 
2012). CECs include a wide range of different substance groups that include brominated flame 9 
retardants, nanoparticles, microplastics, and pharmaceuticals and personal care products (PPCP), 10 
among others, which may consequently affect non-target organisms in impacted environments 11 
(Patel et al., 2019; Sehonova et al., 2018).  Many CECs, particularly PPCPs, are considered 12 
pseudo-persistent – compounds that may have short half-lives and are released at low 13 
concentrations but are consistently and continually infused into the aquatic environment, thus 14 
essentially becoming persistent (Daughton, 2003). Aquatic organisms are then chronically exposed 15 
to these low sub-lethal concentrations of CECs that do not result in immediate lethal or acute 16 
outcomes. However, subtle short-term molecular changes that do not immediately manifest at the 17 
physiological level may affect populations and communities of organisms under sub-chronic or 18 
chronic environmental exposure (Kidd et al., 2014; Liney et al., 2006).  19 
Environmental quality criteria under current regulatory frameworks to support 20 
environmental risk assessments (ERA) are mostly based on endpoints that have direct ecological 21 
and/or regulatory relevance such as survival, reproduction, growth, and development. These 22 
endpoints rely heavily on the use of extensive tests with live vertebrate animals, which is 23 
increasingly becoming of ethical concern. Furthermore, lengthy-time requirements render the 24 
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current process of chemical hazard assessment tedious, resource-intensive, and prone to 25 
uncertainty (Hecker, 2018). It is therefore apparent that there is an urgent need to establish 26 
alternative, high-throughput approaches for screening and prioritizing of chemicals to improve the 27 
current ERA process. In addition, traditional testing approaches in support of ERA, by and large, 28 
utilize a few select model organisms, which may not necessarily assure protectiveness towards the 29 
huge diversity of native species living in local ecosystems of concern because of our limited 30 
understanding of their sensitivity and vulnerability. For instance, there have only been a few 31 
studies investigating the effects of CECs on fishes of commercial, cultural, and recreational 32 
importance to Canadians (Beitel et al., 2015, 2014; Schultz et al., 2021). Questions have been 33 
raised on whether values derived from model organisms are protective of native organisms and 34 
whether they respond similar to organisms of different ancestral origin, and therefore, would be 35 
able to predict impacts on ecological species, which is the ultimate protection goal (Doering et al., 36 
2018; Schultz et al., 2021).  37 
  Recent developments in the field of predictive ecotoxicology advocate alternative toxicity 38 
testing approaches such as the use of in vitro, in silico or embryonic assays combined with 39 
mechanism-based testing as promising new approach methods (NAMs), particularly for 40 
prioritizing chemicals for further testing (Basu et al., 2019). Advances in ‘omics technologies offer 41 
high-throughput and cost-effective approaches by examining patterns of mechanisms of toxicity 42 
that could guide tests and endpoint selection across species in predictive ERA (Villeneuve et al., 43 
2012; Waters & Fostel, 2004). In particular, next-generation whole systems technologies allow the 44 
interrogation of a full suite of molecular families (i.e., transcripts, proteins, etc.) of an organism 45 
without a priori knowledge of the chemical’s mode of action (MOA). For instance, molecular 46 
toxicity pathways from non-target gene and protein expression analyses, when developed as 47 
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extrapolative models, could be used as diagnostic tools in predicting apical responses across 48 
biological organizations that are of ecological and regulatory relevance. Similarly, the use of the 49 
earliest life stages (ELS) of animals, specifically in fish, has been proven effective in deriving 50 
benchmark concentrations that are protective of a chemical’s effects at more advanced life stages 51 
(Wheeler et al., 2014). Life stages of oviparous vertebrates, such as fish, prior to independent 52 
exogenous feeding are not considered live animals under current legislations (Canadian Council 53 
on Animal Care, 2005; European Union, 2010; Strähle et al., 2012; UK, 1993). Thus, short-term 54 
ELS assays utilizing ‘omics technologies show great promise in advancing efforts that aim to 55 
replace, reduce and refine (3Rs) live animal testing while increasing throughput to improve hazard 56 
assessment strategies and support regulatory decision-making. 57 
 58 
1.2. Objectives and hypotheses 59 
The current paradigm shift necessitated by the need for the reduction of the use of live 60 
vertebrate animals in toxicity testing is resulting in the accelerated development of NAMs to 61 
streamline chemical hazard assessment. Most NAMs are based on mechanistic toxicity models to 62 
identify molecular and cellular events that could lead to adverse apical outcomes of regulatory 63 
relevance (Ankley et al., 2010; Villeneuve et al., 2014). While mechanistic molecular analyses in 64 
support of chemical hazard assessment have been conducted for decades, only a few focused on 65 
the quantitative derivation of toxicity thresholds and most of these developments have relied on in 66 
silico (Brinkmann et al., 2014), in vitro (Doering et al., 2020), and ex vivo (Rahman et al., 2020) 67 
studies. However, many of these approaches are limited in estimating apical toxicity thresholds as 68 
they do not represent the complex interactions occurring within an organism after a toxic insult; 69 
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hence, there is a need to quantitatively anchor these models to relevant apical outcomes to fully 70 
realize their predictive capability in regulatory ecotoxicology. 71 
Therefore, the overall objective of this dissertation was to develop and evaluate short-term 72 
embryonic exposure assays to derive protective points-of-departure (POD) from transcriptomic 73 
datasets across phylogenetically distant fish species using 17α-ethinylestradiol (EE2) and 74 
fluoxetine (FLX) as model CECs. EE2 is a synthetic estrogenic compound frequently used as an 75 
active ingredient in contraceptives while FLX is one of the most highly prescribed selective 76 
serotonin reuptake inhibitors (SSRI). These compounds are commonly found in surface waters and 77 
their toxicities are well described in the literature (reviewed in Brooks, 2014 and Laurenson et al., 78 
2014), and therefore, there is a wealth of information on their respective MOAs. Empirically 79 
derived apical PODs for these compounds across several fish species have also been reported 80 
previously, allowing comparisons to transcriptomics PODs (tPODs). Specifically, this project 81 
aimed to (1) develop short-term ELS assays to assess the toxicity of CECs, (2) construct toxicity 82 
pathway models for EE2 and FLX using the embryo assays developed in (1), (3) calculate tPODs 83 
for EE2 and FLX from short-term ELS assays using molecular benchmark dose/concentration 84 
(BMD; BMC) modeling, and (4) apply the transcriptomics benchmark models established under 85 
the earlier objectives to derive tPODs for three phylogenetically distant ray-finned fish species – 86 
fathead minnow (FHM; Pimephales promelas), rainbow trout (RBT; Oncorhynchus mykiss), and 87 
white sturgeon (WS; Acipenser transmontanus). This research utilized non-targeted techniques 88 
such as the evaluation of the effects of the two chemicals on the whole transcriptome and the global 89 
proteome with the goal of linking molecular perturbations to adverse apical outcomes and to derive 90 
tPODs to approximate protective apical thresholds. This study serves as a proof-of-concept in the 91 
use of short-term embryonic assays in deriving tPODs as alternative testing strategy to support 92 
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regulatory decision-making. The main objectives and testable hypotheses for each chapter were as 93 
follow: 94 
 95 
Objective 1. To build a toxicity pathway model for embryo-larval stages of fathead minnows 96 
(Pimephales promelas) exposed to EE2, using a combination of whole transcriptomics, non-target 97 
proteomics, and physiological/histological/apical analyses. (Chapter 2) 98 
1. Ho: There are no statistical differences in the expression of transcripts across treatment 99 
groups after exposure of embryonic FHM to EE2 from <6 hours post-fertilization (hpf) 100 
to 4 days post-hatch (dph). 101 
2. Ho: There are no statistical differences in the abundance of proteins between the control 102 
and high treatment groups after exposure of embryonic FHM to EE2 from <6 hpf to 4 103 
dph. 104 
3. Ho: There is no statistical correlation between the transcriptomic and proteomic 105 
responses after exposure of embryonic FHM to EE2 from <6 hpf to 4 dph. 106 
4. Ho: There are no statistical differences in apical responses across treatment groups after 107 
exposure of embryo-larval FHM to EE2 from <6 hpf to 28 dph. 108 
5. Ho: There are no statistical differences in survival rates across treatment groups after 109 
exposure of embryo-larval FHM to EE2 from <6 hpf to 28 dph. 110 
 111 
Objective 2. To establish a 4-day embryo-alevin assay for rainbow trout (RBT) to characterize the 112 
effects of EE2 across biological levels of organization and to calculate tPODs using a 113 
transcriptomic BMD approach. (Chapter 3) 114 
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1. Ho: There are no statistical differences in the expression of transcripts across treatment 115 
groups after exposure of embryo-alevin RBT to EE2 from hatch to 4 dph. 116 
2. Ho: There are no statistical differences in the abundance of proteins across treatment 117 
groups after exposure of embryo-alevin RBT to EE2 from hatch to 4 dph. 118 
3. Ho: There is no statistical correlation between the transcriptomic and proteomic 119 
responses after exposure of embryo-alevin RBT to EE2 from hatch to 4 dph. 120 
4. Ho: There are no statistical differences in the apical responses across treatment groups 121 
after exposure of embryo-alevin RBT to EE2 from hatch to 4 dph or to swim-up stage 122 
(21 dph). 123 
5. Ho: There are no statistical differences in survival rates across treatment groups after 124 
exposure of embryo-alevin RBT to EE2 from hatch to 4, 21, or 60 dph. 125 
 126 
Objective 3. To characterize the effects of FLX to early-life stage FHM across biological levels of 127 
organization and to develop and validate the utility of a short-term embryo-larval FHM assay to 128 
estimate tPODs using FLX. (Chapter 4) 129 
1. Ho: There are no statistical differences in the expression of transcripts across treatment 130 
groups after exposure of embryo-larval FHM to FLX from <6 hpf to 4 dph. 131 
2. Ho: There are no statistical differences in the abundance of proteins between the control 132 
and medium treatment groups after exposure of embryo-larval FHM to FLX from <6 133 
dpf to 4 dph. 134 
3. Ho: There are no statistical differences in apical responses across treatment groups after 135 
exposure of embryo-larval FHM to FLX from <6 dpf to 28 dph. 136 
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4. Ho: There is no statistical correlation between the transcriptomic and proteomic 137 
responses after exposure of embryonic FHM to FLX from <6 hpf to 4 dph. 138 
5. Ho: There are no statistical differences in locomotor responses across treatment groups 139 
after exposure of embryo-larval FHM to FLX from <6 dpf to 4 dph. 140 
6. Ho: There are no statistical differences in survival rates across treatment groups after 141 
exposure of embryo-larval FHM to FLX from <6 hpf to 28 dph. 142 
 143 
Objective 4. To derive tPODs from three phylogenetically distant ray-finned fish species – FHM, 144 
RBT and WS – at embryo-larval/alevin stages, using EE2 and FLX. (Chapter5) 145 
1. Ho: There are no statistical differences in the abundance of transcripts across treatment 146 
groups after exposure of embryo-larval FHM to FLX and EE2 from <6 hpf to 4 dph. 147 
2. Ho: There are no statistical differences in the abundance of transcripts across treatment 148 
groups after exposure of embryo-alevin RBT to FLX and EE2 from hatch to 4 dph. 149 
3. Ho: There are no statistical differences in the abundance of transcripts across treatment 150 
groups after exposure of embryo-larval WS to FLX and EE2 from hatch to 4 dph. 151 
 152 
1.3. Review of related literature 153 
1.3.1 Contaminants of emerging concern (CEC) 154 
Contaminants of emerging concern (CECs) are pollutants that have recently been detected 155 
or which have been previously reported in the environment but that had only recently been 156 
discovered to have adverse effects. They also include well-known chemicals that have recently 157 
become a toxicological concern due to the potential adverse effects they may have on non-target 158 
organisms (Sauvé and Desrosiers, 2014).   CECs do not have regulatory standards and are usually 159 
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not included in routine monitoring activities but may be candidates for future monitoring programs 160 
due to their potential adverse effects and ubiquity (USEPA OW/ORD Emerging Contaminants 161 
Workgroup, 2008). The qualification of a chemical contaminant as “emerging” is relative to its 162 
importance as a contamination issue at present, as chemicals are continuously synthesized and 163 
discovered in the environment.  164 
Many CECs are introduced into aquatic ecosystems through municipal wastewater 165 
effluents, or as runoff from agricultural and urban areas. The ubiquity of most of these compounds 166 
in surface waters was not recognized until recent developments of more advanced chemical 167 
analytical methods that improved our ability to detect these compounds with greater sensitivity in 168 
the environment (Anderson et al., 2013; Comerton et al., 2009; Martín-Pozo et al., 2019). For 169 
instance, CECs such as pharmaceuticals have been used for a long time but have only been 170 
recognized as contaminants of concern in the past decade or two due to the limitations of traditional 171 
analytical technologies. This is true for many natural and degradation products, as well as newly 172 
synthesized compounds that were not previously known in the scientific literature. Based on CAS 173 
registry alone, more than 159 million unique chemicals have been registered as of 2020, and 250 174 
million unique chemical substances were registered in April 2021 (www.cas.org). These numbers 175 
are expected to increase further as the demands for improved raw materials and active ingredients 176 
intensify, resulting in more common occurrences of CECs.  177 
Pharmaceuticals and personal care products (PPCPs) are one of the major categories of 178 
CECs, which includes a suite of human-prescribed and over-the-counter drugs and medications, 179 
steroids and hormones, disinfectants, synthetic musks, etc. Significant concerns have been raised 180 
about CECs due to their unintentional presence and their inherent ability to induce effects at low 181 
doses/concentrations, as well as their persistent input and potential threats to human and ecological 182 
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health (Ebele et al., 2017). These chemicals find their way into the aquatic environment mainly 183 
through municipal wastewater and sewage treatment effluents. Relatively little is known about the 184 
occurrence of these compounds in freshwater environments compared to other pollutants, and 185 
while many of these compounds are broken down and degraded, parent compounds and 186 
degradation products could persist and create potential hazards to the environment and human life. 187 
Two PPCPs of particular interest are the endocrine disrupting compound (EDC), EE2, and the 188 
selective serotonin reuptake inhibitor (SSRI), FLX, due to their wide use and their reported 189 
occurrence in surface waters in North America. 190 
 191 
1.3.1.1. CEC in focus: 17α-ethinylestradiol 192 
Perhaps one of the most studied endocrine disrupting compounds (EDC) is 17α-193 
ethinylestradiol (EE2). EE2 is a synthetic hormone modeled after the endogenous estrogen 194 
estradiol (E2), and is used as a contraceptive, as well as a treatment for menopausal and 195 
postmenopausal syndrome, prostatic cancer, and breast cancer in postmenopausal women, and 196 
osteoporosis (Aris et al., 2014). It alters processes of the endocrine system by mimicking or 197 
antagonizing the effects of endogenous hormones, disrupting the synthesis and metabolism of 198 
endogenous hormones, or disrupting the synthesis of specific hormone receptors. It is generally 199 
known that estrogens in the environment originate from poorly or untreated sewage discharged 200 
into water bodies, with approximately 40% of the hormones entering a conventional wastewater 201 
treatment plant not being removed in secondary treated effluents (Froehner et al., 2011). Due to 202 
its lipophilic and persistent properties, EE2 can bioaccumulate and biomagnify in aquatic 203 
organisms (Matozzo et al., 2008). The occurrence of EE2 in water, sediment, and biota has been 204 
observed globally (Aris, 2014; Laurenson et al., 2014), with the highest concentration of 129.8 205 
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ng/g having been reported in surface sediments in a mangrove forest in Brazil (Froehner et al., 206 
2012).  When detected in waterways, EE2 is typically found in single digit or sub ng/L range, but 207 
concentrations in WWTP effluents from urbanized areas of up to 62 ng/L have been reported (Aris 208 
et al., 2014). 209 
 Research on the effects of EE2 in fish has been extensive (Aris, 2014; Overturf et al., 210 
2015). EE2 is known to affect reproductive function in fish, specifically affecting endocrine 211 
pathways influencing behaviour, gonadal differentiation, and the production of vitellogenin (Vtg) 212 
(Zhang et al., 2008). It has been shown to alter molecular signaling cascades resulting in increased 213 
plasma vitellogenin concentrations in male and female fish, increased proportions of intersex fish, 214 
decreased egg and sperm production, reduced gamete quality, complete feminization of male fish, 215 
and reduced fertility (Andersson et al., 2007; Kidd et al., 2007; Partridge, Boettcher, & Jones, 216 
2010). Aquatic organisms are sensitive to the exposure with EE2 throughout their life, and 217 
particularly during embryonic and juvenile stages (van Aerle et al., 2002).  However, while overall 218 
types of responses are similar, species-specific differences in sensitivities exist among fishes. For 219 
instance, while it has generally been shown that EE2 reduces reproductive capability of fish 220 
populations (Schwindt et al, 2014), certain species such as the mummichog do not show 221 
comparable impacts on egg production as was observed in other fishes (Bosker et al., 2016).  Even 222 
an improved egg production occurred in Gulf pipefish (Rose et al., 2013). In fish species native to 223 
North America, it has been reported that EE2 altered vtg transcript abundance in vitro but there 224 
were great differences in sensitivities among species (Beitel et al., 2015, 2014). Therefore, while 225 
there have been extensive research efforts in the assessment of the effects of EE2, there is still a 226 
great deal of remaining uncertainties and issues concerning the hazard assessment of this 227 
compound in freshwater ecosystems (Hecker and Hollert, 2011). To date, there is no official water 228 
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quality guideline for EE2, albeit there are recommendations in the literature (European 229 
Commission, 2011; Caldwell et al., 2012). Further research is necessary to ascertain that values 230 
set for environmental quality criteria are robust and protective of non-model organisms. 231 
 232 
1.3.1.2. CEC in focus: Fluoxetine 233 
Fluoxetine was first introduced as Lilly 110140 (Wong et al., 1974). It was approved by 234 
the US Food and Drug Administration (FDA) as an antidepressant drug, treatment for obsessive-235 
compulsive disorder (OCD), and recommended for treatment of bulimia. This drug exerts its action 236 
within the central nervous system by reducing the clearance rate of serotonin (5-237 
hydroxytrypamine), a neurotransmitter, through binding to presynaptic serotonin reuptake 238 
receptors, potentiating the effects of serotonin in the post synaptic cleft. While the mechanism of 239 
action of FLX is not fully understood, Guest et al. (2004) suggested that FLX alters cortical 240 
expression of multiple heat shock protein 60 forms along with neurofilaments and related proteins 241 
that are critical determinants of synaptic structure and function.   242 
In the US, more than 27 million prescriptions of FLX were issued in 2019 243 
(https://clincalc.com/DrugStats/Drugs/Fluoxetine). On average, 80% of FLX administered is 244 
excreted through the urine and feces (Gracia, 2005). At this rate, and with increasing global usage, 245 
an increasing amount of trace FLX has been detected in the environment, with concentrations 246 
likely to further increase in the future (Mole and Brooks, 2019). In general, aquatic discharges are 247 
usually from domestic pharmaceutical consumption, which pass through wastewater treatment 248 
plants mostly at sub-therapeutic levels that are of negligible acute toxicological risk, but with 249 
elevated concentrations in areas where manufacturing plants are located (Bringolf et al., 2010). 250 
Unfortunately, FLX is not readily biodegradable in wastewater treatment plants. A summary of 251 
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published reports on the distribution of FLX shows a median concentration of 17.9 ng/L with a 252 
maximum concentration reported at 596 ng/L in freshwater ecosystems (Hughes et al., 2013). The 253 
compound is hydrolytically and photolytically stable (photodegradation t1/2 of ~160 days) in 254 
aqueous environments but is rapidly adsorbed in sediment systems, hence, concentrations in the 255 
aqueous phase will be lower and the potential impacts of FLX in the aquatic environments are 256 
decreased (Black and Armbrust, 2007; Kwon and Armbrust, 2006). However, since FLX is 257 
recalcitrant against physico-chemical and biological degradation processes, it is persistent as a 258 
substrate-adsorbed compound, and therefore, poses a significant threat to bottom-dwelling 259 
organisms.  260 
Read-across hypotheses have driven much of the research on the likely effects of 261 
pharmaceuticals to non-target organisms. The read-across hypothesis stipulates that if a drug’s 262 
molecular targets are conserved and plasma concentrations are similar to human therapeutic 263 
concentrations in non-target organisms, it is expected that the drug will have a similar effect (Rand-264 
Weaver et al., 2013). It should therefore be possible to predict potential environmental impacts of 265 
a drug using model organisms. For instance, effects on active avoidance behaviour were observed 266 
in fish exposed to FLX, as previously observed in rats, suggesting that serotonin mechanisms were 267 
highly conserved among vertebrates (Beulig and Fowler, 2008). Fish elicited anxiolytic responses 268 
when exposed to an equal range of Human Therapeutic Plasma concentrations (HTPCs) of FLX, 269 
showing comparable sensitivity to that observed in human patients affected by general anxiety 270 
disorder (Margiotta-Casaluci et al., 2014a). Even at concentrations as low as 1 μg/L, FLX 271 
significantly impacted mating behaviour in male freshwater fish, displaying increased aggression, 272 
isolation, and repetitive behaviors at higher concentrations, as well as lack of predator avoidance 273 
behaviors (Beulig & Fowler, 2008; Painter et al., 2009; Winder et al., 2009). There were also 274 
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effects observed that went beyond what was expected from the read-across approach. Acute and 275 
chronic exposure of other fishes to FLX were reported to cause endocrine disruption (Mennigen 276 
et al., 2010a; Schultz et al., 2011), impaired energy metabolism (Mennigen et al., 2010) and altered 277 
nitrogen waste excretion and osmoregulation (Morando et al., 2009). At the genomic level, 278 
transcriptomic studies showed FLX-induced alteration in stress- and behaviour-linked pathways, 279 
lipid and amino acid metabolic processes, and steroid biosynthesis (Mercier et al., 2004; Wong et 280 
al., 2013). However, the absence of lethal effects and the diversity of behavioral and biomarker 281 
response endpoints in FLX toxicity makes it difficult for regulatory bodies to set reliable standard 282 
criteria for FLX in the aquatic environment (Kumar et al., 2016). Therefore, at present, freshwater 283 
guideline values are still scarce, if there are any, and are still at the recommendatory stage 284 
(European Commission, 2011). Nevertheless, the diverse adverse side effects of FLX attest that 285 
exploration of FLX-induced mechanisms merits further investigation through untargeted and 286 
unbiased approaches. 287 
 288 
1.3.2. Transcriptomic points-of-departure (tPOD) as a toxicogenomic tool in chemical hazard 289 
assessment 290 
Toxicogenomics play an important role in the current efforts to reduce, refine and eliminate 291 
live animal-based conventional toxicity testing, which is expensive, lengthy, and ethically 292 
questionable. It exploits rapidly evolving genomic technologies that serve as powerful tools in 293 
mechanism-based and predictive toxicology. Approaches such as RNA sequencing and ultra-high 294 
resolution liquid chromatography tandem-mass spectroscopy (LC-MS/MS) enable exploration of 295 
the interconnections of changes in molecular circuitry across different molecular families (e.g., 296 
genome, proteome, metabolome, etc.), without a priori knowledge of a compound’s mode of 297 
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action (MOA) (Health Canada, 2018; Liu et al., 2019). While apical responses may not be apparent 298 
immediately, toxicogenomic responses may reveal toxicological effects at earlier time points. In 299 
particular, transcriptional profiling enables the detection of a snapshot of the earliest cellular 300 
responses following an exposure scenario, which generally correlate with a system’s response to 301 
a stressor. Thus, these responses may be linked to overt health effects typically observed at later 302 
time points. In the context of chemical hazard assessment, toxicogenomics is currently being used 303 
to complement traditional toxicological approaches as it enables assessment of toxicity endpoints 304 
for which there are no current conventional toxicity tests. The approaches show promise with 305 
regard to the assessment of probable human relevance and provide weight-of-evidence and insights 306 
into the linkage of MOA and apical outcomes (Health Canada, 2018).  307 
Recently, toxicogenomics have evolved from a tool primarily used for mechanistic inquiry 308 
to one that is focused on the assessment of biological potency (Auerbach and Paules, 2018). In 309 
particular, genomic dose-response studies (GDRS) have gained significant interest as they 310 
generally provided good approximation of toxicological potencies typically observed in long-term 311 
and expensive traditional toxicity studies (Thomas et al., 2013a). GDRS leverages genome-312 
/transcriptome-wide inquiry that is identical to assessing nearly all biological responses, and can 313 
be applied to both in vivo and in vitro studies by assessing alterations in mRNA expression 314 
following chemical exposure. It uses the traditional benchmark dose (BMD) approach to determine 315 
a point-of-departure (POD) at the molecular level. The process involves the identification of genes 316 
that were responsive to treatments, then fitting a dose-response model to identify a benchmark 317 
dose/concentration level that caused gene expression change relative to the control group, much 318 
similar to how traditional apical dose-response modelling is conducted. To identify the 319 
transcriptome-wide POD (transcriptomic point-of-departure; tPOD), the US National Toxicology 320 
52 
 
Program (NTP) recommended the use of the most sensitive set of genes based on functional 321 
annotation, which are assumed to best approximate the doses at which adverse apical effects occur. 322 
However, due to the limited number of species with annotations and the very nature of gene 323 
annotation itself where less studied processes are less represented and most ontologies are human-324 
centric, this approach is not feasible for most ecological receptors of concern. Hence, there is 325 
currently no consensus on the process to derive tPODs. Keeping these limitations in mind, a variety 326 
of approaches have been suggested to derive reproducible tPODs that closely approximate PODs 327 
from traditional methods for ecological risk assessment. These include the mean of gene-level 328 
BMDs (geneBMD) of the 20 genes that contribute to the greatest number of enriched pathways, 329 
the mean of 20 geneBMDs with the largest fold-change (FC) relative to the control, and the mean 330 
of 20 significantly enriched pathways with the lowest BMD (Farmahin et al., 2017).  331 
While most BMD approaches result in tPODs that are within one order of magnitude of 332 
empirically derived chronic apical PODs, the most sensitive and protective tPODs were those 333 
derived from the mode of the first peak of the geneBMD distribution, the median of the 20 most 334 
sensitive geneBMDs, and the tenth percentile of the all geneBMDs (Pagé-Larivière et al., 2019). 335 
Still, the advantage of pathway-level BMDs cannot be discounted as these values present the most 336 
plausible biological interpretation, and therefore, the possible link to apical PODs, which is 337 
important information in providing weight-of-evidence in the regulatory acceptance of GDRS. 338 
Nevertheless, it should be noted that the main purpose of GDRS is to identify the concentration 339 
that would significantly perturb biology and would potentially result in a phenotypic outcome; the 340 
mechanism or identification of this phenotypic outcome is secondary due to often limited 341 
information particularly when testing new compounds.  342 
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1.3.3. Early-life stages of fish as models for toxicity testing 343 
Full life cycle (FLC) and partial life cycle toxicity testing strategies are animal- and 344 
resource-intensive and logistically challenging. Thus, there have been significant efforts in 345 
developing NAMs that would closely approximate responses typically observed in chronic 346 
scenarios while reducing the need for live animals. To date, many NAMs rely on in silico 347 
(Brinkmann et al., 2014), in vitro (Doering et al., 2020), and ex vivo (Rahman et al., 2020) studies. 348 
While some of these models have proven successful in predicting downstream effects of specific 349 
molecular key events (Doering et al., 2018), many of the abovementioned approaches are limited 350 
in estimating apical toxicity thresholds as they do not represent the complex interactions occurring 351 
within an organism after a toxic insult; hence, there are still gaps in the predictive capability of 352 
these models as they need to be anchored quantitatively to relevant apical outcomes to fully realize 353 
their potential applications in regulatory ecotoxicology. In this light, much attention has been given 354 
to the use of fish embryos as surrogate for juvenile and adult fish as the ELS has the advantage of 355 
being the most sensitive stages in the fish life cycle that already express the majority of molecular 356 
features characteristic of adult fish (Lillicrap et al., 2016; Sobanska et al., 2018). In many 357 
jurisdictions, ELS are not considered to be a protected life stage (i. e., life stage prior to 358 
independent exogenous feeding) (Canadian Council on Animal Care, 2005; European Union, 359 
2010; Strähle et al., 2012; UK, 1993). Furthermore, it has been shown that ELS assays, along with 360 
the inclusion of other test endpoints such as developmental abnormalities and gene expression, are 361 
more sensitive than FLC (Jeffries et al., 2015, 2014; Lillicrap et al., 2016; Roush et al., 2018; 362 
Wheeler et al., 2014). Gene expression analyses using ELS of model fish species such as zebrafish 363 
have been previously proposed (Wang et al., 2018; Weil et al., 2009; Zhang et al., 2020), although 364 
they have not gained regulatory acceptance. Nevertheless, ELS represent a promising alternative 365 
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to adult fish tests and may possibly bridge regulatory acceptance and utility of other prospective 366 
animal alternatives such as cell-based assays and quantitative structure–activity relationship 367 
(QSAR) models (Halder et al., 2010). 368 
 369 
1.4. Scope and limitations 370 
 This dissertation implemented six separate ELS exposure experiments using three 371 
(representative) species of ray-finned fishes, and which were conducted based on the availability 372 
of fish embryos. The differences in the start time and study duration were due to logistical 373 
limitations (FHM were bred in-house, RBT arrived as eyed-up eggs, WS were spawned in a 374 
hatchery from wild populations, and therefore, needed to be quarantined) and differences in natural 375 
growth rates of the fishes. Nevertheless, whole embryo transcriptomics and non-target proteomics 376 
were conducted at 4 dph for all species. A range of apical responses were measured/observed at 377 
different time points whenever logistically possible: at 4 dph, at swim up, and at early fry/juvenile 378 
life stages. Some observations were also opportunistic and qualitative, and thus, statistical tests 379 
were not possible. Lastly, this research did not aim to develop and establish new statistical methods 380 
and bioinformatics workflows. Instead, it used well established methods, software, and workflows 381 
recommended by reputable groups and organizations and which are well cited in the literature. 382 
This dissertation leveraged the use of these existing tools and applied these to datasets derived 383 
from ELS fish. It is acknowledged that these bioinformatics workflows can be further optimized 384 

















CHAPTER 2:  DEVELOPMENT OF A COMPREHENSIVE TOXICITY PATHWAY 386 
MODEL FOR 17α-ETHINYLESTRADIOL IN EARLY LIFE STAGE FATHEAD 387 




While there is a huge body of literature on the toxicity of EE2 in fish, little research has 390 
been done to characterize and link the molecular toxicity pathways from early life stages (ELS) of 391 
fish to apical outcomes at later life stages. This chapter aimed to test the hypothesis that early 392 
embryonic life stages could be used as an alternative to live animal testing, with “live animals” 393 
being defined as those capable of independent exogenous feeding (reviewed in Halder et al., 2010). 394 
Sequence-by-synthesis mRNA sequencing and non-target proteomics were used to characterize 395 
molecular responses (changes in the abundance of transcripts and proteins) at 4 dph and were 396 
subsequently linked to apical outcomes of regulatory relevance measured at later life stage 397 
(histology, survival, length, weight). This chapter sets the stage for the use of ELS transcriptomic 398 
data in deriving tPODs to approximate apical PODs presented in the subsequent chapters.  399 
The content of Chapter 2 was reprinted (adapted) from Alcaraz, A.J.G., Potěšil, D., 400 
Mikulášek, K., Green, D., Park, B., Burbridge, C., Bluhm, K., Soufan, O., Lane, T., Pipal, M., 401 
Brinkmann, M., Xia, J., Zdráhal, Z., Schneider, D., Crump, D., Basu, N., Hogan, N., Hecker, M., 402 
2021. Development of a Comprehensive Toxicity Pathway Model for 17α-Ethinylestradiol in 403 
Early Life Stage Fathead Minnows (Pimephales promelas). Environ. Sci. Technol. 55, 5024–5036. 404 
https://doi.org/10.1021/acs.est.0c05942. Copyright (2021), with permission from the American 405 
Chemical Society. 406 
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2.1. Abstract 444 
There is increasing pressure to develop alternative ecotoxicological risk assessment 445 
approaches that do not rely on expensive, time-consuming and ethically questionable live animal 446 
testing. This study aimed to develop a comprehensive early-life stage toxicity pathway model for 447 
the exposure of fish to estrogenic chemicals that is rooted in mechanistic toxicology. Embryo-448 
larval fathead minnows (FHM; Pimephales promelas) were exposed to graded concentrations of 449 
17α-ethinylestradiol (water control, 0.01% DMSO, 4, 20, and 100 ng/L) for 32 days. Fish were 450 
assessed for transcriptomic and proteomic responses at four days post-hatch (dph), and for 451 
histological and apical endpoints at 28 dph. Molecular analyses revealed core responses that were 452 
indicative of observed apical outcomes, including biological processes resulting in overproduction 453 
of vitellogenin and impairment of visual development. Histological observations indicated 454 
accumulation of proteinaceous fluid in liver and kidney tissues, energy depletion, and delayed or 455 
suppressed gonad development. Additionally, fish in the 100 ng/L treatment group were smaller 456 
than controls. Integration of omics data improved the interpretation of perturbations in early-life 457 
stage FHM, providing evidence of conservation of toxicity pathways across levels of biological 458 
organization. Overall, mechanism-based embryo-larval FHM model showed promise as a 459 
replacement for standard adult live animal tests. 460 
Keywords: fathead minnow; transcriptomics; proteomics; histology; estrogen; toxicity pathway  461 
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2.2. Introduction 462 
Contaminants of emerging concern (CEC) constitute a significant issue in many aquatic 463 
environments due to their continuous discharge from wastewater treatment plants that are often 464 
not equipped to remove these classes of compounds. Their unabating discharge to surface water 465 
systems results in the pseudo-persistence of many CECs, posing potential toxicological risks to 466 
aquatic organisms, including fish (Nilsen et al., 2019). Fishes are among the most sensitive aquatic 467 
organisms chronically exposed to sub-lethal concentrations of CECs that often do not cause 468 
immediate lethal or acute effects but may result in long-term impacts such as alterations in 469 
reproductive success, abnormal growth/development, and disruption of normal behaviour (Rose et 470 
al., 2013). Furthermore, studies suggest that subtle and seemingly unimportant short-term 471 
molecular changes that do not immediately manifest at the physiological level may affect 472 
populations and communities of organisms under sub-chronic or chronic environmental exposure 473 
(Matthiessen et al., 2018). 474 
One CEC of particular concern is the xenoestrogen, 17α-ethinylestradiol (EE2). There is 475 
ample evidence that EE2 affects the endocrine system by mimicking or antagonizing the actions 476 
of endogenous hormones, resulting in the disruption of reproductive functions at concentrations 477 
between 0.47 and 117 ng/L (summarized in Armstrong et al., 2016). Xenoestrogens in the 478 
environment originate from poorly and/or untreated sewage discharged into water bodies, with 479 
approximately 55% of the hormones entering a wastewater treatment plant (WWTP) not being 480 
removed by conventional secondary wastewater treatment (Froehner et al., 2011). When detected 481 
in waterways, EE2 is typically found in the single digit or sub ng/L range, but concentrations in 482 
WWTP effluents from urbanized areas of up to 62 ng/L have been reported (Aris et al., 2014).   483 
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Current risk assessment approaches for CECs, including endocrine disruptors such as EE2, 484 
rely heavily on live animal testing and are therefore expensive, time-consuming, prone to 485 
uncertainty and of significant ethical concern (Hecker, 2018). National and international regulatory 486 
communities have recognized these concerns, which has triggered a paradigm shift towards the 487 
development of alternative approaches rooted in mechanistic toxicology. Examples of emerging 488 
approaches under this paradigm shift are in vitro systems (Beitel et al., 2015), the utilization of 489 
embryos as surrogate models for adults (Capela et al., 2020) and the use of toxicogenomics 490 
technologies to elucidate mechanisms of toxicity with the aim to predict apical outcomes of 491 
regulatory relevance (Brockmeier et al., 2017; National Research Council, 2007). The 492 
opportunities that these advancements provide are expected to guide the future of regulatory 493 
ecotoxicology as they promise to lower the cost, save time, and reduce uncertainties of chemical 494 
hazard evaluations, while significantly reducing the need for live animal testing (Villeneuve and 495 
Garcia-Reyero, 2011).  However, there is a lack of calibrated and validated approaches and tools 496 
that can conclusively and reliably link mechanistic information to toxic outcomes (Basu et al., 497 
2019). 498 
The main objective of this study was to develop a comprehensive toxicity pathway model 499 
for embryo-larval stages of a model fish species, fathead minnow (FHM; Pimephales promelas), 500 
exposed to EE2, using a combination of non-targeted transcriptomics and proteomics, and 501 
physiological/histological/apical analyses. Furthermore, this study tested the hypothesis that early 502 
embryonic life stages, which are not considered live animals under current legislations (Halder et 503 
al., 2010), could be used as an alternative to live animal testing. This work is part of a series of 504 
studies that aim to establish an alternative testing approach using embryonic FHM and other 505 
species for chemical testing and prioritization (Basu et al., 2019).  506 
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2.3. Materials and Methods 507 
2.3.1. Test organisms  508 
FHM (source: Aquatic Research Organisms Inc., NH, USA) were reared from in-house 509 
cultures at the Aquatic Toxicology Research Facility, Toxicology Centre, University of 510 
Saskatchewan. Sexually mature FHM were maintained and bred following the procedures 511 
described previously (Lane et al., 2019). Fertilized eggs from different breeding groups were 512 
collected (< 6 hours post-fertilization, hpf), sorted for quality, and randomly assigned to treatment 513 
groups.  514 
 515 
2.3.2. Exposure conditions 516 
FHM embryos were exposed to graded concentrations (water control, solvent control, low 517 
= 4, medium = 20, high = 100 ng/L) of EE2 (≥ 98% purity, Sigma-Aldrich, MO, USA) (Figure 518 
B.S1). The final concentration of DMSO in all treatments was 0.01%, except for the water only 519 
controls. Exposures were initiated by placing late cleavage to high blastula stage embryos in Petri 520 
dishes containing the corresponding test solutions. Separate Petri dishes were used for each 521 
endpoint. Transcriptomics were conducted in quintuplicates for each treatment group, with 20 522 
embryos per replicate. For proteomics and apical assessments, there were six and five replicates 523 
per treatment group, respectively, each containing 30 embryos. All Petri dishes were maintained 524 
under static renewal conditions (> 50% of test solution was replaced daily), a 16:8 light:dark cycle, 525 
and at a temperature of 24±1oC. 526 
Embryos for omics analyses were reared to four days post-hatch (dph) and sampled by 527 
pooling all larvae in each Petri dish. Pooled larvae were flash-frozen in liquid nitrogen and kept at 528 
-80oC until further analyses. Larvae for apical assessments were then transferred to 9L glass 529 
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aquaria and maintained under flow-through conditions using a randomized design, where they 530 
were exposed to the same test concentrations and physico-chemical conditions until 28 dph 531 
following OECD 210 (OECD, 2013). Each tank was monitored daily for temperature, pH, 532 
conductivity and dissolved oxygen, and weekly for ammonia, nitrates, nitrite, hardness and 533 
alkalinity, following the procedures described in Lane et al. (2019). Surviving larvae at the end of 534 
the exposure period were euthanized using buffered tricaine methanesulfonate (MS222; Sigma-535 
Aldrich). Length and weight of each larva were measured and overt morphological abnormalities 536 
were qualitatively recorded during takedown by a designated subjective observer. From each 537 
replicate, randomly selected whole larvae were then decalcified and fixed for 24 hours using Cal-538 
Ex™ (≥98.5%; Fisher Scientific, MA, USA), and stored in 70% ethanol for histological analyses. 539 
All methods reported here were approved by the Animal Research Ethics Board of the University 540 
of Saskatchewan (Protocol #20160090). 541 
 542 
2.3.3. Chemical analyses 543 
Water samples from exposure tanks were collected at three time points during the exposure 544 
experiment (4, 14 and 28dph). EE2 was quantified by SGS AXYS Analytical Services Ltd. (BC, 545 
Canada) using a protocol published previously (Long et al., 2013). Water samples were extracted 546 
by solid-phase extraction and were spiked with d4-17α-ethinylestradiol (d4-EE2; CDN Isotopes, 547 
QC, Canada). Concentrations of EE2 were measured using a Waters LC-MS/MS system, operating 548 
in negative ion electrospray mode at unit resolution. Measured concentrations were corrected for 549 




2.3.4. Transcriptomics 552 
Only samples from the solvent control, medium, and high treatment groups were used to 553 
assess transcriptional responses. Total RNA was extracted from each replicate pool using the 554 
RNEasy Plus Universal Mini Kit (Qiagen, Germany) following the manufacturer’s protocol. 555 
Samples with a RIN > 8 were sent to the McGill University and Génome Québec Innovation Centre 556 
for 200 base-pair paired-end (100x2) sequencing using a HiSeq 4000 instrument (Illumina, CA, 557 
USA).  558 
Raw fastq files were assessed for quality, trimmed, and aligned to the latest FHM genome 559 
assembly (NCBI Acc# WIOS00000000). Expression levels of genes were estimated and then 560 
filtered to remove features with less than five counts per million in at least five samples. edgeR 561 
(Robinson et al., 2010) was used to assess the significance of differentially expressed genes (DEG) 562 
using the quasi-likelihood pipeline and scored with a cut-off false discovery rate (FDR; Benjamini-563 
Hochberg) ≤ 0.05 and a minimum effect size threshold fold-change |FC| > 1.5 relative to the 564 
solvent control group. Raw fastq files are available through the NCBI GEO accession# 565 
GSE156916. 566 
 567 
2.3.5. Proteomics 568 
Transcriptomic analyses showed more pronounced perturbations in the high treatment 569 
group; thus, only the samples from the solvent and high treatment groups were selected for non-570 
targeted proteomics analysis. Protein samples were processed by filter-aided sample preparation 571 
(FASP) (Wiśniewski et al., 2009) using Microcon filters with molecular weight cut-off size of 30 572 
kDa (Merck Millipore, MA, USA) covering alkylation and digestion steps. LC-MS/MS analyses 573 
of peptide mixtures were done using an RSLCnano system (Thermo Fisher Scientific, MA, USA) 574 
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connected to an Orbitrap Fusion™ Lumos™ hybrid spectrometer (Thermo Fisher Scientific). MS 575 
data were acquired in a data-dependent strategy selecting up to top 20 precursors for HCD 576 
fragmentation. The analysis of the mass spectrometric data was carried out using MaxQuant. 577 
MS/MS ion searches were done against the modified cRAP database 578 
(http://www.thegpm.org/crap/, accessed January 2020; 246 sequences) and the FHM reference 579 
proteome (NCBI Acc# WIOS00000000, number of protein sequences: 35,108). Peptides and 580 
proteins with an FDR (q-value) < 1% and at least one razor peptide were selected for downstream 581 
analyses. Differential protein abundance analyses were done in KNIME (Berthold et al., 2008) 582 
using the OmicsWorkflow (https://github.com/OmicsWorkflows). Median normalization strategy 583 
was applied to all protein group intensities across samples (Figure B.S2). Significance of 584 
differentially abundant protein (DAP) groups was assessed using limma (Ritchie et al., 2015), with 585 
a cut-off moderated p-value ≤ 0.05 and a minimum effect size threshold |FC| > 1.5 relative to the 586 
solvent control. The MS proteomics data have been deposited to the ProteomeXchange 587 
Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with the dataset 588 
identifier PXD021155. 589 
 590 
2.3.6. Enrichment and interaction network analyses 591 
Enrichment  analyses were conducted in g:Profiler(Raudvere et al., 2019) using databases 592 
for Danio rerio (Gene Ontology, REACTOME pathways, KEGG, and Human Phenotype 593 
Ontology). Significantly dysregulated genes or proteins were ordered based on FC and assessed 594 
for enrichment using modified Fisher’s test with statistical domain based on annotated zebrafish 595 
genes only, and with a g:SCS significance cut-off threshold (p-value) < 0.05.   596 
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Protein-protein interaction (PPI) networks were built using STRING (Szklarczyk et al., 597 
2019) with a medium confidence level (P <0.05). Further analyses to assess network topological 598 
parameters of DEGs and DAPs were conducted using NetworkAnalyzer (Assenov et al., 2008) in 599 
Cytoscape (Shannon et al., 2003). 600 
Evaluation of RNA-seq and MS-based proteomics data set concordance was done using 601 
QuanTP (Kumar et al., 2019)  in usegalaxy.eu (Afgan et al., 2018). Since the number of detected 602 
proteins was limited to the detected protein groups, the protein IDs were used to filter the list of 603 
genes for concordance analyses. Gene abundance ratios were plotted against protein abundance 604 
ratios in a scatterplot of individual gene-protein pairs. Correlation coefficients were calculated to 605 
assess the relative correspondence of gene–protein abundance ratios across the data set. Regression 606 
analysis was conducted using the least square method.  607 
 608 
2.3.7. Histology 609 
A subset of three fixed whole embryos from each replicate of the solvent control, medium, 610 
and high treatment groups were dehydrated in graded concentrations of alcohol, cleared in xylene, 611 
and infiltrated with molten paraffin using a Belair RVG/1 Vacuum Tissue Processor (Adelsus, 612 
OH, USA), and subjected to 5-µm longitudinal step-sectioning in frontal plane. For each 613 
individual, representative sections were taken at a minimum of eight different levels through the 614 
body cavity at approximately 75 µm intervals, mounted on glass slides, and stained with Harris’ 615 
hematoxylin and eosin.  616 
Gonadal sex was determined based on the criteria of Van Aerle et al. (2004). All liver 617 
sections were assessed for the presence/absence of glycogen-type and lipid-type vacuolation (Wolf 618 
and Wheeler, 2018), eosinophilic or basophilic staining of the hepatocyte parenchyma, and 619 
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presence of excessive proteinaceous intravascular fluid in the sinusoids of the liver parenchyma. 620 
Histology of both the head kidney and posterior kidney were assessed at multiple levels for overall 621 
structure and relative sizes of tubules and epithelial cells, as well as glomeruli. An opportunistic 622 
assessment of eye histology was also conducted on selected embryos with acceptable eye sections 623 
from the solvent control and high treatment groups, whenever possible. Total cross-sectional area, 624 
total retinal thickness and thickness of retinal layers (photoreceptor, outer plexiform, inner 625 
plexiform), and the eye index (eye size relative to body size) were measured. 626 
 627 
2.3.8. Statistical Analyses 628 
Apical outcomes (length, weight, condition factor, and survival rates) were assessed for 629 
significant differences across treatment groups using a one-way analysis of variance (ANOVA), 630 
followed by Tukey’s multiple comparison post-hoc test, with a cut-off adjusted p-value < 0.05. 631 
Regression analyses were done on all treatment groups, excluding the water control group, using 632 
ordinary least-squares (OLS) linear regression. Significant differences of the measurements in eye 633 
histology were assessed using student’s t-test, with cut-off p-value < 0.05. All non-omics statistical 634 
analyses were carried out in GraphPad Prism. 635 
Detailed description of Materials and Methods can be found in the Appendix B1-B3. All 636 
software versions used in this study are summarized in Table B.S1.   637 
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2.4. Results and Discussion 638 
2.4.1. Chemical analysis 639 
The average measured concentrations of EE2 in medium (23.5 ± 8.1 ng/L) and high (96.0. 640 
± 19.6 ng/L) treatment groups were within 20% of the nominal concentrations, while water, 641 
solvent, and low were below the method detection limit (Table B.S2). Measured physico-chemical 642 
characteristics of exposure solutions were generally in accordance with OECD 210 (OECD, 2013); 643 
however, measured temperature was 23.12 ± 0.77 oC, which was slightly lower than the prescribed 644 
25.0 ± 1.5 oC (Table B.S3).  645 
 646 
2.4.2. Global gene expression at four days post-hatch  647 
The abundance of 505 and 11 transcripts in the high and medium treatment groups, 648 
respectively, were significantly altered compared to the solvent control group (Dataset S1). All 649 
DEGs in the medium treatment group were upregulated and also highly dysregulated in the high 650 
treatment group (Figure 2.1A). Furthermore, all commonly dysregulated genes exhibited a 651 
concentration-dependent response, suggesting that core responses were activated at medium and 652 
high concentrations of EE2. For instance, genes encoding for egg yolk precursor proteins, vtg and 653 
vtg-like variants, were highly dysregulated with > 1900-FC and > 49-FC for every variant in the 654 
high and medium treatment groups, respectively. The overexpression of vtg is a classic biomarker 655 
for the exposure of fish to estrogens (Denslow et al., 1999; Jones et al., 2000).  Additionally, in 656 
accordance with a previous study that exposed FHM to EE2 (Villeneuve et al., 2006), cyp19a1b, 657 
which encodes the enzyme aromatase that catalyzes estrogen biosynthesis, was also significantly 658 
upregulated in both treatment groups. Similarly, three forms of the f13a1a gene were highly 659 
dysregulated in both treatment groups. While the role of f13a1a in normal endocrine functioning 660 
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has not been fully elucidated, it was associated with the prothrombotic effects of estrogens in 661 
higher mammals (Reiner et al., 2003).  Furthermore, f13a1a was highly upregulated (> 20-fold 662 
change) in the testis of EE2-exposed male FHM (Feswick et al., 2016) and in whole-tissue of 663 
estradiol-treated adult zebrafish (Hao et al., 2013). The dysregulation of multiple variants of some 664 
notable genes (e.g. vtg and f13a1a) highlights the advantage of RNA-seq technology for 665 
characterizing transcriptional responses. That is, multiple, if not all, forms of a certain gene were 666 
captured, which might have been missed in targeted analyses like qRT-PCR or microarrays, 667 
potentially rendering false-negative results. This is particularly important as gene expression may 668 
have high variability among individuals as has been previously observed for the expression of vtg 669 
in FHM (Biales et al., 2007).  670 
The majority of other genes that were significantly dysregulated in the high treatment group 671 
are involved in less-specific molecular functions and biological processes typically observed in 672 
organismal stress response including regulatory functions, biosynthetic processes, and 673 
metabolism. The significant increase in the number of dysregulated genes in the high treatment 674 
group could, therefore, be due to the very high concentration of EE2 having started to overwhelm 675 
the organisms’ ability to maintain homeostasis of systemic processes. Overexpression of core 676 
genes in our study using whole FHM embryos corroborates previously reported transcriptional 677 
estrogenic responses observed in later life stages despite reported high tissue-specificity of gene 678 
expression (Mohamed et al., 2018). 679 
Transcriptomics-based PPI network for DEGs in the high treatment group showed a high 680 
degree of connectedness of genes that are relevant to estrogenic responses (Figure File S1; 681 
Dataset S2). fn1a, pax6a, try/prss1, and ctsz had the highest degree of centrality, with 21, 18, 14, 682 
and 14 nodes directly connected, respectively. Isoforms of fn1a, pax6a, and prss1 were associated 683 
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with the estrogen receptor (ER) in human cancer studies (Chan et al., 2012; Sampayo et al., 2018; 684 
Zong et al., 2011), while isoforms of ctsz have been implicated in the proteolysis of vtg in aquatic 685 
animals (Hiramatsu et al., 2002). Though these hub genes have not often been associated with EE2 686 
toxicity, they are well connected to each other and are connected to highly dysregulated genes 687 
associated with xenoestrogen exposure such as vtg, esr, nots, and f13a1a. These connections mean 688 
that effects on a node may directly or indirectly affect neighboring nodes (Koschützki and 689 
Schreiber, 2008); however, the relative impacts of changes on a connected node towards the hub 690 
gene have yet to be investigated.  691 
There were a total of 62 (44 from up- and 18 from down-regulated genes) and four 692 
significantly enriched GO terms (all from upregulated genes) in the high and medium treatment 693 
groups, respectively (Figure 2.1B-1C; Figure B.S3.1-B.S3.3). In the high treatment group, 694 
enriched GO terms included 38 biological processes, 12 molecular functions, and 12 cellular 695 
components. Enrichment analyses revealed all significantly enriched GO terms in the medium 696 
treatment group were also significantly enriched in the high treatment group (response to estradiol, 697 
cellular response to estrogen stimulus, response to estrogen, and lipid transporter activity). These 698 
GO terms have also been observed by Colli-Dula et al. (2014) in largemouth bass exposed to 699 
dietary EE2, while Hultman et al. (2015) observed lipid-related molecular functions and processes 700 
moderated by EE2 in rainbow trout primary hepatocytes. The intersection of significantly enriched 701 
terms in medium and high treatments suggests that these GO terms represent the core 702 
transcriptional response of embryonic FHM to EE2. This hypothesis is further supported by > 703 
20-FC in contributing genes in both treatment groups while the remaining significantly 704 
dysregulated genes found in the high group had relatively lower dysregulation (< 6-FC), with few 705 
exceptions: fam20cl (25-FC), nots (203-FC), and esr1 (20-FC), which are also involved in cellular 706 
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response to estrogen stimulus. Additionally, there were significantly enriched GO terms in the high 707 
treatment group that are associated with nervous and visual system development. EE2 has been 708 
implicated in disruptions in brain and nervous system-specific gene expression in medaka 709 
(Kitagawa et al., 2009). While there were no reports in the literature showing direct effects of EE2 710 
to visual development, the increase in plasma levels of 17β-estradiol, a closely related estrogen, 711 
was concomitant with the increase in ERα and ERβ transcripts in the choriocapillary layer and 712 
photoreceptor in artificially-induced maturation of Japanese eel (Hyeon et al., 2019). Furthermore, 713 
it has been reported that estrogen signaling is involved in retinal development in developing 714 
embryos of zebrafish (Hamad et al., 2007). This would suggest a possible physiological effect of 715 
elevated estrogen exposure on eye development.  716 
 717 
2.4.3. Proteome-wide responses to the high concentration of EE2 718 
There were 3767 protein groups identified, with the intensities of 244 protein groups 719 
(consisting of a total of 378 proteins) having been significantly altered in the high treatment group 720 
compared to the solvent control group (Dataset S3). The most upregulated protein was Selenof, a 721 
stress-regulated selenoprotein found in the endoplasmic reticulum that is functionally associated 722 
with protein folding and selenium-mediated antioxidative process (Ren et al., 2018). In mice, 723 
Selenof is involved in the regulation of non-functional immunoglobulins and in redox quality 724 
control of other client proteins exiting the endoplasmic reticulum (Yim et al., 2018); thus, it may 725 
also have a role in the complex sub-cellular secretome gatekeeping in other species like fish. 726 
However, there have been no reports that directly link Selenof to elevated levels of estrogen. The 727 
most downregulated protein was Vtnb, a member of the mutifunctional glycoprotein family, which 728 
is predicted to be involved in immune response and scavenger receptor activity. While there have 729 
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been no studies on the direct effects of EE2 on the expression of Vtnb, 17β-estradiol decreased the 730 
expression of the Vtnb receptor, resulting in the inhibition of the development of human osteoclasts 731 
in vitro (Chen et al., 2009). Hence, the associated decrease in abundance of Vtnb protein may have 732 
implications in bone formation in developing FHM, although this hypothesis remains to be 733 
investigated. Three variants of the estrogenic biomarker protein Vtg were significantly upregulated 734 
(4- to 8-FC), showing steroidogenic plasticity as an early response of embryo-larval FHM at the 735 
proteome level. While the relative abundance of Vtg proteins was lower than their transcript 736 
counterparts, it should be noted that basal Vtg protein levels were also high. The likely reason for 737 
this high background level is that Vtg is one of the main components of the yolk sac, and therefore, 738 
found at high concentrations in developing larvae, which likely led to the seemingly low 739 
differential protein abundance. Furthermore, the induction of Vtg protein synthesis may not have 740 
immediately occurred at the early embryonic stage, but rather at the later stages when the yolk sac 741 
was almost absorbed (Andersen et al., 2003); thus, at 4dph, larvae may have just actively started 742 
producing Vtg protein. The abundance of Vtg proteins in larval fish exposed to xenoestrogens has 743 
been rarely reported, unlike in their adult counterparts; moreover, recent studies showed organ- 744 
and sex-specific proteomic responses of adult fish exposed to EDCs (Ayobahan et al., 2019; Voisin 745 
et al., 2019). Thus, the use of pooled whole embryos might have diluted the relative abundance 746 
levels, resulting in lower DAP. Other dysregulated proteins associated with EE2 exposure are 747 
involved in cellular growth, organization and transport, metabolic processes, biosynthetic 748 
processes, and development; however, most of these proteins had low differential abundance and 749 
are not functionally specific, which may suggest that there was a delayed onset of responses at the 750 
proteome level. 751 
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Enrichment analysis showed only one significantly enriched GO term - response to 752 
estradiol (Figure 2.1D; Figure B.S4). This GO term was also found to be significantly enriched 753 
at the transcriptome level suggesting that it is well conserved and a major response across the two 754 
omics layers, even after a short exposure at very early life stages. While the lone enriched GO term 755 
may indicate possible delayed response at the proteome level, this would also imply a highly 756 
specific and immediate response to EE2. Proteomics-based PPI network analysis showed Ddx49, 757 
Wdr18, and Rrs1 proteins had the highest degree of centrality, with 12, 11 and 10, respectively 758 
(Figure File S2; Dataset S4). A Ddx isoform serves as a co-activator of ERα while ribosome 759 
biogenesis has previously been observed in response to estrogen exposure in brown trout (Uren 760 
Webster et al., 2015), albeit as an enriched term based on transcriptional response. While these 761 
proteins have high centrality, there have not been reports directly linking them to xenoestrogen 762 
toxicity. Furthermore, the magnitude of dysregulations of these proteins was relatively low, 763 
rendering their biological relevance uncertain; nevertheless, it would be interesting to investigate 764 
the potential roles these proteins may play in EE2-induced toxicity response mechanisms.  765 
  766 
2.4.4. Analysis of gene-protein pair concordance 767 
There were 22 features significantly dysregulated at both the transcriptome and proteome 768 
levels (Figure 2.1E). The direction (up- or down-) of dysregulation in most of these gene-protein 769 
pairs was the same, with only four exceptions. However, correlation analysis of gene-abundance 770 
ratios and protein-abundance ratios showed weak concordance (Pearson’s ρ = 0.130). This is not 771 
uncommon, because there are many post-translational factors that influence protein product 772 
abundance (Liu et al., 2016). In zebrafish, De Wit et al. (2010) observed limited concordance 773 
between the transcriptomic and proteomic response to EE2, but noted that affected signaling 774 
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pathways perturbed at the transcriptome level were projected at the protein level. Nonetheless, 775 
combined transcriptomic and proteomic analyses have been instrumental in providing a more 776 
comprehensive understanding of certain mechanisms of toxicity in fish; for example, the 777 
connection of TBCO-induced molecular perturbations to cardiac and vision toxicity in medaka 778 
(Sun et al., 2016). 779 
Dysregulated gene-protein pairs included features that are linked to estrogen signaling. 780 
There were three forms of Vtg where the levels of abundance ratios were among the highest at 781 
both the transcriptome and proteome levels. Isoforms of Chymotrypsin, Ankyrin repeat domain-782 
containing protein, Phospholipase B, Carboxylic ester hydrolase, and N-acetylserotonin O-783 
methyltransferase, among others, were all associated with the regulation of the estrogen receptor 784 
signaling pathway. Combined transcriptomics- and proteomics-based PPI network analysis 785 
reinforced the observed high degrees of centralities of several gene and protein products from 786 
separate PPI network analyses, including Fn1a, Grb2b, and Pax6a, suggesting the relative 787 
importance of these features in the regulation of molecular processes in response to EE2 (Figure 788 
File S3). Nonetheless, our current results suggest that while many post-transcriptional 789 
modifications occur, certain processes are still conserved and are projected from the transcriptomic 790 




Figure 2.1. Intersections of molecular responses and list of significantly overrepresented GO 793 
terms. (A) Intersection of DEGs in medium (yellow) and high (green) treatment groups. All 794 
significantly dysregulated genes (FDR <0.05; |FC| > 1.5) in the medium treatment (11) were also 795 
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significantly dysregulated (FDR <0.05; |FC| > 1.5) in the high treatment (505) group. (B) 796 
Manhattan plot and list of overrepresented GO terms based on DEGs in medium treatment group. 797 
(C) Manhattan plot and list of 10 most overrepresented (sorted based on adj p-value) GO terms 798 
based on DEGs in high treatment group. (D) Manhattan plot and list of overrepresented GO terms 799 
based on DAPs in high treatment group. (E) Intersection of DEGs (green) and DAPs (red) in the 800 
high treatment group. The abundance of 22 features (gene-protein pairs) were altered at both the 801 
transcriptome and proteome levels. (Note: sizes of the circles of Venn diagrams do not reflect the 802 
relative numbers of DEGs or DAPs in their respective group. Venn diagrams were constructed 803 
using InteractiVenn (Heberle et al., 2015); complete list of overrepresented GO terms are in Figure 804 
B.S3). GO – Gene Ontology; BP – Biological Process; CC – Cellular Component, MF – Molecular 805 
Function; REAC – REACTOME Pathways; KEGG – Kyoto Encyclopedia of Genes and Genomes; 806 




2.4.5. Physiological and histological responses 809 
2.4.5.1. Survival, length, weight, and condition factor 810 
Exposure to EE2 significantly altered length and weight but neither survival nor the overall 811 
condition of FHM at 28dph (Figure 2.2; Dataset S5). The lack of acute toxicity of EE2 in early-812 
life stage FHM, even at high concentrations, is consistent with previous studies in teleosts. In 813 
contrast, significant and linear concentration-dependent decreases were observed for standard 814 
lengths (R2 = 0.8486, p<0.0001) and weights (R2 = 0.6038, p=0.0004) (Dataset S6), suggesting 815 
direct effects of EE2 on growth in terms of length and weight (Shved et al., 2008). This decrease 816 
in fish size may also be explained by the significant energy requirements of xenobiotic metabolism 817 
and massive overproduction of Vtg  protein (Tompsett et al., 2012). However, Fulton’s condition 818 
factor was not significantly affected. Similar observations have been reported previously (Hill and 819 
Janz, 2003; Papoulias et al., 2000; Schäfers et al., 2007). Lastly, there was no indication of gross 820 



























































































Figure 2.2. Survival, condition factor, weight, and standard length at 28dph of FHM exposed to 824 
graded concentrations of EE2. There was no significant difference in survival rates (p = 0.9709) 825 
and overall condition factor (p = 0.9590) across all treatment groups, while significant differences 826 
were observed in weight (Kruskal-Wallis p = 0.0314) and standard length (p < 0.0001). ns = not 827 
significant; Control = facility water; Solvent = 0.01% DMSO; Low < limit of detection; Medium 828 
= 23.46 ± 8.13; High = 95.99 ± 19.58. Whiskers represent minimum and maximum values, boxes 829 
represent 1st and 3rd quartile, lines at the middle of the boxes represent the median.830 
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2.4.5.2. Histological Observations 831 
Gonadal sex differentiation in larval FHM was affected in treated groups (Figure 2.3A-832 
3D). Differentiated gonads were present in all larvae from the solvent control group, with sex ratios 833 
of 6 males and 9 females. In contrast, only 1 individual each from the high and medium treatment 834 
groups exhibited a differentiated gonad (female), whereas remaining individuals had gonads that 835 
were either undifferentiated and poorly developed or not detected (Table B.S4). This result is 836 
consistent with previously reported EE2-concentration-associated impaired juvenile growth, 837 
delayed time to sexual maturity (Weber et al., 2003) and increase of undeveloped gonads in 838 
zebrafish (Hill and Janz, 2003). While reduced overall fish size or development may have 839 
contributed to the delayed gonad development, EE2 exposure is known to directly affect the 840 
hepatic GH/IGF-I system, which causes inhibitory effects to both fish size and gonad development 841 
(Shved et al., 2008, 2007). However, in this study, genes and pathways involved in the GH/IGF-I 842 
system were not found to be significantly dysregulated, which may be due to the dilution effect of 843 
analyzing whole larval tissues instead of liver tissues.  844 
Exposure to EE2 caused concentration-associated incidence of histological changes to the 845 
liver and kidneys of FHM (Figure 2.3E-2.3H, Table B.S4). Glycogen-type vacuolation of 846 
hepatocytes was evident in the majority of solvent control fish, whereas it was absent in all of the 847 
medium and high dose fish. Loss of hepatic glycogen was reported previously in EE2-exposed 848 
adult FHM (Palace et al., 2002), suggesting the occurrence of high energy consumptive processes 849 
(e.g. Vtg production, xenobiotic metabolism), which result in more rapid degradation of glycogen. 850 
Furthermore, livers from treated groups exhibited increased hepatocyte basophilia relative to the 851 
solvent controls. Thus, our findings are in accordance with previous studies, which demonstrated 852 
that basophilic hepatocytes are highly correlated to estrogen-induced excessive production of Vtg 853 
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(Bogers et al., 2006; Wolf and Wheeler, 2018). Intravascular proteinaceous fluid was also 854 
observed in treated groups but was completely absent in the control group, which may suggest the 855 
presence of excess Vtg in the extracellular fluid, as previously identified by Van den Belt et al. 856 
(2002) and Tompsett et al. (2012) Furthermore, individuals in treated groups had relatively larger 857 
and distorted kidney tubules with dilated lumens containing eosinophilic fluids. Tubule epithelial 858 
cells were hypertrophied, vacuolated, and swollen. An increase in number and size of glomeruli 859 
were observed, as well as the presence of eosinophilic fluid in the cells. These observations were 860 
consistent with previous studies of Palace et al. (2002) and Weber et al. (2003) where tubule 861 
enlargement, necrosis, glomerular dilation, and the presence of eosinophilic amorphous deposits 862 
were observed in the kidney tubules of adult male FHM and larval zebrafish, respectively, after 863 
exposure to EE2. 864 
Amorphous eosinophilic staining in the spaces adjacent to organs was observed in all 865 
individuals from treated groups but was absent in the body cavities of individuals from the solvent 866 
control group. The degree of fluid accumulation in EE2-exposed individuals ranged from one to a 867 
few localized spots in a few sections, to extensive accumulation throughout the majority of the 868 
sections. Similar to the eosinophilic staining in the livers, this staining is presumed to be 869 
extracellular fluid that is laden with excess protein, presumptively Vtg (Weber et al., 2003). 870 
Based on the conservation of some molecular features associated with visual development, 871 
inspection of eye sections was conducted, whenever possible. Cross-sectional histological analysis 872 
of the eyes showed decrease in retinal thickness, OPL and IPL, and a decreasing trend in eye area, 873 
eye index, and PRL (Dataset S7). Estrogens promote retinal development in developing zebrafish 874 
(Hamad et al., 2007), although the consequences of its excess are still unknown. In humans, limited 875 
evidence suggests the role of sex hormones in optic nerve functions and ocular hemodynamics 876 
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(reviewed in Nuzzi et al., 2019). It has been suggested that the effects of EDCs on eye development 877 
were due to perturbations in the retinoid pathway (Martínez et al., 2018); still, the implications of 878 
elevated estrogen levels in visual development and its mechanism are poorly understood. While it 879 
is interesting to characterize the physiological effects of EE2 in visual development of FMH, eye 880 
histology was not part of our original experimental design and thus the analysis presented here was 881 
opportunistic in nature; hence, there is a need for a more thorough investigation of the possible 882 
damages and impairments in visual development in embryo-larval FHM, especially as it cannot be 883 







Figure 2.3. Photomicrographs of FHM gonads, liver, and kidney tissues (hematoxylin and eosin 887 
stain). (A) Solvent control male gonad. Somatic cells are interspersed among germ cells. (C) 888 
Solvent control female. Meiotic germ cells are present up to the primary oocyte stage. Somatic 889 
cells are at the gonad periphery. (B) and (D) EE2-exposed gonads (circled); small with inhibited 890 
development, not clearly differentiated. (E) Solvent control liver. Hepatocytes have normal 891 
appearance with abundant glycogen-type vacuolation (⃝). (F) EE2-exposed liver. Hepatocytes 892 
are strongly basophilic, characterized by dark blue stain (X) and lack glycogen-type vacuolation. 893 
Eosinophilic (pink-staining) proteinaceous fluid is evident in the sinusoids (→). (G) Solvent 894 
control kidney. Normal-appearing tubules have regular structure, and are lined with cuboidal 895 
epithelial cells (⃝). (H) EE2-exposed kidney. Tubules are large and distorted, with dilated lumens 896 
(*). Tubule epithelial cells are hypertrophied with vacuolated swelling (□). Glomeruli are more 897 
prominent, typically swollen with eosinophilic fluid (→). 898 
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2.4.6. Linking molecular responses to apical outcomes 899 
Exposure of fathead minnows to EE2 at early-life stages resulted in a series of key events 900 
ranging from molecular perturbations at the transcriptomic and proteomic level to apical outcomes 901 
(Figure 2.4). EE2 is a highly potent drug designed as an ER agonist, significantly upregulating esr 902 
gene coding for ER, indicating the onset of ER signaling activation. Transcriptomics-based PPI 903 
network and gene set enrichment analyses showed various linked gene-level perturbations, 904 
including significant enrichment in estrogen-associated gene sets. This cascade of transcriptional 905 
responses includes the induction of multiple forms of vtg gene, resulting in the overproduction of 906 
its Vtg protein products. Consequently, excess Vtg protein appeared to accumulate in liver, kidney, 907 
and body cavity, which has numerous downstream biochemical and physiological implications. 908 
While massive protein abundance was observed, exposure to EE2 did not translate to the onset of 909 
gonadal development in potential females.  At the same time, it affected gonadal development in 910 
potential males or females, as indicated by the inhibition of developing gonads in the treated 911 
groups. This observation may be due to the organism channeling most energy towards adaptive 912 
mechanisms to counter further damage brought about by continuous EE2 exposure rather than 913 
normal development and/or the interactions of EE2 to the brain-pituitary-gonad axis, causing 914 
negative or positive feedback mechanisms on the secretion of pituitary gonadotropins, resulting in 915 
alterations and/or delay of growth and gonadal development (Fenske et al., 2005; Scholz and 916 
Klüver, 2009). The observed reduction in glycogen-type vacuolation of hepatocytes may be due 917 
to the continuous utilization of energy beyond what the organism can produce that is required to 918 
cope with the damage caused by EE2. The continuous demand for large amounts of energy for Vtg 919 
production and to maintain overall systemic homeostasis might have caused direct or indirect 920 
delays, or inhibition of gonad development, as well as smaller body size. Moreover, delayed 921 
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development of gonads, which is known to be involved with regulating overall growth in teleosts 922 
(Bhatta et al., 2012), may have led to shorter lengths and lower weights observed in FHM. It should 923 
be noted that somatic growth is also directly regulated by the GH/IGF-I system (Degani et al., 924 
1996; Shved et al., 2007), although it was not significantly dysregulated in our molecular studies. 925 
Furthermore, the accumulation of Vtg protein in the kidneys altered renal histo-architecture, which 926 
is expected to cause renal function failure and may possibly lead to mortality (Folmar et al., 2001; 927 
Thorpe et al., 2007; Weber et al., 2004). It is noteworthy that wild FHM exposed to EE2 in a multi-928 
year whole lake addition study showed VTG induction, kidney damage, liver and gonad effects, 929 
as well as near extinction of the population from the lake (Kidd et al., 2007; Palace et al., 2002). 930 
However, the population collapse was associated with year-class failure/lack of recruitment, and 931 
was not directly attributed to kidney or liver effects. 932 
While most of the current legislation still mandates the use of adult animal models for the 933 
assessment of EDCs, recent developments in toxicity testing favor the use of alternative testing 934 
strategies, including embryonic bioassays as high throughput tools in toxicity testing and 935 
prioritization (Capela et al., 2020). Our study successfully demonstrated that the embryonic 936 
exposure approach identified disruptions of processes typically observed in adult fish models. 937 
Furthermore, molecular perturbations at the early-life stage resulted in apical outcomes typically 938 
observed at later life stages. Omics integration added a layer of biological complexity, which 939 
enhanced the understanding of the connectivity of molecular events to apical outcomes, providing 940 
support and evidence to better understand the mode of EE2 action across biological levels and 941 
providing information for a more robust extrapolation (Van Aggelen et al., 2010). Moreover, 942 
transcriptomic responses in this study showed relatively greater sensitivity compared to other 943 
alternative test systems such as the use of precision cut livers(Yadetie et al., 2018), rainbow trout 944 
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primary hepatocytes (Finne et al., 2007), and in vitro cultured rainbow trout hepatocytes (Hultman 945 
et al., 2015). Future studies should be directed towards assessing the sensitivity of the ELS test 946 
system in forecasting potential physiological or apical outcomes at later life stages, in addition to 947 
further validation of the utilization of this test system using other compounds which may act 948 
through different mechanisms. The findings of this study add to the increasing body of literature 949 
that successfully links gene expression changes to phenotypic responses to promote utilization of 950 




Figure 2.4. Putative toxicity pathway model for early-life stage FHM exposed to EE2 based on 953 
the progression of responses across biological levels. Shadowed boxes are effects observed in this 954 
study. (Note: Boxes without shadows are effects/processes likely to occur based on mined 955 
literature.)  956 
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halo color is based on the rank of FC-sorted proteins with red representing highest FC and blue 967 
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CHAPTER 3: ASSESSING THE TOXICITY OF 17α-ETHINYLESTRADIOL IN 1015 
RAINBOW TROUT USING A FOUR-DAY TRANSCRIPTOMICS BENCHMARK DOSE 1016 




Building upon the results of Chapter 2, this chapter leveraged the compelling evidence of 1019 
the link of molecular toxicity pathways at ELS with apical outcomes at later life stages. In this 1020 
chapter, a representative salmonid species, RBT, was used to estimate tPODs from transcriptomic 1021 
datasets generated from whole embryos exposed to graded concentrations of EE2 from hatch to 4 1022 
dph. A molecular benchmark dose approach was used to calculate concentrations that would cause 1023 
significant changes in gene expression relative to the control group. Estimated tPODs were then 1024 
compared to observed physiological outcomes at 60 dph (length, weight, survival) and to those 1025 
reported in the literature. Similar to Chapter 2, this chapter also attempted to link transcriptomic 1026 
and proteomic changes at 4 dph to apical outcomes observed at later life stages. 1027 
The content of Chapter 3 was reprinted (adapted) from Alcaraz, A.J.G., Mikulášek, K., 1028 
Potěšil, D., Park, B., Shekh, K., Ewald, J., Burbridge, C., Zdráhal, Z., Schneider, D., Xia, J., 1029 
Crump, D., Basu, N., Hecker, M., 2021. Assessing the Toxicity of 17α-Ethinylestradiol in 1030 
Rainbow Trout Using a 4-Day Transcriptomics Benchmark Dose (BMD) Embryo Assay. Environ. 1031 
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3.1. Abstract 1059 
There is an urgent demand for more efficient and ethical approaches in ecological risk 1060 
assessment. Using 17α-ethinylestradiol (EE2) as a model compound, this study established an 1061 
embryo benchmark-dose (BMD) assay for rainbow trout (RBT; Oncorhynchus mykiss) to derive 1062 
transcriptomic points-of-departure (tPODs) as an alternative to live-animal tests.  Embryos were 1063 
exposed to graded concentrations of EE2 (measured: 0, 1.13, 1.57, 6.22, 16.3, 55.1, and 169 ng/L) 1064 
from hatch to 4 and up to 60 days post-hatch (dph) to assess molecular and apical responses, 1065 
respectively. Whole proteome analyses of alevins did not show clear estrogenic effects. In contrast, 1066 
transcriptomics revealed responses that were in agreement with apical effects, including excessive 1067 
accumulation of intravascular and hepatic proteinaceous fluid and significant increases in mortality 1068 
at 55.1 and 169 ng/L EE2 at later time points.  Transcriptomic BMD analysis estimated the median 1069 
of the 20th lowest geneBMD to be 0.18 ng/L, the most sensitive tPOD.  Other estimates (0.78, 3.64, 1070 
and 1.63 ng/L for the tenth percentile geneBMD, first peak geneBMD distribution, and median 1071 
geneBMD of the most sensitive overrepresented pathway, respectively) were within the same order 1072 
of magnitude as empirically derived apical PODs for EE2 in the literature.  This 4-day alternative 1073 
RBT embryonic assay was effective in deriving tPODs that are protective of chronic effects of 1074 
EE2. 1075 
Keywords: estrogen; risk assessment; transcriptomic benchmark dose, endocrine disruption; 1076 
alternative toxicity testing 1077 
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3.2. Introduction 1078 
Societal demands and practices result in a steady increase in the production of chemical 1079 
compounds and their release into aquatic environments where they can cause unintended adverse 1080 
effects in non-target organisms. However, current regulatory frameworks for assessing the 1081 
potential toxicological risks this ever-increasing number of chemicals poses are hampered because 1082 
they are costly, time-consuming, and of significant ethical concern due to their reliance on live 1083 
animal tests (Bernhardt et al., 2017; Hecker, 2018).  For instance, tests with rainbow trout (RBT; 1084 
Oncorhynchus mykiss), one of the key model test organisms extensively used in traditional 1085 
ecological risk assessment (ERA) studies in freshwater ecosystems, are particularly time-1086 
consuming due to slow developmental times, and thus are prohibitively expensive.  Furthermore, 1087 
there are still significant uncertainties with regard to the use of traditional acute toxicity testing in 1088 
predicting thresholds (points-of-departure; PODs) for chronic exposures as acute-to-chronic safety 1089 
factors vary considerably (Ahlers et al., 2006).  Consequently, there have been considerable efforts 1090 
towards the development of new approach methodologies (NAM) to advance and improve current 1091 
ERA strategies (Basu et al., 2019; Gwinn, 2020; Interagency Coordinating Committee on the 1092 
Validation of Alternative Methods, 2018).  Several NAMs have been developed for RBT, 1093 
primarily in vitro and in silico approaches such as tissue explants (Beitel et al., 2015), stable cell 1094 
lines (Fischer et al., 2019), and toxicokinetic and -dynamic models (Brinkmann et al., 2014). 1095 
However, these approaches are limited with regards to reliably assessing potential hazards as they 1096 
do not represent the complexity of whole organisms.  Recently, short-term fish embryo assays 1097 
have emerged as a promising alternative testing concept (reviewed in Lillicrap et al. (2016) and 1098 
Sobanska et al. (2018)).  Embryo-larval stages of oviparous animals such as fish (prior to 1099 
independent feeding) are not considered live animals under current legislations in Europe and 1100 
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North America (reviewed in Halder et al. (2010)).  Furthermore, this life-stage is known to be the 1101 
most sensitive to exposure to many chemicals, and toxicological insults incurred at this stage could 1102 
result in chronic health impairments at later life-stages (Bhandari et al., 2015). 1103 
Another approach increasingly being considered to support ERAs is the use of mechanism-1104 
based testing strategies (Basu et al., 2019).  Recent advancements in molecular biology and 1105 
biotechnology have enabled the characterization of molecular responses, without a priori 1106 
knowledge of specific mechanisms of toxicity, using next-generation omics technologies such as 1107 
global transcriptomics.  However, prospective toxicogenomic risk assessment approaches such as 1108 
the use of transcriptomics-based benchmark-dose (BMD) strategies to predict the hazard of 1109 
chemical contaminants have yet to be fully accepted for their use in regulatory risk assessment. 1110 
Molecular perturbations generally occur rapidly after toxic insults, prior to phenotypic 1111 
manifestations, and therefore provide early insights into the complex sublethal and/or chronic 1112 
effects typically missed in standard acute toxicity testing (Ankley et al., 2010). In transcriptomics 1113 
dose-response studies, toxicant-responsive genes are identified by means of BMD approaches, 1114 
which  are subsequently used to estimate transcriptome-wide PODs as discussed in a recent 1115 
National Toxicology Program (NTP) report (National Toxicology Program, 2018) and in Farmahin 1116 
et al. (2017).  In particular, a recently developed transcriptomic BMD method showed promise in 1117 
deriving transcriptomic PODs (tPODs) for estimating in vivo dose-responses that are protective of 1118 
chronic effects (Farmahin et al., 2017; Pagé-Larivière et al., 2019; Yang et al., 2007).  In fish, a 1119 
reduced transcriptome approach was developed to estimate gene- and pathway-level effect 1120 
concentration in embryonic zebrafish (Wang et al., 2018; Zhang et al., 2020). Regardless, the use 1121 
of tPODs in quantitative risk assessment is still limited and much work is needed to establish such 1122 
an approach for ecological species that can be reliably used in ERA and gain regulatory acceptance. 1123 
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Given the promise fish embryo assays have shown for use in chemical hazard assessments, 1124 
here we propose an embryo assay to derive tPODs using RBT. Specifically, considering that 1125 
larval/alevin stages of fish express the full complement of genes that are also regulated in adults, 1126 
we hypothesized that transcriptomic perturbations at this early stage may serve as an early indicator 1127 
of possible later chronic and apical effects (reviewed in Ankley and Edwards, 2018).  The main 1128 
objective of this study was to establish a 4-day embryo-alevin assay for RBT to characterize the 1129 
effects of chemicals using a transcriptomic BMD approach. This assay could then serve as an 1130 
advanced tool in chemical testing prioritization as well as an alternative strategy to more extensive 1131 
live-animal testing. 17α-ethinylestradiol (EE2), the active ingredient in many birth-control pills, 1132 
was chosen as the model compound because it is a well-studied and potent emerging contaminant 1133 
that has been thoroughly described with regards to its toxicity in fish.  Furthermore, EE2 has been 1134 
ubiquitously detected in surface waters globally, and represents a priority contaminant of concern 1135 
(reviewed in Aris et al. (2014)).  Together, these characteristics render it an ideal compound to 1136 
establish a tPOD approach for embryonic fish. This study specifically aimed to: (1) characterize 1137 
the trends in global transcriptome responses of RBT embryos/alevins exposed to EE2 for 96h, (2) 1138 
assess downstream features after short (96h; proteomics) and sub-chronic (60d; histology, 1139 
biometrics and survival) EE2 exposure, (3) link molecular responses to apical outcomes, and (4) 1140 
derive tPODs and compare these with higher level physiological and apical response reported in 1141 




3.3. Materials and Methods 1144 
3.3.1. Fish maintenance and exposure conditions 1145 
Eyed-stage RBT embryos were acquired from Troutlodge, Inc (WA, USA) and were kept 1146 
in McDonald-type hatching jars until the first signs of hatching were observed. Approximately 100 1147 
unhatched eggs were then transferred (Day 0) into hatching cups, which were kept in 9-liter tanks 1148 
containing exposure solutions. Unhatched eggs were removed after 48 hrs. Embryos were exposed, 1149 
in triplicate, to graded concentrations of EE2 (nominal: 1, 3, 10, 30, 100 and 300 ng/L; >98% 1150 
purity, Sigma Aldrich, MO, USA) and controls (water control, 0.01% DMSO solvent control) 1151 
under flow-through conditions (at least 50% v/v renewal per day) (Figure C.S1; Appendix C.1). 1152 
Temperature was maintained at 15 ± 1 oC, under a 16:8 light:dark cycle, and conditions were 1153 
monitored daily for temperature, and weekly for pH, conductivity, dissolved oxygen, ammonia, 1154 
nitrates, nitrites, hardness, and alkalinity.  1155 
Three and five alevins were collected and pooled from each tank at 4 days post-hatch (dph) 1156 
for transcriptomics and proteomics analyses, respectively. Samples were immediately flash frozen 1157 
in liquid nitrogen and kept at -80oC until further analyses. At 21 dph, fish were culled to 20 1158 
individuals per tank to avoid overcrowding.  Surviving juveniles at 60 dph were euthanized and 1159 
assessed for overt morphological abnormalities. Five randomly selected whole fish at 60 dph from 1160 
each replicate were also fixed using HealthCare™ PROTOCOL™ SafeFix™ II All-Purpose 1161 
Fixative (Fisher Scientific, MA, USA) for 48 hours, transferred to 70% ethanol, and then stored at 1162 
room temperature until further processing for histological assessment. Lengths and weights were 1163 
recorded at 4, 21, and 60 dph, and survival was recorded daily. The study was approved by the 1164 
University of Saskatchewan Animal Research Ethics Board (Protocol# 20140079). 1165 
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3.3.2. Chemical analyses 1166 
Concentrations of EE2 were measured in water samples collected from each tank at 4 and 1167 
21 dph (Appendix C.2). Collected samples were extracted by solid-phase extraction using 100 1168 
mg/6 ml Strata X polymeric cartridges (Phenomenex Inc, CA, USA). Concentrations of EE2 were 1169 
measured using EE2-specific competitive enzyme-linked immunosorbent assay (ELISA) 1170 
(Ecologiena®, Fukuoka, Japan, purchased from Eurofins Abraxis, PA, USA), following the 1171 
manufacturer’s protocol. The Ecologiena® EE2 ELISA kit is highly specific and has previously 1172 
been used in measurements of EE2 in laboratory and environmental samples (Bailey et al., 2019; 1173 
King et al., 2016). 1174 
 1175 
3.3.3. Transcriptomics  1176 
Alevins from solvent control, 1, 3, 10, 30, and 100 ng/L treatment groups were used for 1177 
transcriptomic analyses (Appendix C.3). Total RNA was extracted from each replicate using 1178 
RNeasy Plus Universal Mini Kit (Qiagen, Germany). Samples with an RNA integrity number 1179 
(RIN) ≥ 8 were sent for 200 base-pairs paired-end mRNA (100 x 2) sequencing using a NovaSeq 1180 
6000 S4 lane (Illumina, CA, USA) at Génome Québec Centre d’Expertise et de Services (Genome 1181 
Quebec, QB, Canada).  1182 
Reads were assessed for quality, then trimmed to a minimum phred score of 20 and a 1183 
minimum length of 35 bases using Trimmomatic (Bolger et al., 2014). The abundance of 1184 
transcripts was estimated using Kallisto (Bray et al., 2016) with the reference RBT transcriptome 1185 
(GenBank Acc# GCA_002163495.1).  Significance of differentially expressed (DE) transcripts 1186 
were assessed using DESeq2 (Love et al., 2014), with a minimum effect size threshold of the 1187 
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absolute value of log2 fold-change (|log2FC|) ≥ 1 and a false discovery rate (FDR, Benjamini-1188 
Hochberg) ≤ 0.05.  Raw fastq files are available through the NCBI GEO accession# GSE171788. 1189 
 1190 
3.3.4. Proteomics 1191 
Alevins from the solvent control, 30, and 100 ng/L treatment groups were used for non-1192 
targeted proteomics analysis, as described by Alcaraz et al. (2021), with minor modifications 1193 
(Appendix C.4).  Briefly, whole body tissues were processed by filter-aided sample preparation 1194 
(Wiśniewski et al., 2009; Wiśniewski and Rakus, 2014) using 30 kDa Microcon® filters (Merck 1195 
Millipore, MA, USA).  LC-MS/MS analyses of peptide mixtures were conducted using a Q 1196 
Exactive™ HF-X Hybrid Quadrupole-Orbitrap™ mass spectrometer (Thermo Fisher Scientific, 1197 
MA, USA) connected online to an Ultimate 3000 RSLCnano system (consisted of SRD-3400, 1198 
NCS-3500RS CAP, WPS-3000 TPL RS; Thermo Fisher Scientific). Spectral characterization was 1199 
carried out in MaxQuant v1.6.14(Tyanova et al., 2016) using default contaminant database (247 1200 
protein sequences) and the RBT reference proteome (GenBank Acc# GCA_002163495.1; 71,233 1201 
protein sequences).  Significance of differentially abundant protein groups was assessed using 1202 
limma with a cut-off moderated p-value ≤ 0.05 and a minimum effect size threshold |log2FC| ≥ 1 1203 
relative to the solvent control group. The MS proteomics data were deposited in the 1204 
ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with 1205 
dataset identifier PXD025251.  1206 
 1207 
3.3.5. Overrepresentation analyses 1208 
Significantly dysregulated transcripts and proteins were mapped to their respective RBT 1209 
Entrez IDs. These IDs were then searched for their zebrafish orthologs using g:Profiler (Raudvere 1210 
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et al., 2019).  The mapping rate of RBT Entrez IDs to zebrafish was between 51 and 62%. 1211 
Functional overrepresentation analyses were conducted using STRING v.11 (Szklarczyk et al., 1212 
2019) in Cytoscape (Shannon et al., 2003), with a cut-off FDR ≤ 0.05 and the whole zebrafish 1213 
genome as the statistical domain.   1214 
 1215 
3.3.6. Histological assessments 1216 
Liver histology was assessed in a subset of individuals from the solvent control and 100 1217 
ng/L treatment groups (3-4 individuals per replicate) (Appendix C.5). Briefly, fixed whole-body 1218 
samples were embedded in paraffin, step-sectioned through the internal organs and stained with 1219 
hematoxylin and eosin. Livers were assessed for changes in hepatocellular staining (i.e. basophilia) 1220 
and vacuolation, and other changes were noted as well.  Histological analyses were done 1221 
qualitatively in support of molecular studies, and thus, only the highest concentration with 1222 
transcriptomic data was assessed relative to the control group, and histological features were 1223 
reported as presence/absence of phenotypes in individual fish examined.  No statistical analysis 1224 
was conducted on histological data. 1225 
 1226 
3.3.7. Benchmark-dose analysis 1227 
Derivation of transcriptomic points-of-departure (tPOD) was conducted by means of the 1228 
benchmark dose (BMD) approach using FastBMD (fastbmd.ca) (Ewald et al., 2020).  DESeq2-1229 
normalized (relative log expression normalization) count estimates from Kallisto were filtered to 1230 
remove 5% and 10% of the genes with lowest variance and abundance across treatment groups, 1231 
respectively. This independent filtering step removes genes that are less likely to be informative; 1232 
thus, it increases the statistical power of the differential expression analysis (Bourgon et al., 2010). 1233 
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Then, DE (|log2FC| ≥ 1; FDR ≤ 0.05) was conducted to reduce the number of computationally 1234 
extensive curve-fittings and avoid modelling data with no statistical significance by removing 1235 
features that are unlikely to exhibit concentration-response behaviour. A total of 1499 features 1236 
were fitted using statistical models (Exp2, Exp3, Exp4, Exp5, Linear, Poly2, Hill, and Power), 1237 
with a threshold lack-of-fit p-value > 0.1 and a benchmark-response (BMR) factor = 1. Control 1238 
expression was set to the mean of control samples. Three tPOD estimates were derived based on 1239 
the distribution of gene-level BMDs (geneBMD): (1) the median of the 20 lowest geneBMDs 1240 
(omicBMD20), (2) the tenth percentile geneBMD value (omicBMD10th), and (3) the mode of the 1241 
first peak geneBMD distribution (omicBMDmode) (Pagé-Larivière et al., 2019).  Lastly, a pathway-1242 
level BMD (pathBMD) was derived by bootstrapped median calculation of geneBMDs in a 1243 
pathway and selecting the most sensitive (lowest value) pathBMD with a minimum of three 1244 
geneBMDs (National Toxicology Program, 2018). 1245 
 1246 
3.3.8. Statistical Analyses 1247 
Length, weight, condition factor (K), and survival rates were assessed at three time points 1248 
(4, 21, 60 dph) for significant differences among treatment groups using one-way analysis of 1249 
variance (ANOVA), followed by Tukey’s multiple comparison post-hoc test, with a cut-off 1250 
adjusted p-value < 0.05.   In cases where assumptions of ANOVA were not met, the non-parametric 1251 
ANOVA analogue, Kruskal-Wallis test, was performed, followed by Dunn’s multiple comparison 1252 
test with a cut-off p-value < 0.05.  All non-omics statistical analyses were carried out in GraphPad 1253 




3.4. Results and Discussion 1256 
3.4.1. Chemical measurements and physicochemical characteristics of exposure solutions 1257 
 Measured concentrations of EE2 were between 52 and 62% of nominal concentrations, 1258 
except the lowest concentration which was 113% of the nominal concentration (Table C.S1). 1259 
Water and solvent controls were below the detection sensitivity of the method. Physico-chemical 1260 
characteristics of exposure solutions were within the acceptable range according to OECD 210 1261 
(OECD, 2013)  (Table C.S2).  From this point-forward, treatment groups are referred to as the 1262 
measured concentrations. 1263 
 1264 
3.4.2. General features of transcriptomic responses 1265 
 Four-day exposure of RBT embryos/alevins to EE2 caused significant changes in global 1266 
transcript expression. There were 930, 688, 210, 281, and 331 dysregulated transcripts in the 1.13, 1267 
1.57, 6.22, 16.3, and 55.1 ng/L treatment groups, respectively (Figure 3.1A).  Of these, 48 1268 
overlapped across all treatment groups, all of which were upregulated.  Downregulated transcripts 1269 
were less consistent - none were common across all concentrations.  Interestingly, the 1.13 ng/L 1270 
and 6.22 ng/L treatments had the greatest and least number of dysregulated transcripts, 1271 
respectively, which is in contrast to a previously reported dose-dependent increase in the number 1272 
of significantly dysregulated genes in EE2-treated rats (Naciff et al., 2003).  The number of 1273 
dysregulated features is influenced by a multitude of factors, such as the number of replicates and 1274 
set statistical thresholds, as well as the test concentrations used in a study.  Considering their high 1275 
biological activity and physiological role in many biological processes, low levels of estrogenic 1276 
steroids may trigger a host of responses that are not necessarily indicative of toxic outcomes. At 1277 
higher concentrations, the global response pattern may then shift to genes indicative of a toxic 1278 
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response that may exhibit a classic concentration-dependent change (Pagé-Larivière et al., 2019).  1279 
Here, we observed that the number of highly dysregulated transcripts (|log2FC| > 10) followed a 1280 
concentration-dependent trend (1.13 ng/L = 67, 1.57 ng/L = 67, 6.22 ng/L = 69, 16.3 ng/L = 74, 1281 
55.1 ng/L = 90; slope = 0.428; R2 = 99.92%).  Common dysregulated transcripts included signature 1282 
markers associated with exposure to estrogens such as transcripts coding for Vitelline envelope 1283 
protein (Zona pellucida glycoprotein; Zp), as well as multiple variants of vitellogenin (Vtg), among 1284 
others (Dataset 1, Tab A1-A5 & B).  Consistently among the highest upregulated transcripts were 1285 
those associated with lipid metabolism, a biological process where estrogens are known to exert 1286 
regulatory control (reviewed in Palmisano et al. (2017).  Upregulation of these transcripts was 1287 
previously observed in response to EE2-treatment in primary RBT hepatocytes (Hultman et al., 1288 
2015) and in other teleosts in vivo (Huff et al., 2018).  Additionally, similarities between 1289 
dysregulated transcripts at two successive concentrations tested were substantial, except between 1290 
1.57 and 6.22 ng/L, suggesting a possible shift in molecular response patterns between these two 1291 
concentrations (Table C.S3).   The differences in the general features of responses between 1.13 1292 
and 1.57 ng/L and between 6.22 and 55.10 ng/L also suggest hormetic effects at lower 1293 
concentrations where transcripts involved in the maintenance of cytoskeletal architecture, 1294 
metabolic homeostasis, scavenging, and tight junction interactions, among others, were observed, 1295 
features which indicate general early cell responses. In hormesis, independent molecular functions 1296 
necessary for cellular survival are activated to counter toxic insults and to survive in challenging 1297 
environments through intrinsically generated multiple interacting signal transduction processes 1298 
(Calabrese and Mattson, 2017). Furthermore, the overview heatmap profiles of differentially 1299 
expressed transcripts in each treatment group showed distinct clustering of DE transcripts in the 1300 
1.13 and 1.57 ng/L treatment groups, while clear concentration-dependent responses of DE 1301 
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transcripts occurred in the 6.22-55.1 ng/L treatment groups (Figure C.S2), supporting this 1302 
hormesis hypothesis.  At 6.22 ng/L, transcriptomic responses suggest that the biological system of 1303 
exposed RBT had exceeded molecular response plasticity as most energy was expended towards 1304 
specific responses, as evidenced by distinct concentration-associated increase or decrease in 1305 
transcriptional expression of significantly dysregulated features.  For instance, the common 1306 
estrogenic biomarker estrogen receptor 1 (esr1) only started showing significant dysregulation at 1307 
6.22 ng/L, although other biomarkers like vtg showed significant dysregulation at concentrations 1308 
as low as 1.13 ng/L.  1309 
Functional enrichment analyses showed significant overrepresentation of 151, 135, 12, 65, 1310 
and 83 terms and pathways in the 1.13, 1.57, 6.22, 16.3, and 55.1 ng/L treatment groups, 1311 
respectively. None of these terms were consistently overrepresented across all treatment groups 1312 
(Figure C.S3), further supporting the hypothesis that there could have been a shift in molecular 1313 
responses between lower (1.57 ng/L) and higher (6.22 ng/L) EE2 concentrations.  Most 1314 
overrepresented terms and pathways in fish exposed to 1.13 and 1.57 ng/l were generally 1315 
associated with cellular repair and maintenance pathways, while those at 6.22-55.1 ng/L were 1316 
generally endocrine- and metabolism-associated processes (Dataset 1, Tabs C1-C5). Nine terms 1317 
were overrepresented in at least four treatment groups, including chylomicron assembly, retinoid 1318 
metabolism and transport, post-translational protein phosphorylation, regulation of insulin-like 1319 
growth factor (IGF) transport and uptake by insulin-like growth factor binding proteins (IGFBPs), 1320 
apolipoprotein A1/A4/E domain, and lipid transport, all of which have been previously associated 1321 
with endocrine functions (Bravo et al., 2001; Kam et al., 2000).  For instance, EE2 has been 1322 
reported to interfere with the IGF system during development of bony fish (Shved et al., 2007), 1323 
resulting in stunted growth (Shved et al., 2008), although this particular apical response was not 1324 
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observed here.  Similarly, apolipoproteins are important proteins responsible for lipid transport 1325 
and were significantly dysregulated in estradiol-treated embryonic zebrafish (Hao et al., 2013).   It 1326 
has also been suggested that estrogens are possibly involved in post-translational modifications 1327 
(Doyle et al., 2013), though very few studies investigated the role of estrogens in these processes. 1328 
 1329 
3.4.3. Downstream responses in support of transcriptomic perturbations 1330 
3.4.3.1. Proteome-wide alterations 1331 
 A total of 3200 protein groups were detected across all treatment groups, with the 1332 
abundance of 243 and 300 having been significantly altered in 16.3 ng/L and 55.1 ng/L treatment 1333 
groups, respectively (Dataset 2, Tab A).  Of these differentially abundant protein groups, 123 1334 
were differentially abundant in both treatments (Figure 3.1B; Dataset 2, Tab B). Interestingly, 1335 
all the distinctive estrogen-responsive Vtg protein variants were not significantly dysregulated in 1336 
both treatment groups, which may be attributed to the high basal intensities of these proteins in 1337 
alevins in all treatments, including controls, rendering any changes below detectable thresholds.  1338 
Notably, the yolk sac is still prominent in RBT at 4 dph, and maternally transferred Vtg protein 1339 
may still be present at high concentrations. Additionally, considerable fractions of proteins present 1340 
in the yolk-sac may have diluted the detection of other EE2-responsive proteins in the main body 1341 
of the yolk-sac alevin. In contrast, previously observed estrogen-responsive precursor 1342 
glycoproteins Zp α, β and γ proteins were differentially abundant in both treatment groups, 1343 
suggesting treatment-associated significant induction at the post-embryonic stage (Salinas et al., 1344 
2010).   Then again, other estrogen-responsive proteins may not have been synthesized to 1345 
detectable levels given the short 4 day exposure, and thus, may not be reflective of the initial gene 1346 
expression (Figure 3.1C).   1347 
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Overrepresentation analyses showed 108 and 153 significantly overrepresented terms and 1348 
pathways for 16.3 ng/L and 55.1 ng/L treatment groups, respectively. Thirty-seven of these terms 1349 
were common between the groups (Dataset 2, Tab C & D). However, most of these terms and 1350 
pathways appear to be part of concerted immediate endogenous stress responses such as clathrin-1351 
mediated endocytosis, transport, metabolic signaling, activation of heat shock proteins, and 1352 
oxidative phosphorylation, which protect the organism from toxicological insults.  Results of 1353 
overrepresentation analyses further support the idea that 4 days of exposure at the yolk-sac alevin 1354 
stage may not have been long enough to elicit specific proteomic responses that are reflective of 1355 
transcript expression particularly for a fish like RBT that has a relatively long life cycle.  Future 1356 
proteomics studies on RBT alevins should consider the removal of the yolk-sac prior to protein 1357 







Figure 3.1. Omics analyses. (A) Venn diagram of differentially expressed transcripts of 4 dph 1361 
RBT exposed to EE2 (Dataset 1, Tab A1-A5 & Tab B). (B) Venn diagram of DA proteins in 16.3 1362 
and 55.1 ng/L treatment groups. (C) Intersection of DE transcripts and differentially abundant 1363 
proteins across all concentrations. Venn diagrams were constructed using InteractiVenn (Heberle 1364 
et al., 2015).1365 
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3.4.3.2. Histological changes 1366 
 EE2-exposed juvenile RBT exhibited histological characteristics typical of those observed 1367 
in other early-life teleost species exposed to estrogenic compounds (Weber et al., 2003) (Table 1368 
C.S4).  Livers from solvent control fish showed normal histological appearance, with hepatocytes 1369 
arranged into two cell-thick cords interspersed with sinusoids. Hepatocytes featured nuclei with 1370 
prominent central nucleoli.  Glycogen-type vacuolation was abundant, and lipid-type vacuolation 1371 
was largely absent (Figure 3.2A).  In contrast, livers of all individuals from the 55.1 ng/L treatment 1372 
group exhibited greatly reduced glycogen-type vacuolation relative to the solvent control, and 1373 
increased lipid-type vacuolation was observed in seven out of nine individuals examined. 1374 
Furthermore, individuals from the treated group exhibited increased hepatocyte basophilia relative 1375 
to the solvent control (Figure 3.2B), a common histological characteristic of estrogen-induced 1376 
upregulation of Vtg protein (reviewed in Wolf and Wheeler, 2018).  Similarly, signs of 1377 
intravascular proteinaceous fluid were apparent in all livers from the treated group, which is 1378 
presumed to be due to overproduction of proteins like coagulation factors, Vtgs, and other 1379 
estrogen-responsive hormones and enzymes in the extracellular fluid (Van den Belt et al., 2002).  1380 
Additionally, hepatocytes surrounding the sinusoids and bile canaliculi from the treated group 1381 
were often tall columnar, and sinusoids were often dilated.  Occasional hepatocyte cytomegaly and 1382 
karyomegaly were also observed in EE2-exposed individuals, although not quantified. 1383 
Proteinaceous eosinophilic extracellular fluid was absent in the body cavities of individuals 1384 
from the solvent control (Figure 3.2C) but was notably present in all individuals from the treated 1385 
group (Figure 3.2D).  The degree of fluid accumulation in individual fish from the treated group 1386 
ranged from one to a few localized spots in a few sections, to extensive accumulation throughout 1387 
most sections. This observation revealed a varied degree, but consistent occurrence of 1388 
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proteinaceous fluid that leaked into the coelom. Similar histological observations have been 1389 
previously reported in early-life stage fathead minnows (FHM) (Alcaraz et al., 2021b) and 1390 
Xenopus laevis (Tompsett et al., 2012) exposed to the same or greater concentration of EE2, 1391 








Figure 3.2. Photomicrographs of livers (A1&A2; Scale = 50µm) and coelom (A3&A4; Scale = 1396 
500µm) from EE2-exposed 60 dph RBT (hematoxylin and eosin stain). (A) solvent control, 1397 
showing normal liver parenchyma, with abundant glycogen-type vacuolation (O); (B) 55.1 ng/L 1398 
treatment group, showing increased hepatocyte basophilia (dark blue stain), reduced glycogen-1399 
type vacuolation, increased lipid-type vacuolation, and abundant eosinophilic (pink-staining) 1400 
proteinaceous fluid within the sinusoids (□); (C) solvent control, showing clear space adjacent to 1401 
internal organs; (D) 55.1 ng/L treatment group, showing eosinophilic proteinaceous fluid 1402 
accumulation in the body cavity (*) near the body wall (arrowheads) adjacent to the intestine (Int) 1403 
and liver (L).  1404 
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3.4.3.3. Survival and morphometric measurements 1405 
 Exposure to EE2 affected survival rates but not morphometric measurements in early-life 1406 
RBT, with significant mortalities at very high concentrations during the early fry (55.1 and 169 1407 
ng/L) and swim-up stages (169 ng/L) (Figure 3.3; Dataset C.S4).  Reports of mortalities due to 1408 
acute and sub-chronic exposure to EE2 in fish are scarce, owing to its estrogenic but relatively low 1409 
acute toxicity, with a previously reported LC50 of 1.7 mg EE2/L for adult zebrafish (Versonnen 1410 
et al., 2003).  This observation suggests that RBT alevins and fry are approximately one order of 1411 
magnitude more sensitive than adult zebrafish. However, it should be noted that effects on survival 1412 
in this study did not occur at environmentally relevant concentrations that were reported previously 1413 
at sub-ng/L to single digit ng/L range (summarized in Aris et al., 2014).  On the other hand, fish 1414 
size and condition factor at 4 dph and 21dph were not significantly affected at any of the 1415 
concentrations tested (Figure C.S4). These observations were in contrast to previously reported 1416 
stunted growth in early-life stage FHM (Alcaraz et al., 2021b) and tilapia (Shved et al., 2008).  1417 
The difference in these observations may be due to species-specific responses, particularly with 1418 
regard to the length of exposure relative to the life-cycle of a given species of fish. 1419 
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4dph Swim-up Early fry
 1420 
Figure 3.3. Survival rates (%) at early-life stages: 4 dph (all concentrations), swim-up (21 dph; all 1421 
concentrations) and early fry (60 dph; solvent control, 16.3, 55.1, and 169 ng/L EE2). x-axis – 1422 
survival rates in %; y-axis – log2 scale of concentration (in ng/L EE2). Datasets are presented as 1423 
mean ± standard deviation. 1424 
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3.4.3.4. From molecular responses to apical outcomes 1425 
 Transcript-protein concordances of dysregulated features at 16.3 and 55.1 ng/L were weak, 1426 
with only four and nine common features at the same concentration, respectively (Figure 3.1C).  1427 
Zp α, β, and γ were the only transcript-protein pairs that were commonly dysregulated in the two 1428 
treatment groups.  While many protein-coding transcripts were highly dysregulated, particularly 1429 
those associated with estrogenic responses, similar dysregulations were not reflected at the 1430 
proteome level.  Limited concordance between transcriptomic and proteomic responses was 1431 
previously observed in EE2-exposed zebrafish (De Wit et al., 2010) and FHM (Alcaraz et al., 1432 
2021b).  These observations were expected due to many post-translational factors influencing 1433 
protein-product synthesis (Liu et al., 2016).  Moreover, the limited direct projection of significant 1434 
dysregulation of transcripts to proteins might also be ascribed to the short study duration, limiting 1435 
the time to synthesize proteins.  Furthermore, the coincident sampling for transcriptomic and 1436 
proteomic analyses may be another reason for some of the low concordance, considering the delay 1437 
of mRNA translation to proteins. Lastly, the presence of maternally transferred proteins in the yolk 1438 
sac might have dominated measured proteins, as corroborated by very high spectral intensities of 1439 
yolk proteins like Vtg.  These very high levels of proteins could have masked changes in protein 1440 
abundance brought about by EE2 exposure.  1441 
Observed histological features at 60 dph suggest excessive utilization of energy and the 1442 
presence of large amounts of proteinaceous fluid within the liver and leaking into the coelom, 1443 
which is hypothesized to be due to EE2-induced overproduction of estrogen-associated proteins 1444 
(Alcaraz et al., 2021b; Palace et al., 2002; Van den Belt et al., 2002).  These histological changes 1445 
can be linked to observed perturbations at the transcriptome level.  While gonads were not assessed 1446 
in the current study, significant dysregulation of estrogen-associated transcripts suggests that 1447 
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continuous exposure to EE2 would delay gonad development and shift gonadal sex ratio towards 1448 
more females in exposed alevins, as previously observed in other fish species (Kidd et al., 2007; 1449 
Weber et al., 2003).  However, other expected apical responses, such as stunted growth, were not 1450 
observed in this study.  This may be due to the long life-cycle of RBT such that weight and length 1451 
measurements at 4 dph and 21 dph did not result in any significant changes.  Nonetheless, it can 1452 
be concluded that transcriptional perturbations after 4 days of EE2 exposure were indicative of 1453 
potential physiological or apical outcomes at a later life stage. 1454 
 1455 
3.4.4. Transcriptomic dose-response 1456 
Benchmark-dose analysis showed that estimates of transcriptomic BMDs were effective 1457 
predictors of empirically derived (apical) benchmark concentrations of EE2-associated 1458 
toxicological responses reported in previous studies (Table C.S5).  Of the 1499 features passing 1459 
cut-off thresholds, 569 fitted the models, with most genes converging through the 2o polynomial 1460 
(Poly2) model based on the lowest Akaike information criterion (AIC) (Figure C.S5). There were 1461 
464 features with gene-level BMDs (geneBMDs) after filtering low confidence and geneBMDs 1462 
greater than the highest concentration (Figure 3.4A; DataSet S3, Tab A) (National Toxicology 1463 
Program, 2018) . It should be noted that the BMD modelling was conservative in that higher order 1464 
polynomial models were not included since these models tend to fit data poorly and are prone to 1465 
variability, and therefore, may add greater uncertainty with regard to predicting benchmark doses. 1466 
Still, future analyses should specifically investigate the implications of and consider these models 1467 
in BMD modelling. 1468 
 Known estrogen-responsive genes exhibited robust concentration-response curves with 1469 
narrow confidence intervals and notable minimal variations across replicates within a 1470 
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concentration, particularly those that were highly expressed (Figure 3.4B). These include genes 1471 
coding for extracellular serine/threonine protein kinase FAM20C (fam20c), esr1, zona pellucida 1472 
glycoprotein 2 (zp2.3), coagulation factor XIIIA (f13a), and multiple variants of vtg, among others.  1473 
In contrast, concentration-response curves of many of the down-regulated genes exhibited higher 1474 
variance (Figure 3.4C), owing to the intrinsic nature of data transformation (log-normalized) in 1475 
modelling lowly expressed features.  This observation implies that downregulated concentration-1476 
response trends may present greater challenges in transcriptome-wide dose-response analyses, 1477 
especially when biological systems tend to diminish mRNA expression.  Highly sensitive genes 1478 
which are downregulated could result in low and below-detectable levels at higher treatment 1479 
concentrations unless the abundance of transcripts was inherently high such that biological effects 1480 
would still result in detectable mRNA levels.  However, for genes that are expressed at lower levels 1481 
(e.g. many nuclear receptors), deeper sequencing will be required.  Optimal sequencing depth and 1482 
number of replicates should be further evaluated for tPOD applications in the context of risk 1483 
assessment, with considerations of the sensitivity, cost, and reasonable experimental design.  1484 
The recommended approach in deriving PODs at the transcriptomic level (Pagé-Larivière 1485 
et al., 2019) yielded threshold concentrations of omicBMD20 = 0.18 ng/L, omicBMD10th = 0.78 1486 
ng/L, and  omicBMDmode = 3.64 ng/L (Figure 3.4D; Figure C.S6).  The most sensitive KEGG 1487 
pathway was cysteine and methionine metabolism, which is generally associated with amino acid 1488 
synthesis, with a pathBMD of 1.63 ng/L (DataSet S3, Tab B).  The pathway with the highest 1489 
number of dysregulated genes was cholesterol metabolism (pathBMD = 3.65 ng/L) with 7 1490 
contributing genes.  Estrogens are generally involved in lipid metabolic processes (Palmisano et 1491 
al., 2017).  Gene-set level BMDs have been shown to be highly correlated with apical BMDs 1492 
(Thomas et al., 2013b) and NTP has recommended pathBMD in deriving tPODs, particularly when 1493 
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using rats and human cell lines (National Toxicology Program, 2018).  However, pathBMDs 1494 
should be interpreted with caution as many ecologically relevant species that are important in ERA 1495 
have poorly annotated reference genomes or transcriptomes, or were arbitrarily mapped against 1496 
other species without extensive curation.  For instance, RBT is not officially included in the KEGG 1497 
database of organisms, and while users may perform functional annotation, these are loosely based 1498 
on computationally inferred KEGG orthology. Accordingly, Pagé-Larivière et al. (2019) cautioned 1499 
with regard to the use of pathBMD with non-model organisms lacking fully assembled genomes 1500 
and well-curated annotations since the resulting estimates were largely variable and dependent on 1501 
the annotation and pathway mapping. 1502 
To date, there have been no robust transcriptomic concentration-response studies that have 1503 
been conducted for EE2. Metadata analyses for a 76-day RBT-fry exposure (Pagé-Larivière et al., 1504 
2019) and hepatic gene expression in zebrafish using microarrays (Yang et al., 2007) used 1505 
concentrations that were too high (10 – 10000 ng/L EE2) to derive realistic omicBMDs.  1506 
Consensus on apical EE2-associated lowest observed effective concentration (LOEC) values based 1507 
on literature reports were generally between sub- to low-ng/L concentrations.  For instance, Jobling 1508 
et al. (2004) reported a LOEC for disruption of egg production of spawning pairs of FHM  of 1 1509 
ng/L.  Runnalls et al. (2015) observed inhibition of egg production in FHM at a LOEC of 0.5 ng/L, 1510 
while Parrott and Blunt (2005) reported decreased egg fertilization and shift in sex ratio, as well 1511 
as decreased male sex characteristics in FHM at a LOEC of 0.32 ng/L.  In RBT, intersex was 1512 
observed at 10 ng/L (Depiereux et al., 2014), while the number of eggs attaining the eyed stage of 1513 
embryonic development was significantly affected at 16 ng/L (Schultz et al., 2003).  The predicted 1514 
no-effect concentration (PNEC) for EE2 was 0.35 ng/L based on available chronic toxicity data in 1515 
2008 (Caldwell et al., 2008) while a more conservative 0.10 ng/L was derived in 2012 based on 1516 
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additional fish reproductive studies (Caldwell et al., 2012).   Compared to all these cases, estimates 1517 
of transcriptomic BMD in our study on short-term early-life stage RBT exposure were well within 1518 
the range and are mostly protective with regards to apical LOECs, particularly omicBMD20 and 1519 
omicBMD10th.  While estimates for the omicBMD20 and omicBMD10th were below the lowest 1520 
measured concentration in this study and may have to be further validated experimentally using 1521 
lower concentrations, these transcriptomic BMDs were within 10-fold of the lowest measured 1522 
concentration and are good estimates of empirically derived apical BMDs. However, the main 1523 
limitation of using omicBMD20 and omicBMD10th is the lack of definitive biological interpretation 1524 
typically inferred from gene sets (pathBMD).  While still protective towards apical chronic effects 1525 
of EE2, the estimate for omicBMDmode appeared to be the least sensitive. As this value typically 1526 
suggests the primary onset of biological perturbations corresponding to specific biomolecular 1527 
targets, therefore, it may be used to guide the elucidation of a particular mode of action. 1528 
Nevertheless, it should be noted that the main purpose of the derivation of tPODs is to identify the 1529 
concentration that would significantly perturb biology and would potentially result in a phenotypic 1530 
outcome; mechanism or identification of this phenotypic outcome is secondary due to often limited 1531 
information particularly when testing new compounds (National Toxicology Program, 2018).  1532 
Still, establishing relationships between tPODs and apical outcomes add to the weight of evidence 1533 
of the value of using tPODs in support of ERA of chemicals. Furthermore, current benchmark dose 1534 
approaches do not allow for the calculation of confidence limits or variance of omicBMDs, and 1535 
existing statistical tools should be optimized to include such estimates to increase confidence in 1536 
derived threshold values.  1537 
 Next-generation sequencing has enabled the integration of transcriptomic dose-response 1538 
studies that can potentially advance ERA towards high throughput screening, particularly for 1539 
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prioritization of chemical testing.  Here, we have shown that the use of a transcriptomic BMD 1540 
approach using short-term exposures with early embryonic/alevin life stages, which are not 1541 
considered live animals under current legislations (Canadian Council on Animal Care, 2005; 1542 
European Union, 2010; UK, 1993), can effectively estimate tPODs for EE2 that are as protective 1543 
as those empirically derived using lengthy live-animal tests.  Furthermore, we have also shown 1544 
that relevant genes and pathways associated with EE2 in adult fish were significantly perturbed at 1545 
the embryonic stage, confirming the hypothesis that embryo models can detect gene-level 1546 
disturbances indicative of adult responses.  More importantly, this study demonstrated that short-1547 
term whole embryo tPOD assays may have significant promise to replace adult fish tests, and as 1548 
such may represent a powerful alternative testing strategy, especially when compared to in vitro 1549 
NAMs that are prone to significant uncertainties.  Future studies should be directed towards further 1550 
validation of toxicogenomic benchmarking approaches using additional compounds and by 1551 
including early life-stages of other species.  In particular, there is an urgent need for curation of 1552 
genome annotations for species relevant to ERA, as well as the development of strategies to derive 1553 








Figure 3.4. Transcriptomic points-of-departure (tPOD) based on benchmark response (BMR) 1558 
factor = 1.0 for EE2-exposed RBT at 4 dph. (A) Differential expression heatmap of features with 1559 
gene-level BMD (geneBMD). (B) Representative upregulated gene-level concentration-response 1560 
curve (vtg-like). (C) Representative downregulated gene-level concentration-response curve 1561 
(alpha-1-antitrypsin-like protein CM55-ST). For B and C, the intersection of the solid red line and 1562 
blue line corresponds to the geneBMD; the red shaded area corresponds to the boundaries of the 1563 
upper (BMDu) and lower (BMDl) limits of specific geneBMD at a 95% confidence interval. 1564 
Shaded grey areas represent the 95% confidence interval. x-axis – EE2 concentration in ng/L 1565 
(figure scaled at log2Concentration); y-axis – normalized expression (logCPM). (D) 1566 
Transcriptomic PODs. Estimated concentrations at which the whole transcriptome responded to 1567 
EE2 (omicBMD): □ median of the 20 most sensitive genes (omicBMD20 = 0.18 ng/L), □ tenth 1568 
percentile of all geneBMDs (omicBMD10th = 0.78 ng/L), and □ first mode of the geneBMD 1569 
distribution (omicBMDmode = 3.64 ng/L) (Figure S6). □ Pathway-level BMD (pathBMD = 1.63 1570 
ng/L) based on the most sensitive (lowest value) bootstrapped median of constitutive geneBMDs 1571 
in that specific pathway (with at least 3 genes, using KEGG annotation database). Inset bar: 1572 
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CHAPTER4:  COMPARATIVE ANALYSIS OF TRANSCRIPTOMIC POINTS-OF-1611 
DEPARTURE (tPODs) AND APICAL RESPONSES IN EMBRYO-LARVAL FATHEAD 1612 




In Chapter 2, results suggest that embryo-larval FHM exposed to EE2 showed conserved 1615 
toxicity responses across levels of biological organization that are indicative of apical effects 1616 
typically observed in more advanced life stages. In Chapter 3, transcriptional responses from short-1617 
term ELS exposure of RBT to EE2 effectively estimated tPODs that were protective of chronic 1618 
apical effects at later life stages. Building upon these previous chapters, this chapter estimated 1619 
tPODs for FLX using short-term embryo-larval exposure of FHM. Calculated tPODs were 1620 
compared to behavioral bechmark concentrations at 4 dph and to physiological (standard length, 1621 
weight, condition factor) and survival rates at 28 dph, as well as to other apical benchmark 1622 
concentrations reported in the literature. This chapter also attempted to link significantly perturbed 1623 
gene sets/pathways from global gene expression and non-target proteomics at 4 dph to apical 1624 
responses. 1625 
Chapter 4 is currently under review (after revisions) for publication in Environmental 1626 
Pollution as Alcaraz, A.J.G., Baraniuk, S., Mikulášek, K., Park, B., Lane, T. Burbridge, C., Ewald, 1627 
J., Potěšil, D., Xia, J., Zdráhal, Z., Schneider, D., Crump, D., Basu, N., Hogan, N., Brinkmann., 1628 
M., Hecker, M. Comparative analysis of transcriptomic points-of-departure (tPODs) and apical 1629 
responses in embryo-larval fathead minnows exposed to fluoxetine. 1630 
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4.1. Abstract  1663 
Current approaches in chemical hazard assessment face significant challenges because they 1664 
rely on live animal testing, which is time-consuming, expensive, and ethically questionable.  These 1665 
concerns serve as an impetus to develop new approach methodologies (NAMs) that do not rely on 1666 
live animal tests.  This study explored a molecular benchmark dose (BMD) approach using a 7-1667 
day embryo-larval fathead minnow (FHM) assay to derive transcriptomic points-of-departure 1668 
(tPODs) to predict apical BMDs  of fluoxetine (FLX), a highly prescribed and potent selective 1669 
serotonin reuptake inhibitor frequently detected in surface waters.  Fertilized FHM embryos were 1670 
exposed to graded concentrations of FLX (confirmed at <LOD, 0.19, 0.74, 3.38, 10.2, 47.5 µg/L) 1671 
for 32 days.  Subsets of fish were subjected to omics and locomotor analyses  at 7 days post-1672 
fertilization (dpf) and to histological and biometric measurements  at 32 dpf.  Enrichment analyses 1673 
of transcriptomics and proteomics data revealed significant perturbations in gene sets associated 1674 
with serotonergic and axonal functions.  BMD analysis resulted in tPOD values of 0.56 µg/L 1675 
(median of the 20 most sensitive gene-level BMDs), 5.0 µg/L (tenth percentile of all gene-level 1676 
BMDs), 7.51 µg/L (mode of the first peak of all gene-level BMDs) , and 5.66 µg/L (pathway-level 1677 
BMD).  These tPODs were protective of locomotor and reduced body weight effects (LOEC of 1678 
10.2 µg/L) observed in this study and were reflective of chronic apical BMDs of FLX reported in 1679 
the literature.  Furthermore, the distribution of gene-level BMDs followed a bimodal pattern, 1680 
revealing disruption of sensitive neurotoxic pathways at low concentrations and metabolic 1681 
pathway perturbations at higher concentrations.  This is one of the first studies to derive protective 1682 
tPODs for FLX using a short-term embryo assay at a life stage not considered to be a live animal 1683 
under current legislations.  1684 
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4.2. Introduction 1687 
Current testing frameworks supporting chemical and environmental risk assessment (ERA) 1688 
are falling short of the global need to rapidly test the vast and ever-increasing numbers of chemicals 1689 
that are of emerging concern (Bernhardt et al., 2017).  This is particularly true for aquatic 1690 
environments that serve as sinks for most environmental contaminants.  Current toxicity testing 1691 
approaches to support ERA rely heavily on the use of live organisms, which require extensive 1692 
husbandry, are costly, and present significant ethical concerns.  Thus, the development of new 1693 
approach methodologies (NAMs) aimed at replacing, reducing and refining (3Rs) live animal 1694 
testing while increasing throughput is imperative to improve hazard assessment strategies and 1695 
regulatory decision-making.  This has led to a paradigm shift towards the use of mechanistic  data 1696 
to identify molecular and cellular events indicative of phenotypic outcomes using alternative (i.e. 1697 
in vitro and in silico) and short-term animal tests (Ankley and Edwards, 2018; Villeneuve et al., 1698 
2014).  However, many mechanistic toxicity pathway models still need to be conclusively 1699 
anchored to quantitative experimental data to fully realize the potential of these models in 1700 
regulatory risk assessment.  Additionally, most current models are based on in vitro and ex vivo 1701 
studies, which are limited with regard to their ability to quantitatively predict empirical toxicity 1702 
thresholds as they do not represent the complexity of whole organism.  1703 
A promising alternative toxicity testing approach is the use of embryonic assays combined 1704 
with mechanism-based testing strategies, particularly for prioritizing chemicals for further testing 1705 
(Basu et al., 2019).  For instance, life stages of oviparous vertebrates, such as fish, prior to 1706 
independent exogenous feeding are not considered live animals under current legislations 1707 
(Canadian Council on Animal Care, 2005; European Union, 2010; Strähle et al., 2012; UK, 1993). 1708 
However, they still express the majority of the complementary molecular features present in more 1709 
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advanced life stages.  Furthermore, the high sensitivity of the earliest life stages of fish render them 1710 
an ideal model in toxicological studies (Wheeler et al., 2014).  Thus, assessing changes in 1711 
molecular response patterns at early life stages could potentially be used as an alternative testing 1712 
strategy to support chemical hazard assessment.  Indeed, it has been recently demonstrated that 1713 
transcriptomics data from 96-hour rainbow trout embryo-alevin exposures can effectively estimate 1714 
benchmark doses (transcriptomic points-of-departure, tPODs) that are well within the range 1715 
(protective) of empirically derived chronic apical PODs from extensive live animal experiments 1716 
(Alcaraz et al., 2021a).  1717 
A model fish species of interest in chemical hazard assessment and regulatory testing is the 1718 
fathead minnow (FHM; Pimephales promelas).  FHM is a temperate freshwater fish that is native 1719 
to North America and is widely used as a model species in toxicological studies.  A recent study 1720 
exposing embryo-larval FHM to ethynylestradiol showed conserved toxicity responses across 1721 
levels of biological organization that are indicative of apical effects typically observed in more 1722 
advanced life stages (Alcaraz et al., 2021b).  Therefore, transcriptomic benchmark dose (BMD) 1723 
analysis based on early-life stage FHM could be used to estimate tPODs in support of hazard 1724 
assessment.   1725 
The objective of the present study was to develop and validate the utility of a short-term 1726 
embryo-larval FHM assay to estimate tPODs using fluoxetine (FLX) as the model chemical.   FLX 1727 
is among the most potent and commonly prescribed selective serotonin reuptake inhibitors (SSRI).    1728 
FLX is commonly found at sub-therapeutic levels ( <1 µg/L) in surface waters (Mole and Brooks, 1729 
2019) and is of significant concern in the aquatic environment due to its ability to induce 1730 
inadvertent sub-lethal effects in aquatic organisms exposed at low concentrations (Martin et al., 1731 
2020).  This neuroactive compound is known to affect reproduction, feeding, anxiety, and 1732 
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cognitive behaviors in fish (Beulig and Fowler, 2008; Brooks, 2014; Mennigen et al., 2010a; 1733 
Weinberger and Klaper, 2014).  In this study, non-targeted whole transcriptome and proteome 1734 
analyses were used to identify and characterize biological pathways that have conserved 1735 
perturbations across levels of organization.  Furthermore, morphometric, histological, and 1736 
locomotor responses were assessed to anchor and link molecular perturbations to adverse apical 1737 
outcomes.  Finally, tPODs were estimated using a recently published transcriptomic BMD 1738 
approach (Ewald et al., 2020; National Toxicology Program, 2018; Pagé-Larivière et al., 2019) 1739 
and were compared to apical BMDs derived in this study and in the literature. 1740 
 1741 
4.3. Materials and Methods 1742 
4.3.1. Fish culture and exposure conditions 1743 
 All methods involving live animals reported here were approved by the Animal Research 1744 
Ethics Board of the University of Saskatchewan (Protocol #20160090).  Adult FHM (source of 1745 
original brood stock: Aquatic Research Organisms Inc., NH, USA) were reared, maintained, and 1746 
bred in-house.   Fertilized eggs (<6 hours post-fertilization (hpf)) from multiple breeding pairs 1747 
were pooled, then randomly assigned, and distributed to different treatment groups.  The exposure 1748 
experiment was initiated by placing embryos, between late cleavage and high blastula stage, in 1749 
Petri dishes containing test solutions (Figure 4.1).  Separate Petri dishes for each end point were 1750 
established and maintained in a temperature-controlled environmental chamber and kept at 25 ± 1 1751 
oC and 16:8 light:dark cycle.  Fish were exposed to 1.75, 7 and 28 µg/L fluoxetine (FLX; Certified 1752 
reference material; Sigma-Aldrich, MO, USA) in quintuplicates for transcriptomics (20 1753 
embryos/replicate), proteomics (30 embryos/replicate) and histological/apical (30 1754 
embryos/replicate) assessments.  Furthermore, three replicate Petri dishes were subjected to 1755 
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behavioral analysis (15 embryos per replicate). To estimate transcriptomic points-of-departure 1756 
(tPODs), FHM were exposed to two additional concentrations of FLX (0.44 and 112 µg/L), in 1757 
triplicates, containing 20 embryos each, concurrently done and bracketing the above exposure 1758 
regime for transcriptomics.  For omics and behavioral analyses, embryos were reared to 7 days 1759 
post-fertilization (dpf).  For omics analyses, all larvae per replicate petri dish were pooled, flash-1760 
frozen in liquid nitrogen, and kept at -80oC.  After 7 dpf, larvae for histological and biometric 1761 
analyses were transferred to 9L glass aquaria, in a completely randomized design, containing the 1762 
same test concentrations and maintained under flow-through conditions (~3x complete water 1763 
exchanges per day) until 32 dpf, following OECD 210 (OECD, 2013).  Larvae were fed daily ad 1764 
libitum with Artemia nauplii starting 7 dpf.  Each tank was monitored daily for temperature, pH, 1765 
conductivity, and dissolved oxygen, and weekly for ammonia, nitrate, nitrite, hardness, and 1766 
alkalinity.  Surviving larvae at the end of the exposure (32 dpf) were euthanized using an overdose 1767 
of buffered tricaine methanesulfonate (150 mg/L; MS222; Sigma-Aldrich).  Whole larvae samples 1768 
for histology from each replicate were placed individually in histocassettes and fixed whole in Cal-1769 
Ex™ II Fixative/Decalcifier (Fisher Chemical™, MA, USA) for 48 hours, and then transferred to 1770 
70% ethanol for storage until further processing.  The body length and weight of each larva were 1771 
measured, and overt morphological abnormalities were qualitatively recorded during takedown by 1772 
a designated subjective observer.  Fulton’s condition factor (Froese, 2006) was calculated (Eq.1):  1773 
Fulton`s condition factor, k = 
w x 100
l3
   (1) 1774 
where: w = weight (mg) and l = length (mm)  1775 
Statistical analyses were carried out in Prism v.9.1 software (GraphPad Inc., LaJolla, 1776 
USA).  Biometric measurements and survival rates were assessed for significant differences across 1777 
treatment groups using a one-way analysis of variance (ANOVA), followed by Tukey’s multiple 1778 
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comparison post-hoc test, with a cut-off p-value < 0.05.  Outliers were removed (ROUT method, 1779 
Q = 1%) and tests for assumptions of normality and homogeneity of variance were performed prior 1780 
to ANOVA.  In cases where assumptions of ANOVA were not met, the non-parametric ANOVA 1781 
analogue, Kruskal-Wallis test, was performed, followed by Dunn’s multiple comparison test with 1782 




Figure 4.1. Study design. Exposures were initiated at <6 hours post-fertilization (hpf) by 1785 
introducing the embryos to FLX-dosed solutions in Petri dishes. Transcriptomics and proteomics 1786 
were conducted in pools of larvae sampled at 7 days post-fertilization (dpf). Histology and 1787 
biometric measurements of whole larvae were done at 32 dpf. A separate study for the locomotor 1788 
response assay was set up with the same exposure conditions. The locomotor assay was done at 7 1789 
dpf. Treatment groups/concentrations are nominal. rep = replicate 1790 
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4.3.2. Chemical analyses 1791 
Concentrations of FLX in test solutions were measured at SGS AXYS Analytical Services 1792 
Ltd (BC, Canada).  FLX was quantified following a previously described method (Long et al., 1793 
2013), with minor modifications (Appendix D1).  Briefly, FLX from water samples was extracted 1794 
by solid-phase extraction, then quantified using a Waters 2690 HPLC, equipped with Xterra MS 1795 
C18 column (Waters; 10.0 cm, 2.1 mm i.d., 3.5 µm particle size), coupled with a Micromass 1796 
Quattro Ultima MS/MS (Waters).  For exposures in Petri dishes only (0.44 and 112 µg/L FLX), 1797 
concentrations were based on the average % of nominal concentrations across all measured 1798 
concentrations in tanks because the volumes used in petri dishes were too low for analytical testing.  1799 
This was deemed an appropriate approximation of actual concentrations since the working 1800 
solutions were from serially diluted stock solutions for all treatments. 1801 
 1802 
4.3.3. Transcriptomics 1803 
Total RNA was extracted from pooled whole larvae using the RNeasy Plus Universal Mini 1804 
Kit (Qiagen, Hilden, Germany) following the manufacturer`s protocol for whole tissue total RNA 1805 
extraction.  Samples with a RIN > 8 were sent to the McGill University and Génome Québec 1806 
Innovation Centre for 200 cycles paired-end (100x2) sequencing on an Illumina NovaSeq S4 lane 1807 
(Illumina Inc, San Diego CA, USA).  RNASeq libraries were constructed following Alcaraz et al. 1808 
(2021a). 1809 
 Raw fastq files were assessed for quality using FastQC v0.11.9 (Andrews, n.d.).  Adapters 1810 
were trimmed and reads were filtered to a minimum Phred score of 20 and a minimum length of 1811 
35 bases using Trimmomatic v0.38 (Bolger et al., 2014).  Reads were aligned to the latest fathead 1812 
minnow transcriptome assembly (NCBI Acc# GCA_016745375.1; Martinson et al., n.d.) and 1813 
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counts were estimated using Kallisto 0.46.0.4 (Bray et al., 2016).  Features with less than five 1814 
counts-per-million in at least 3 samples per treatment group were filtered out.  The remaining 1815 
features were normalized by use of the relative log expression (RLE) approach (Anders and Huber, 1816 
2010).  Significance of differentially expressed (DE) transcripts were assessed using DESeq2 1817 
v1.31.18 (Love et al., 2014) and scored with a cut-off false discovery rate (FDR; Benjamini-1818 
Hochberg, BH) of ≤ 0.05 and a minimum effect size threshold fold-change |FC| ≥ 1.5 relative to 1819 
the water control group.  Default software settings were used for analyses unless otherwise stated.  1820 
Raw fastq files are available through the NCBI GEO accession# GSE179232. 1821 
 Overrepresentation analyses were conducted using ClueGo v.2.5.7 (Bindea et al., 2009) in 1822 
Cytoscape v.3.7.2 (Shannon et al., 2003).  FHM gene symbols were mapped to D. rerio Gene 1823 
Ontology (GO) databases (MF - Molecular function, BP - Biological process, and CC - Cellular 1824 
component).  Significantly dysregulated transcripts from all treatment groups were pooled and run 1825 
through ClueGo functional analysis, identifying significantly overrepresented gene sets using two-1826 
sided hypergeometric test with BH corrected p-value ≤ 0.05.  1827 
 1828 
4.3.4. Transcriptomic dose-response 1829 
Derivation of transcriptomic points-of-departure (tPOD) was conducted using FastBMD 1830 
(fastbmd.ca; Ewald et al., 2020).  Transcript count estimates were collapsed into gene-level 1831 
features and normalized using RLE strategy.  Normalized count estimates were filtered to remove 1832 
5% and 10% of all the genes with the lowest variance and abundance across treatment groups, 1833 
respectively.  Features that were unlikely to exhibit concentration-response were removed by 1834 
filtering features without significant differences across treatment groups using the limma R 1835 
package (Ritchie et al., 2015) with FDR ≤ 0.05 threshold cut-off.  A total of 2343 features passed 1836 
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the threshold and were fitted using statistical models (Exp2, Exp3, Exp4, Exp5, Linear, 2o 1837 
Polynomial (Poly2), Hill, and Power), with a threshold lack-of-fit p-value > 0.1 and a benchmark-1838 
response (BMR) factor = 1.  The benchmark-dose (BMD) analysis was conservative such that 1839 
higher-level models (Poly3 and Poly4) were not used as these models tend to overfit the datasets.  1840 
The model with the lowest Akaike information criterion (AIC) was selected for each gene.  Control 1841 
expression was set to the mean of control samples.  Individual gene-level (geneBMD), 1842 
transcriptome-level (omicBMD) and pathway-level (pathBMD) tPODs were estimated based on 1843 
previous recommendations (Ewald et al., 2020; National Toxicology Program, 2018; Pagé-1844 
Larivière et al., 2019).  tPODs for the transcriptome-level include (1) the median of the 20 most 1845 
sensitive geneBMDs (omicBMD20), the tenth percentile of all geneBMDs (omicBMD10th), and the 1846 
mode of the first peak of all gene BMDs (omicBMDmode).  pathBMD was estimated as the most 1847 
sensitive pathway based on bootstrapped median of constitutive geneBMDs of that specific 1848 
pathway, which should have at least 3 geneBMDs. 1849 
 1850 
4.3.5. Proteomics 1851 
An estimate from a separate study on early-life stage rainbow trout sub-chronic survival 1852 
assay (data not shown) showed a NOEC of 7 µg/L FLX (nominal); hence, to assure that proteomic 1853 
responses were not due to non-specific toxic responses, this concentration was selected for analysis 1854 
in this study.  Proteomics were conducted following Alcaraz et al. (2021a), with minor 1855 
modifications (Appendix D2).  Cell disruption and protein solubilization were done using SDT 1856 
lysis buffer.  The quality of protein extracts was assessed by use of 1-D SDS-PAGE (12% gels).  1857 
Protein extracts were then processed by filter-aided sample preparation (FASP) (Wiśniewski et 1858 
al., 2009; Wiśniewski and Rakus, 2014) in a 30 kDa membrane filter unit, using iodoacetamide 1859 
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(Sigma-Aldrich) for alkylation and trypsin (Sequencing grade; Promega, WI, USA) for digestion.  1860 
Cleaned and reconstituted FASP eluates were processed in an LC-MS/MS system consisting of a 1861 
Q-Exactive™ HF-X Hybrid Quadrupole-Orbitrap™ mass spectrometer (Thermo Fisher Scientific, 1862 
MA, USA) connected online to an Ultimate 3000 RSLCnano system (consisted of SRD-3400, 1863 
NCS-3500RS CAP, WPS-3000 TPL RS; Thermo Fisher Scientific). 1864 
Raw mass spectrometric data files were analyzed using MaxQuant v.1.6.15 (Cox and 1865 
Mann, 2008; Tyanova et al., 2016) with a built-in Andromeda search engine (Cox et al., 2011). 1866 
Chromatograms were characterized using the FHM proteome assembly (NCBI Acc# 1867 
GCA_016745375.1; 48,456 sequences; Martinson et al., n.d.), combined with the cRAP 1868 
contaminant database (April 2021; 246 sequences).  The first and main search were set with 1869 
carbamidomethylation (C) as fixed modification, acetyl (protein N-term), oxidation (M), oxidation 1870 
(P) and deamidation (N, Q) as optional modifications, and a maximum of two enzymes miss-1871 
cleavages.  Peptides and proteins with an FDR (q-value) < 1% and at least one razor peptide were 1872 
selected for differential abundance analyses.  All downstream differential protein abundance 1873 
analyses were done in KNIME (Berthold et al., 2008).  Protein groups (PGs) with missing 1874 
quantification values for all replicates within a treatment group were filtered out.  Datasets were 1875 
further filtered to keep PGs with 2 or more peptides, and at least two measured intensity values in 1876 
both experimental groups.  Log2-transformed PG intensities were quantile-normalized (Figure 1877 
D.S1).  The remaining missing values were imputed by the global minimum strategy.  The 1878 
significance of differentially abundant (DA) PGs was assessed using limma with a cut-off 1879 
moderated p-value of ≤ 0.05 and a minimum effect size threshold of |FC| > 1.5 relative to the 1880 
control group.  Raw data were deposited in the ProteomeXchange Consortium via the Proteomics 1881 
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Identifications (PRIDE) (Perez-Riverol et al., 2019) partner repository under accession# 1882 
PXD027024. 1883 
All significant DA proteins with at least 2 peptides identified were used in the 1884 
overrepresentation analyses as previously described (Sec 4.3.3). 1885 
 1886 
4.3.6. Correlation analysis 1887 
 Protein and transcript IDs were matched to their corresponding Entrez IDs.  Since the 1888 
number of proteins is limited by the instrument detection limit and chromatographic identification, 1889 
the list of transcripts was filtered using Entrez IDs of the leading protein in each PG.  The relative 1890 
correspondence ratios of transcript-protein pairs were then analyzed by calculating Pearson’s 1891 
correlation of transcript expression ratios from each treatment group against their respective 1892 
protein abundance ratios. 1893 
 1894 
4.3.7. Histology 1895 
Ten individual fish were randomly selected from the control, five from 7 (n=1 per 1896 
replicate), and ten from 28 µg/L FLX treatment groups (n=2 per replicate).  Whole-body samples 1897 
were dehydrated in graded alcohol concentrations, cleared in xylene, and infiltrated with molten 1898 
paraffin using a Belair RVG/1 Vacuum Tissue Processor (Histology Core Facility, University of 1899 
Saskatchewan).  The samples were then embedded in paraffin blocks for longitudinal step-1900 
sectioning in the frontal plane (5 µm thick).  Representative sections from each individual were 1901 
taken at a minimum of five different levels through the body cavity at approximately 75 µm 1902 
intervals, mounted on glass slides, and stained with Harris’ hematoxylin and eosin.  1903 
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Slides were analyzed using Axiostar Plus microscope (Carl Zeiss X-Ray Microscopy, LLC, 1904 
CA, USA), interfaced with INFINITY1-1M digital camera and Infinity Analyze v7.0.2.930 1905 
software (Teledyne Lumenera, ON, Canada). Liver sections were assessed qualitatively for 1906 
histological changes in the treated fish relative to the control group, including changes in 1907 
hepatocyte size/structure, nuclear abnormalities, staining properties (i.e., the degree of the 1908 
eosinophilic (pink) or basophilic (blue) staining of the hepatocyte parenchyma), cytoplasmic 1909 
vacuolation, or any other notable differences.  Histological features were reported as presence or 1910 
absence for individual fish, and no statistical analyses were done for biological replicates. 1911 
 1912 
4.3.8. Locomotor response assay 1913 
The locomotor response assay was conducted following a previously described protocol 1914 
(Thompson and Vijayan, 2020), with minor modifications.  Each replicate Petri dish (n=3), with 1915 
fifteen larvae each, was introduced into a purpose-made temperature-controlled behaviour box that 1916 
consisted of a visible light source, an infrared light source, and a camera, which allowed for the 1917 
observation of the larvae during the dark phases.  The dishes (one control plate and one treated 1918 
plate) were placed in the behaviour box and the light was turned on for acclimatization of larvae.  1919 
Video capture was initiated 6 minutes into the acclimatization period and continuously recorded 1920 
for the assay duration of 16 minutes.  Following 4 minutes recording under light conditions, the 1921 
light was turned off for 4 minutes, turned on for 4 minutes and the experiment finished with another 1922 
dark phase of 4 minutes.  Individual fish were simultaneously tracked within each dish using 1923 
Lolitrack 5 software (Loligo Systems, Viborg, Denmark).  Larvae were then euthanized after the 1924 
assay using an overdose (150 mg/L) of buffered MS-222. 1925 
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The average distance moved over time was calculated for each plate per 1-min period of 1926 
the experiment.  Significant effects on the distance moved in light and dark phases were assessed 1927 
using mixed-effects ANOVA (mixed-effects: lighting and concentration), followed by Dunnett‘s 1928 
multiple comparisons test.  1929 
145 
 
4.4. Results and Discussion 1930 
4.4.1. Chemical analyses and physico-chemical characteristics of exposure solutions 1931 
 Measured concentrations of FLX in exposure solutions were 36 – 48% of nominal values, 1932 
which is in accordance with observations in other studies (Hazelton et al., 2014) .  It is speculated 1933 
that the loss of FLX is due to adsorption of the chemical to the surfaces of the tanks, the possible 1934 
degradation due to the slightly basic pH of the exposure solution, and/or uptake by fish.  Treatment 1935 
groups are subsequently referred to as the measured concentrations (Table D.S1).  All physico-1936 
chemical parameters recommended by OECD 210 guidance document were met (Table D.S2), 1937 
except temperature measurements of 22.43 ± 0.65oC, which were slightly below the recommended 1938 
25 ± 1.5oC.  Nevertheless, this temperature is not expected to have affected the results of this study 1939 
as optimal breeding of parent fish was attained at 23.5 ± 1oC. 1940 
 1941 
4.4.2. Survival, biometric measurements, and histology 1942 
Survival rates were not significantly affected at 32 dpf regardless of treatment (Figure 1943 
4.2A; DataSet S1, Tab A).  This observation was expected as FLX typically causes chronic 1944 
behavioral and physiological changes at lower concentrations than what was previously observed 1945 
to cause acute toxicity (Brooks, 2014), with median lethal concentration (LC50) of 196-212 µg/L  1946 
(Stanley et al., 2007) and 705 µg/L (Brooks et al., 2003) in larval FHM.  Biometric measurements 1947 
revealed significant differences in body weight (Figure 4.2B; DataSet S1, Tab B), but not in body 1948 
length or condition factor (Figure 4.2C&D; DataSet S1, TabC&D).  Larval weight was affected 1949 
at concentrations greater or equal to 10.2 µg/L relative to the control group, and a notable 1950 
decreasing trend in body length and body weight occurred as the concentration of FLX increased, 1951 
suggesting potential effects of FLX on long-term growth.  Stanley et al. (2007) observed a similar 1952 
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trend with a significant decrease in weight occurring at FLX concentrations greater or equal to 50 1953 
µg/L.  Similarly, de Farias et al. (2020) reported a significant loss in weight gain in adult zebrafish 1954 
exposed to 100 µg/L FLX for 30 days.  FLX is known to have anorectic effects in fish (Dorelle et 1955 
al., 2020; Weinberger and Klaper, 2014), leading to weight loss.  This effect had been associated 1956 
with the interaction of FLX with the serotonin target, disrupting metabolic processes (Mennigen 1957 
et al., 2010b) and causing changes in the abundance of anorexigenic neuropeptides, resulting in 1958 
reduced appetite and locomotion impairment, which could lead to reduced food intake and growth 1959 
impairment (Groh et al., 2015). 1960 
Notable histological treatment-associated effects were absent in the liver tissues (Figure 1961 
D.S2).  This observation contrasts previously observed FLX-induced histological alterations 1962 
(decreased hepatocyte vacuolation, blood vessel rupture, atypia, hyperemia, and hepatic cord 1963 
disarrangement) in adult zebrafish at concentrations as low as 0.01 µg/L FLX (de Farias et al., 1964 
2020).  However, normal hepatocyte proliferative activity was observed in livers of embryonic 1965 
zebrafish exposed to 10 µg/L FLX for 96 hours, suggesting no significant changes in liver histo-1966 
structure (Nowakowska et al., 2020).  These varied observations suggest that the histological 1967 




Figure 4.2. Biometric profiles and survival rates of FHM exposed to FLX at 32 dpf. (A) Survival 1970 
rates, (B) body weight, (C) standard length, and (D) condition factor, K of control, 0.74, 3.38, and 1971 
10.2 µg/L FLX treatment groups. These four treatment groups were reared to 32 dpf as these 1972 
concentrations were expected to trigger biological effects but not mortality due to overall non-1973 
specific systemic effects. For B, C, and D, individual points correspond to average measurements 1974 
within tank (biological replicate; ~30 surviving larvae per replicate). For all graphs, line and error 1975 
bars represent mean ± standard deviation (of biological replicates). 1976 





























































































4.4.3. Locomotor response 1977 
 The locomotor response assay during the dark phase revealed distinct preference of FLX-1978 
exposed larvae towards the edges of the plate, in contrast to the preference of the control larvae to 1979 
remain in the middle of the plate (Figure 4.3A).  This observation disagrees with previously 1980 
observed wall-seeking behaviour bias (thigmotaxis) of untreated zebrafish, regardless of age 1981 
(Colwill and Creton, 2011).  In another study, no effects of FLX treatment (control vs 200-2000 1982 
µg/L) was observed on zebrafish behaviour; however, all fish showed edge preference 1983 
(Richendrfer et al., 2012) similar to the thigmotaxis behaviour of FLX-treated fish in this study.   1984 
 Increased movements were observed during the first dark phase in all treatment groups, 1985 
then gradually decreasing into a steady state in the subsequent light and dark phases (Figure 4.3B).  1986 
The locomotor behaviour of untreated larvae was comparable with previously observed locomotor 1987 
responses in untreated larval zebrafish where baseline activity was higher during the dark phase, 1988 
but in contrast with untreated larval FHM where baseline activity was higher at light phase (Lovin 1989 
et al., 2021; Steele et al., 2018).  Moreover, average distance moved by larvae exposed to 0.74 1990 
µg/L appeared lower while 3.38 and 10.2 µg/L were higher relative to the control group, suggesting 1991 
inhibitory locomotor effects of FLX at lower concentrations and stimulatory effects at higher 1992 
concentrations.  However, the variance was mainly due to lighting and not due to the interaction 1993 
of lighting and treatment nor treatment alone (Figure 4.3C; DataSet S2, Tab A).  When grouped 1994 
per treatment, distance moved at 10.2 µg/L was significantly higher relative to control (p = 0.03; 1995 
Figure 4.3D; DataSet S2, Tab A).  In zebrafish, total swimming distance was significantly lower 1996 
after exposure to ≥ 15.8 µg/L FLX (de Farias et al., 2019).  While edge preference and the extent 1997 
of (increased vs. decreased) distance moved might have been different compared to those 1998 
previously described in the literature, significant changes in locomotor responses in this study 1999 
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nevertheless suggest anxiolytic effects of FLX at 10.2 µg/L confirming effects on behaviour that 2000 




Figure 4.3. Locomotor responses at 7 dpf after exposure to FLX. (A) Heatmap of larval frequency 2003 
detection in the exposure dish (water control and 10.2 µg/L FLX are shown in the left and right 2004 
panel, respectively). The scale shows relative time spent of larvae in an area (Red – high frequency; 2005 
white – low frequency). (B) Effects of fluoxetine on distance larvae moved throughout the light 2006 
(white areas) and dark (shaded areas) phases in one-minute increments. (C) Distance moved 2007 
throughout the light (white areas, 4-minute intervals) and dark (shaded areas, 4-minute intervals) 2008 
phases (mixed-effects model with Dunnett`s post-hoc test, p ≤ 0.05) (D) Distance moved 2009 
throughout the light (white bars, 4-minute intervals) and dark (dark bars, 4-minute intervals) 2010 
phases, grouped according to treatments. There were n = 3 replicate dishes per treatment group, 2011 
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4.4.6. Transcriptomics 2014 
Transcriptomics analyses showed 308, 159, 18, 22, and 370 DE transcripts after treatment 2015 
of embryos with 0.19, 0.74, 3.38, 10.2, and 47.5 µg/L FLX (Figure 4.4).  Only two DE transcripts 2016 
were detected across all treatment groups (upregulated): an uncharacterized transcript 2017 
(LOC120467989) and receptor-type tyrosine-protein phosphatase H-like transcript variant 2018 
(LOC120475838; ptprh gene ortholog).  In humans, ptprh is primarily expressed in brain and liver 2019 
and is predicted to be involved in a multitude of cellular processes as a member of the protein-2020 
tyrosine phosphatase family, although there have been no reports directly associating ptprh to 2021 
SSRIs.  For LOC120467989, BLAST pairwise alignment revealed that this feature is an 2022 
uncharacterized transcript variant in most phylogenetic relatives of FHM, with the closest 2023 
predicted identity of RING (Really Interesting New Gene) finger protein 6-like in T. trachurus, 2024 
which similarly has not been previously associated with SSRIs.  Regardless, the consistently high 2025 
expression of these transcripts following FLX exposure merits a closer investigation in future 2026 
studies.  2027 
Larvae exposed to 3.38 and 47.5 µg/L FLX had the least and greatest number of 2028 
dysregulated transcripts, respectively.  The 47.5 µg/L and 0.19 µg/L treatment groups had the 2029 
greatest number of common dysregulated transcripts (100 transcripts), the directions of which were 2030 
relatively similar.  GO terms of common transcripts included those associated with regulation of 2031 
behaviour and molecular transport.  It should be noted, however, that the number of dysregulated 2032 
genes or transcripts does not necessarily translate into a more intense downstream perturbation.  It 2033 
could also mean that early systemic responses consisting of multiple cellular processes were 2034 
activated to counter toxic insults; in fact, hormetic effects of FLX have been previously observed 2035 
in fish and Daphnia (Campos et al., 2013; Lopes et al., 2020).  Instead of the number of 2036 
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dysregulated genes, the level of dysregulation of molecular features could indicate the severity of 2037 
overall organismal responses.  Interestingly, none of the expected transcripts coding for common 2038 
FLX-targets were found dysregulated such as 5-hydroxytryptamine transporter (slc6a4), 2039 
corticotropin-releasing hormone (crh), cocaine and amphetamine-regulated transcript (cart), and 2040 
neuropeptide Y (npy), among others.  Notably, these peptides are typically found in specific 2041 
regions of the central nervous system (CNS); thus, their expression might have been significantly 2042 
diluted by those of other genes expressed throughout other tissues present in whole body samples, 2043 
given the relatively small proportion of CNS-associated gene expression in analyzing whole body 2044 
tissue transcriptomics.  Furthermore, CNS-related systems are more likely to be under rapid 2045 
development in embryos, which may result in limitations with regard to the detection of possible 2046 
affected genes in these regions.  Nevertheless, while the differential expression of transcripts 2047 
coding for common FLX-target neuropeptides might have been below detection, small 2048 
perturbations in the CNS could trigger a cascade of reactions to other signalling processes, leading 2049 
to amplified downstream responses that can be attributed to FLX, albeit indirectly.  Transcripts 2050 
coding for variants of synaptosome-associated and other synaptic proteins such as synapsin, 2051 
synaptoporin, and synaptopodin, were significantly dysregulated in multiple treatment groups.  2052 
Still, the limitations on the detection of tissue-specific or localized gene expression present 2053 
challenges in the use of whole-body tissue transcriptomics in identifying specific molecular events, 2054 
which can trigger downstream molecular responses. 2055 
ClueGo mapped 75.35% (486/645) of significantly dysregulated FHM transcripts to D. 2056 
rerio, 94.86% (461) of which were functionally annotated in GO.  There were 35 clusters 2057 
composed of 130 significantly overrepresented GO terms (Figure D.S3A).  A significant 2058 
proportion of these overrepresented terms were associated with axonal and synaptic ontologies 2059 
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(Figure S3B).  These results agree with the fact that FLX acts by blocking the membrane 2060 
transporter, which reduces the reuptake of serotonin from nerve synapses.  FLX has also been 2061 
shown to disrupt axonal growth and maturation in developing zebrafish, affecting the neural 2062 
ontogeny of spontaneous swimming activity (Airhart et al., 2007).  This is also in concordance 2063 
with findings in rats, where perinatal exposure to FLX similarly disrupted chemoarchitectural and 2064 
electrophysiological brain features, causing neurobiological and behavioral consequences 2065 
(Simpson et al., 2011).  In addition, there were significant perturbations in several gene sets 2066 
associated with bone development.   This may result in skeletal development impairment, similar 2067 
to previously observed compromised embryonic bone development in SSRI-exposed zebrafish 2068 
(Fraher et al., 2016).  In general, while significant dysregulation of immediate FLX-target genes 2069 
such as the serotonin receptor were not observed, significant dysregulation of other associated 2070 
genes and gene sets indicated downstream serotonergic effects of FLX.2071 
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  2072 
Figure 4.4. UpSet plot of significantly dysregulated transcripts from FLX-exposed FHM at 7 dpf.2073 
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4.4.5. Proteomics 2074 
 Proteomics analysis detected 4116 PGs, 407 of which showed significant differences in 2075 
abundance.  Differentially abundant PGs were consisted of 982 protein IDs (identified with at least 2076 
2 peptides), corresponding to 481 unique protein products (DataSet S4A).  This suggests that there 2077 
were multiple protein isoforms/variants coming from the same gene.  Similar to the results of the 2078 
transcriptomic analysis, common FLX-target neuropeptides were not differentially abundant.  2079 
Several synaptic proteins such as synaptotagmin, syntaxin, and calcium/calmodulin-dependent 2080 
protein kinase were significantly dysregulated suggesting different responses among protein 2081 
variants, which suggests that these protein variants have diverse functions.  However, the direction 2082 
of dysregulation of these proteins was not consistent.  Of the 481 protein products, 372 were 2083 
functionally annotated in GO, forming 40 clusters of 127 significantly overrepresented GO terms 2084 
(Figure D.S4; DataSet S4B).  These clusters include proteins associated with synaptic assembly, 2085 
intra- and intercellular transport, metabolic processes, and structural 2086 
differentiation/morphogenesis, among others, many of which have previously been observed to 2087 
respond to FLX exposure.  For instance, FLX disrupted synaptic assembly and activity due to 2088 
suppression of growth of vertebrate and invertebrate neurons (Xu et al., 2010).  In addition, a study 2089 
on FLX-induced morphogenesis of mouse embryoid bodies revealed serotonin signaling-2090 
independent teratogenic effects of FLX (Warkus and Marikawa, 2018); instead, these effects were 2091 
due to disruption of canonical Wnt signaling.  Lastly, waterborne exposure to sub µg/L FLX has 2092 
been observed to significantly affect metabolism in goldfish (Mennigen et al., 2010b), similar to 2093 




4.4.6. Correspondence of molecular features 2096 
 There was no concordance (r < |0.03|, p >>> 0.05) between transcript expression ratios 2097 
from any of the treatment groups and protein abundance ratios.  There were 18 common features 2098 
(based on gene symbols) between all dysregulated transcripts and proteins (Figure 4.5A; Table 2099 
D.S3), although none of these had been previously associated specifically with FLX.  This may 2100 
suggest that these features may be involved in non-specific responses that were triggered in the 2101 
presence of external challenges.  For example, a number of these features are involved in 2102 
inflammatory responses.  Protein and mRNA abundance have been shown to have moderate 2103 
similarity in certain cases such as sturgeons exposed to dioxin-like compounds (Doering et al., 2104 
2016) and disease-state in cancer studies (Tang et al., 2018).  There is an implicit assumption that 2105 
the biological implications of mRNA expression is mediated by its translation to its cognate 2106 
proteins; however, genome-wide correlation between the abundances of mRNA and proteins is 2107 
generally poor, owing to a variety of relevant regulatory mechanisms occurring between transcripts 2108 
and protein products (Maier et al., 2009; Vogel and Marcotte, 2012).  The study reported here 2109 
provides further evidence of these generally weak concordance patterns.  One of the objectives of 2110 
looking into the relative concordances of mRNA and protein expression was to identify potentially 2111 
robust features/biomarkers which were sensitive enough to be detected at both ‘omics levels.  This 2112 
would suggest a rapid and direct translation of mRNA to protein products given the short exposure 2113 
duration.  Interestingly, combined overrepresentation analysis showed that DE transcripts and DA 2114 
proteins were complementary with regards to the characterization of overrepresented GO terms 2115 
(Figure 4.5B) that could have been missed if analyzed separately, suggesting that there were 2116 
interactions and feedback loops among these features at different molecular levels.  This 2117 
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observation highlights the value of comparing and integrating multiple molecular features in 2118 
identifying relevant molecular processes associated with an external stimulus. 2119 
 Proteins are considered the fundamental effectors of biological processes, but current 2120 
sensitivities of methods and instrumentation in non-targeted proteomics limit its utilization in some 2121 
applications, such as that in quantitative hazard characterization, in contrast to mRNA sequencing. 2122 
The limited number of proteins identified also has implications in the statistical characterization 2123 
of overrepresented terms and pathways where background domains are typically the whole 2124 
reference proteome.  In this study, less than 10% of proteins in the FHM proteome assembly were 2125 
identified, which might have resulted in a lesser number of GO terms passing threshold.  Currently, 2126 
it appears that the sensitivity of non-target proteomics methods has limited applications in 2127 
quantitative hazard assessment, but is nevertheless essential in supplementing the biological 2128 
interpretation of molecular processes.  Until the methods and sensitivity of non-target proteomics 2129 
mature further and are more fully developed, quantitative molecular hazard assessment will have 2130 
to rely on the assumption that differential mRNA expression translate into functional differences 2131 




Figure 4.5. Combined transcriptomics and proteomics analyses. (A) Venn diagram of features 2134 
from differentially expressed (DE) transcripts and differentially abundant (DA) proteins. (B) 2135 
Overrepresentation analyses of combined significantly DE transcripts from all FLX treatment 2136 
groups and DA proteins from 3.38 µg/L using gene ontologies (GO: molecular function, biological 2137 
process, cellular component) from D. rerio as reference set. Statistical test was done using two-2138 
sided hypergeometric test with p-value cut off <0.05 followed by Benjamini-Hochberg correction 2139 
for multiple testing (FDR < 0.05) and a kappa score = 0.04. Yellow nodes are based on DE 2140 
transcript, blue nodes are based on DA proteins, while gray nodes are terms where DE transcripts 2141 
and DA proteins both contribute. GO parent-child terms based on similar associated genes were 2142 
fused (GO Fusion). Nodes were set with a minimum of 3 genes or 4% of genes in a term. Size of 2143 
the nodes reflects the statistical significance of the terms. Clustering reflects the relationships 2144 
between the terms based on the similarity of their associated genes. Group leading term is the most 2145 
significant term of the cluster. 2146 
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4.4.7. Transcriptomic points-of-departure and their implications to risk assessment 2147 
The transcriptomic BMD probability distribution curve exhibited a bimodal response 2148 
(Figure 4.6).  At lower concentrations, FLX-responsive genes appeared to be primarily involved 2149 
in pathways associated with neurotoxic responses. Higher concentrations corresponded to 2150 
metabolic pathways, although neurotoxic responses were still apparent (DataSet S6A).  This 2151 
bimodal response might explain the variability of reported potencies of FLX, with effective 2152 
concentrations ranging from sub-µg/L to mg/L concentrations, depending on the measured 2153 
endpoint.  In this study, neurotoxic (locomotor response) and metabolism-associated (lower body 2154 
weight in treated group) apical responses were significantly different relative to the control group, 2155 
both at 10.2 µg/L FLX.  2156 
Benchmark dose analysis showed tPOD values that were more sensitive than observed 2157 
apical LOECs in this study.  Concentration-response patterns of most features converged following 2158 
the Poly2 model (Figure DS5), resulting to a total of 2298 genes with a fitted model and 2153 2159 
genes with BMDs (DataSet S6B).  Transcriptome-wide BMD analysis (Figure 4.6) estimated 2160 
tPODs as (1) the median of the 20 most sensitive genes (omicBMD20) = 0.56 µg/L FLX, (2) the 2161 
tenth percentile of all geneBMDs (omicBMD10th) = 5.0 µg/L FLX, and (3) the first mode of the 2162 
geneBMD distribution (omicBMDmode) = 7.51 µg/L FLX.  While omicBMD20 and omicBMD10th 2163 
appeared to be the most sensitive tPODs, these values were based mainly on the most conservative 2164 
and stable tPOD calculations and were independent of genome annotation (Pagé-Larivière et al., 2165 
2019), and therefore, should be interpreted with caution with regard to downstream biological 2166 
implications.  On the other hand, omicBMDmode was less sensitive than the other tPOD estimates; 2167 
however, this value typically infers a specific mode of action (MOA) that is potentially biologically 2168 
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relevant compared to omicBMD20 and omicBMD10th and therefore, can be used to guide the 2169 
elucidation of the compound’s MOA. 2170 
The pathway-level BMD was 5.66 µg/L (pathBMD), calculated based on the bootstrapped 2171 
median of constitutive geneBMDs of vasopressin-regulated water reabsorption pathway, the most 2172 
sensitive (lowest pathBMD value) pathway with at least 3 geneBMDs altered by exposure to FLX.  2173 
Vasopressins are neuropeptides influencing water reabsorption in the kidneys, suggesting possible 2174 
modulation in renal processes, similar to those observed in the inner medullary collecting duct in 2175 
kidneys of rats exposed to FLX (Moyses et al., 2008).  The PI3K-Akt signaling pathway had the 2176 
highest number of constitutive geneBMDs, with 44 features exhibiting concentration-dependent 2177 
responses.  FLX has been previously implicated in the regulation of glucolipid metabolism in rats 2178 
through the PI3K-Akt signaling pathway.  However, these pathways should be interpreted with 2179 
caution with regard to predicting potential apical responses induced by FLX.  While these 2180 
pathways may be considered the most sensitive in the context of transcriptomic BMD, one should 2181 
bear in mind that these are not necessarily statistically enriched, but merely based on a minimum 2182 
of three genes, as recommended by NTP (National Toxicology Program, 2018).  It should be noted 2183 
that the purpose of estimating tPODs is to identify the dose or concentration that may potentially 2184 
perturb biology; characterizing apical responses due to these molecular perturbations is secondary 2185 
(National Toxicology Program, 2018; Pagé-Larivière et al., 2019), although this would be an 2186 
important addition to support the weight-of-evidence for regulatory acceptability. 2187 
A limited literature search revealed that, to date, there have been very few alternative (e.g. 2188 
in vitro or ex vivo) testing methodologies utilized successfully to quantitatively assess the potential 2189 
hazards associated with FLX exposure in fish.  For example, a fish hepatoma cell PLHC-1 2190 
cytotoxicity assay reported an EC50 of 6.34 mg/L for FLX (Caminada, 2008), which is several 2191 
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orders of magnitude greater than previously reported threshold concentrations in in vivo studies. 2192 
Although, it is acknowledged that several studies on early-life stage fish have been conducted to 2193 
assess key responses to FLX, which may be used to estimate its apical POD, these studies were 2194 
mechanistic in nature, needed prior knowledge of specific mechanism(s) of action, and would 2195 
require more tedious methodology to quantitatively derive a POD (Bidel et al., 2016; Cunha et al., 2196 
2018; de Farias et al., 2019).  Limited availability of alternative tests for objectively and reliably 2197 
assessing the toxicity of FLX may be due to the fact that serotonergic signaling is best known for 2198 
neural activity and is mainly localized in the CNS, although serotonin regulates numerous 2199 
biological processes outside the nervous system (reviewed in Berger et al., 2009).  A considerable 2200 
range of effect-concentrations  (EC) and hazard concentrations (HCx) of FLX have been reported 2201 
in the literature, from sub-ng/L to mg/L, corresponding to behavioral responses, biochemical 2202 
endpoints, and biometric measurements (Beiras and Schönemann, 2021; de Farias et al., 2019; 2203 
Kumar et al., 2016).  This apparent variable potency of FLX is due to considerable limitations of 2204 
existing studies, including “artifacts” of low dose effects, lack of proper replication, and non-2205 
standard endpoints, which all resulted in the current status of non-consensus for water quality 2206 
guidelines for FLX (Sumpter et al., 2014).  Nevertheless, estimated tPODs in this study appeared 2207 
to be more sensitive than most apical PODs, and thus, we propose they can be considered 2208 
protective towards chronic effects of FLX.  2209 
This study showed that while there are remaining challenges concerning the 2210 
characterization of tissue-specific or localized gene targets and/or molecular initiating events using 2211 
the short-term FHM embryo-larval assay, our approach could successfully characterize molecular 2212 
pathways and mechanisms of action linked to apical outcomes.  Furthermore, the strategy featured 2213 
in our study represents one of the most sensitive alternative testing methods to date that has 2214 
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successfully estimated tPODs comparable to the most sensitive empirically derived apical 2215 
benchmark concentrations without the use of live animals beyond the stage of independent 2216 
exogenous feeding.  Thus, tPODs from the 7-day embryo-larval FHM assay present a significant 2217 
promise to replace labor-intensive, time-consuming, and expensive adult fish tests.  Accordingly, 2218 
it appears to serve as a superior alternative to in vitro NAMs that would still require additional 2219 
tiers of assessment factors to derive PODs that are protective of chronic apical responses.  Future 2220 
studies should be directed towards further development and validation of this testing strategy by 2221 
using other compounds that project toxic insults by means of other mechanisms.  Lastly, there is a 2222 
need to evaluate the relative sensitivity of this approach across species to assess its utility in 2223 







Figure 4.6. Transcriptome-wide points-of-departure (tPOD) in 7 dpf embryo-larval fathead 2227 
minnows exposed to FLX (scaled at log2Concentration). □ median of the 20 most sensitive genes 2228 
(omicBMD20 = 0.56 µg/L), □ tenth percentile of all geneBMDs (omicBMD10th = 5.00 µg/L), and 2229 
□ first mode of the geneBMD distribution (omicBMDmode = 7.51 µg/L). □ Pathway-level BMD 2230 
(pathBMD = 5.66 µg/L) based on the lowest bootstrapped median of constitutive geneBMDs in 2231 
that specific pathway (using KEGG annotation database). Inset bar: □ individual geneBMDs 2232 
involved in the most sensitive pathBMD (vasopressin-regulated water reabsorption pathway). 2233 
Inset figure: normal-scale histogram with probability density plot (blue line) showing bimodal 2234 
curve. Bin-width is set to ℎ = 2
IQR(x)
∛𝑛
, following the Freedman-Diaconis rule, where h = bin width, 2235 
n = number of observations, and IQR(x) = interquartile range. Probability density plot was 2236 
truncated at zero concentration.2237 
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CHAPTER 5: TRANSCRIPTOMIC POINTS-OF-DEPARTURE (tPODs) IN THREE 2282 
PHYLOGENETICALLY DISTANT FISHES: CASE STUDIES FOR 17α-2283 




This chapter concludes and synthesizes the research undertaken in this thesis for the 2286 
derivation of protective tPODs using ELS exposure models of phylogenetically diverse fishes. 2287 
Here, I expanded the work reported in Chapters 3 and 4 by deriving tPOD estimates for EE2 and 2288 
FLX from ELS of the endangered WS, as well as from ELS of RBT exposed to FLX and FHM 2289 
exposed to EE2. Hence, datasets used in this Chapter were comprised of original datasets and  2290 
datasets previously used in Chapters 2 - 4. tPODs (the median of the benchmark concentrations 2291 
(BMC) of the 20 most sensitive active genes, the BMC of the tenth percentile of all active genes, 2292 
the BMC of the first mode of all active genes, and the median of the BMCs of constitutive active 2293 
genes of the most sensitive pathway) were qualitatively compared to identify the most conservative 2294 
estimation approach within and across species. Current limitations of these approaches were also 2295 
discussed. 2296 
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5.1. Abstract 2318 
There is urgent need for developing new approach methods (NAMs) to make chemical 2319 
hazard assessment more efficient and reduce the use of live animals in toxicity testing. This study 2320 
aimed to derive transcriptomic points-of-departure (tPODs) from short-term embryo-larval/alevin 2321 
exposure studies with three phylogenetically distant ray-finned fishes to two contaminants of 2322 
concern.  tPODs were then compared to apical benchmark concentrations described in the 2323 
literature. Embryos of white sturgeon (WS), rainbow trout (RBT), and fathead minnow (FHM) 2324 
were exposed to graded concentrations of 17α-ethinylestradiol (EE2) and fluoxetine (FLX) until 2325 
four days post-hatch and subjected to mRNA sequencing. Transcriptomic benchmark 2326 
concentration (BMC) analyses yielded tPOD estimates that closely approximated apical PODs 2327 
found in the literature. tPOD estimates for the median of the 20 most sensitive gene BMCs 2328 
(omicBMC20) were the most protective estimates across species and across chemicals, while 2329 
annotation-dependent tPOD estimate derived from pathway enrichment analyses (pathBMC) 2330 
appeared to be less sensitive. tPODs from RBT were the most protective for both EE2 and FLX, 2331 
while FHM was the least sensitive species, but all estimates were within the range of reported 2332 
apical PODs. This study highlighted that, despite some remaining uncertainties, tPODs derived 2333 
from short-term embryo-larval/alevin exposures were protective of apical PODs and therefore 2334 
show significant promise as a NAM to support chemical hazard assessment and regulatory decision 2335 
making.  2336 
Keywords: white sturgeon; rainbow trout; fathead minnow; benchmark concentration (BMC); 2337 
animal alternative; toxicogenomics  2338 
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5.2. Introduction 2339 
Current approaches in chemical hazard assessment require extensive live animal testing, 2340 
which is of significant ethical concern and relies on expensive and time-consuming methodologies. 2341 
Such issues present major limitations in evaluating the hazards of the thousands of chemicals of 2342 
emerging concern (CEC) that are generated, used, and released by society. CECs include 2343 
pharmaceuticals and personal care products, brominated flame retardants, nanomaterials, and 2344 
microplastics, among others. These chemicals are of particular concern as they are continuously 2345 
discharged into surface waters through effluents of municipal wastewater treatment plants where 2346 
they can impact non-target organisms (Patel et al., 2019; Sehonova et al., 2018). Thus, there is an 2347 
urgent need to develop innovative approaches that would improve (reduce the use of live animals 2348 
and decrease costs) and accelerate chemical testing strategies to support environmental risk 2349 
assessment (ERA) of and regulatory decision-making for CECs. 2350 
Recent years have witnessed the onset of a paradigm shift and growing global efforts 2351 
towards the use of new approach methodologies (NAMs) that aim to streamline chemical hazard 2352 
assessment and reduce the use of live animals (Kavlock et al., 2018; Krewski et al., 2020). One of 2353 
the featured approaches is the development of mechanistic toxicity models to identify molecular 2354 
and cellular events that lead to adverse apical outcomes of regulatory relevance (Ankley et al., 2355 
2010; Villeneuve et al., 2014). Traditionally, the development of toxicity pathway models has 2356 
relied on in silico (Brinkmann et al., 2014), in vitro (Doering et al., 2020), and ex vivo (Rahman 2357 
et al., 2020) studies. Indeed, some of these models have proven successful in predicting 2358 
downstream effects of specific molecular key events (Doering et al., 2018). However, many of 2359 
these approaches are limited in estimating apical toxicity thresholds as they do not represent the 2360 
complex interactions occurring within an organism after a toxic insult; hence, there are still gaps 2361 
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in the predictive capability of these models as they need to be anchored quantitatively to relevant 2362 
apical outcomes to fully realize their translational capability in regulatory ecotoxicology.  2363 
Recently, the use of molecular approaches involving embryonic life stages has shown great 2364 
promise in estimating chronic apical threshold concentrations in fish (Alcaraz et al., 2021a, 2365 
submitted).  The approach utilized a toxicogenomic benchmark concentration (BMC) method for 2366 
estimating transcriptomic points-of-departure (tPODs) from exposures at embryo/early alevin 2367 
stages of fish.  This approach has the advantages of (1) using the most sensitive stages in the fish 2368 
life cycle that already express the majority of molecular features characteristic of adult fish, (2) 2369 
utilizing a life stage prior to independent exogenous feeding, which is not considered a live animal 2370 
under current legislations (Canadian Council on Animal Care, 2005; European Union, 2010; 2371 
Strähle et al., 2012; UK, 1993), (3) featuring short-term (4-7 day) exposures being relatively less 2372 
labor and resource-intensive, and (4) allowing the interrogation of the full suite of transcriptomic 2373 
responses without a priori knowledge of a chemical’s mechanism of action (MOA).   2374 
While there is an increasing number of studies that apply toxicogenomics in support of 2375 
chemical hazard assessment in fishes, most studies conducted so far utilized a few select model 2376 
fish species such as zebrafish (Danio rerio), fathead minnow (Pimephales promelas) or medaka 2377 
(Oryzias latipes/O. melastigma) (Caballero-Gallardo et al., 2016; Martyniuk et al., 2020).  2378 
However, these species do not assure protection towards the plethora of native species of interest 2379 
in natural ecosystems, and which represent the ultimate protection goal. Thus, there is a need to 2380 
evaluate the utility of this approach across different fishes belonging to phylogentically distant 2381 
families, particularly those that cannot be used in routine toxicity testing. 2382 
 The main objective of this study was to derive tPODs from three phylogenetically distant 2383 
ray-finned fish species – a cyprinid, a salmonid, and an acipenserid (sturgeon) – at the embryo-2384 
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larval/alevin stages, using two CECs, 17α-ethinylestradiol (EE2) and fluoxetine (FLX). EE2 is a 2385 
synthetic estrogenic compound frequently used as a contraceptive while FLX is one of the most 2386 
highly prescribed selective serotonin reuptake inhibitors (SSRI). These compounds are found in 2387 
surface waters and their toxicities are well described in the literature (reviewed in Brooks, 2014 2388 
and Laurenson et al., 2014), and therefore, there is a wealth of information on their respective 2389 
MOAs and empirically derived apical PODs across several fish species are available to anchor and 2390 
compare tPODs. Specifically, this study aimed to assess the potential of tPODs from embryo-2391 
larval/alevin fish exposure in estimating protective apical thresholds reported in the literature from 2392 
CECs acting through distinct mechanisms and whether these estimates were protective across 2393 
species. This study builds upon previous reports (Alcaraz et al., 2021a; Alcaraz et al., submitted; 2394 
Chapters 2-4) on the use of the whole transcriptome BMC approach in estimating tPODs from 2395 
short-term early life stage fish exposures.  2396 
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5.3. Materials and Methods 2397 
This study used transcriptomic datasets that were generated using RNASeq from three 2398 
phylogenetically distant fish species exposed to EE2 and FLX until four days post-hatch (dph).  2399 
These datasets represent a combination of original studies and metadata from previously published 2400 
work (Table E.S1) (Alcaraz et al., 2021a, 2021b, submitted; Chapters 2-4).  All experiments were 2401 
approved by the Animal Research Ethics Board of the University of Saskatchewan (Protocol No. 2402 
20070049 and 20140079) and the use of the endangered white sturgeon was permitted through the 2403 
Species at Risk Act Permit No. 16-PPAC-00002). 2404 
 2405 
5.3.1. Summary of experimental design and exposure conditions  2406 
Exposure experiments were performed according to the seasonal availability of fish 2407 
embryos.  FHM and RBT exposure experiments were conducted at the Aquatic Toxicology 2408 
Research Facility while WS exposures took place at the Fish Quarantine Facility, Laboratory 2409 
Animal Services Unit (all University of Saskatchewan).  All fish were exposed to similar (nominal) 2410 
ranges of five serially diluted concentrations of 17α-ethinylestradiol (EE2; >98% purity, Sigma 2411 
Aldrich, MO, USA), with 0.01% DMSO as solvent control, and five serially diluted concentrations 2412 
of fluoxetine (FLX; Certified reference material; Sigma Aldrich), with filtered facility water as 2413 
control (Table 5.1). During the exposure experiments, test solutions were monitored for 2414 
temperature, pH, conductivity, dissolved oxygen, ammonia, nitrates, nitrites, hardness, and 2415 
alkalinity. The studies described here were parts of longer experiments (60 dph for RBT, 28 dph 2416 
for FHM, 60 dph for WS), similar to those previously reported (Alcaraz et al., 2021a, submitted). 2417 
General fish health status and other observations were noted daily, and survival rates were 2418 
monitored throughout the duration of the individual studies. 2419 
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Table 5.1. Summary of test concentrations for EE2 (in ng/L) and FLX (in µg/L) studies. All 2420 
working solutions for the EE2 study were prepared with a final concentration of 0.01% DMSO. 2421 
All working solutions for the FLX study were prepared using filtered facility water. Measured 2422 
concentrations were expressed as the mean of measurements from multiple timepoints across all 2423 
replicates. 2424 
17α-ethinylestradiol (ng/L) † 
white sturgeon rainbow trout‡ fathead minnow 
nominal measured nominal measured nominal measured 
0 < 0.01 0 < 0.01 0 < 0.01Δ 
1 0.36 1 1.13 1 1.07 
3 1.47 3 1.57 4 4.27 
10 8.85 10 6.22 10 10.67 
30 24.99 30 16.34 20 23.46Δ 
100 73.95 100 55.10 100 95.99Δ 
Fluoxetine (µg/L) * 
white sturgeon rainbow trout fathead minnow⁋ 
nominal measured nominal measured nominal measured 
0 0 0 0 0 0 
0.44 0.09 0.44 0.09 0.44 0.19 
1.75 0.37 1.75 0.37 1.75 0.74 
7 1.83 7 1.83 7 3.38 
28 11.56 28 11.56 28 10.2 
112 107.51 112 107.51 112 47.5 
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† 0.01% DMSO as solvent control 2425 
* facility water/ no solvent used 2426 
‡ from Alcaraz et al., 2021a 2427 
Δ from Alcaraz et al., 2021b 2428 
⁋  from Alcaraz et al. (submitted) 2429 
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5.3.1.1. White sturgeon 2430 
WS eggs were sourced from the Nechako White Sturgeon Conservation Centre 2431 
(Vanderhoof BC, Canada). Gametes were obtained from five males and five female wild-caught 2432 
WS, and fertilized ex vivo. Fertilized eggs were then reared in McDonald-type jars and brought to 2433 
the University of Saskatchewan fish quarantine facility for exposure experiments. Exposures 2434 
commenced after first signs of hatching by transferring 40 unhatched eggs into aerated 1-L jars 2435 
with exposure solution, in triplicates per treatment group. Exposures were maintained at 14 ± 1 oC 2436 
and a 16:8 light:dark cycle,  under static-renewal condition (at least 75% v/v renewal twice per 2437 
day to maintain water quality) for 4 days. After 4 days post-hatch (dph), pools of three yolk-sac 2438 
larvae were collected from each tank, flash-frozen in liquid nitrogen, and kept at -80oC until further 2439 
processing for transcriptomic analysis.  2440 
 2441 
5.3.1.2. Rainbow trout 2442 
RBT exposure experiments were previously described in Alcaraz et al. (2021a). Briefly, 2443 
eyed-stage RBT embryos were acquired from Troutlodge, Inc (WA, USA) and were reared in 2444 
McDonald-type hatching jars until first signs of hatching were observed.  One hundred unhatched 2445 
eggs were then transferred into 9-L tanks containing exposure solutions, in triplicates per treatment 2446 
group. Temperature was maintained at 15 ± 1 oC, under a 16:8 light:dark cycle, under flow-through 2447 
conditions (at least 50% v/v renewal per day) for four days. Pools of three yolk-sac alevins were 2448 
collected from each tank at 4 dph. Tissues were flash-frozen in liquid nitrogen and kept at -80oC 2449 




5.3.1.3. Fathead minnow 2452 
FHM exposure experiments were conducted as previously described (Alcaraz et al., 2453 
2021b). Briefly, 20 embryos (between late cleavage and high blastula stage) from an in-house 2454 
breeding colony (original source: Aquatic Research Organisms Inc., Hampton, USA) were placed 2455 
each into 3-5 replicate petri dishes per treatment group with exposure solutions. All Petri dishes 2456 
were maintained under static renewal conditions (> 50% v/v renewal per day), a 16:8 light:dark 2457 
cycle, and at a temperature of 24 ± 1oC. At 4 dph, all larvae within a replicate petri dish were 2458 
pooled, flash-frozen in liquid nitrogen, and kept at -80oC until further processing for transcriptomic 2459 
analysis.  2460 
 2461 
5.3.2. Chemical analyses  2462 
 Concentrations reported here represent means of measured FLX and EE2 from water 2463 
samples collected throughout longer exposure durations (from fertilization/hatch to early fry 2464 
stages) the studies described here were a part of, with exception of the sturgeon FLX experiment. 2465 
Due to potential risks of pathogenic contamination from wild-caught sources, WS experiments had 2466 
to be conducted in a quarantine facility with limited space, which resulted in not being able to 2467 
collect sufficient water samples for FLX analyses. Hence, measured concentrations for FLX from 2468 
RBT was used for WS since these experiments shared stock solutions. Because the analysis of EE2 2469 
required much lower volumes of water, we were able to confirm EE2 exposure concentrations 2470 
during the WS experiment.  2471 
Analyses of EE2 in water samples were previously described in Alcaraz et al. (2021b) for 2472 
FHM and in Alcaraz et al. (2021a) for RBT and WS.  Water samples were extracted by solid-phase 2473 
extraction prior to analysis. For FHM, EE2 was quantified by spiking extracted samples with 2474 
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deuterated EE2 and measuring the concentrations using high performance liquid chromatography-2475 
tandem mass spectrometry (LC-MS; Waters, MA, USA). For RBT and WS, concentrations of EE2 2476 
were measured using EE2-specific competitive enzyme-linked immunosorbent assay (ELISA; 2477 
Ecologiena®, Fukuoka, Japan).   2478 
The analysis of FLX in the FHM study was previously described (Alcaraz et al., 2479 
submitted). For RBT and WS, concentrations of FLX were measured through quantification by 2480 
isotope dilution.  Briefly, sample aliquots were spiked with fluoxetine-d5 (d5-FLX; CDN Isotopes, 2481 
QB, Canada). FLX in samples was then quantified using a Vanquish UHPLC, coupled to a Q-2482 
ExactiveTM HF Quadrupole-OrbitrapTM mass spectrometer (Thermo Fisher Scientific, MA, USA).  2483 
 2484 
5.3.3. Sample preparation, sequencing, and data pre-processing  2485 
Total RNA was extracted from each replicate using RNeasy Plus Universal Mini Kit 2486 
(Qiagen, Germany).  Samples with an RNA integrity number (RIN) ≥ 8 were used for RNA 2487 
sequencing. Library preparation and sequencing for FHM and RBT were previously described in 2488 
Alcaraz et al. (2021b) and in Alcaraz et al. (2021a), respectively, and were done at Génome 2489 
Québec Centre d’Expertise et de Services (Genome Quebec, QB, Canada). For WS, libraries were 2490 
prepared in-house using NEBNext Ultra Directional kit with poly(A) magnetic isolation module 2491 
(New England Biolabs Ltd, ON, Canada).  Total RNA was poly(A)-enriched prior to the synthesis 2492 
of double-stranded DNA. Size fragments of dsDNA libraries were assessed using the high-2493 
sensitivity DNA analysis kit in the 2100 Bioanalyzer instrument (Agilent Technologies, 2494 
Waldbronn, Germany) and were quantified in a Qubit 4 fluorometer (Thermo Fisher Scientific). 2495 
High quality dsDNA libraries were sequenced in-house using a 150-cycles (75 x 2) paired-end 2496 
sequencing cartridge in a NextSeq 500 instrument (Illumina Inc, San Diego CA, USA). 2497 
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Reads were assessed using FastQC (Andrews, n.d.) and trimmed in pairs to a minimum 2498 
Phred score of 20 and a minimum length of 35 bases per paired read using Trimmomatic (Bolger 2499 
et al., 2014). Cleaned reads were aligned to their respective transcriptome assembly (WS: NCBI 2500 
GEO Acc# GSE79624; RBT: GCA_002163495.1; FHM: GCA_016745375.1) to estimate the 2501 
abundance of transcripts using Kallisto (Bray et al., 2016). Reads that have not been previously 2502 
reported were submitted to the NCBI GEO repository with accession number XXXXXX. Other 2503 
raw files were accessed using the GEO accession numbers GSE156916, GSE171788, and 2504 
GSE179232.  2505 
 2506 
5.3.4. Transcriptomic benchmark concentration analyses 2507 
 Transcriptomic points-of-departure (tPODs) are concentrations corresponding to whole 2508 
transcriptome effect level based on pre-set benchmark response (BMR) that is considered adverse 2509 
or significant.  The most protective and stable tPODs are those focused on active genes – molecular 2510 
features (gene or transcript) that fit into statistical models and have valid benchmark concentration 2511 
(BMC) values as per the National Toxicology Program (NTP) Approach to Genomic Dose-2512 
Response Modeling recommendations (i.e., BMCs not exceeding the highest tested concentration, 2513 
acceptable confidence intervals, etc.)(National Toxicology Program, 2018). These tPOD estimates 2514 
include (1) the median of the 20 most sensitive geneBMCs (omicBMC20), the tenth percentile of 2515 
all geneBMCs (omicBMC10th), and the mode of the first peak of all gene BMCs (omicBMCmode) 2516 
(Pagé-Larivière et al., 2019).  2517 
Transcriptomic BMC analyses were conducted separately on each study using FastBMD 2518 
(Ewald et al., 2020). FastBMD follows the recommended methods by the NTP. Modules for FHM 2519 
and RBT were used for datasets in the respective species. Transcript counts were collapsed to 2520 
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genes prior to downstream analyses. Since no WS module is available in FastBMD, annotation-2521 
free mode was used in the BMC analysis. Count estimates were normalized using the relative log 2522 
expression (RLE) normalization (Anders and Huber, 2010). Normalized datasets were filtered to 2523 
remove 5% and 10% of the features with lowest variance and abundance across treatment groups, 2524 
respectively. Features that were unlikely to exhibit concentration-response behaviour were 2525 
removed by calculating differential gene expression relative to the control group using limma 2526 
(Ritchie et al., 2015), with a threshold cut-off false discovery rate (FDR) ≤ 0.05. The remaining 2527 
features were fitted using statistical models (Exp2, Exp3, Exp4, Exp5, Linear, 2o Polynomial 2528 
(Poly2), Hill, and Power), with a threshold lack-of-fit p-value > 0.1 and a BMR factor = 1.  Curve 2529 
fittings were conservative such that higher order polynomials (Poly3 and Poly4) were not used due 2530 
to the tendency of these models to overfit datasets, given the small number of datapoints. Control 2531 
expression was set to the mean of control samples. Gene/transcript-level BMC (geneBMC) values 2532 
from the model with the lowest Akaike information criterion (AIC) were selected for use in the 2533 
estimation of transcriptome-level (omicBMC) tPOD. Pathway-level (pathBMC) tPODs were also 2534 
calculated for RBT and FHM and defined as the most sensitive pathway (lowest pathBMC) based 2535 
on bootstrapped median of constitutive geneBMCs of that specific pathway, with at least 3 2536 
geneBMCs in the pathway. PathBMCs were not calculated for WS as there is currently no 2537 
established genome/transcriptome, and therefore, gene set annotation for this species. 2538 
  2539 
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5.4. Results and Discussion 2540 
5.4.1. Survival rates at 4 dph, physico-chemical characteristics of exposure solutions, and 2541 
chemical analyses 2542 
 No significant mortalities were observed at 4 dph across all studies, which was expected 2543 
as EE2 and FLX are not known to cause acute toxicity at the tested concentrations, with previously 2544 
reported LC50s in the mg/L and high ug/L ranges, respectively (Alcaraz et al., 2021a; Henry and 2545 
Black, 2008; Versonnen et al., 2003). All physico-chemical characteristics of exposure solutions 2546 
were within the recommended parameters of OECD 210 (OECD, 2013), with a few minor 2547 
deviations (± 2 oC) from exact temperature recommendations, although these were not expected 2548 
to affect the results as the test species are known to thrive in habitats with considerable temperature 2549 
ranges.  Measured concentrations were 36 – 117% of nominal for EE2 and 20 – 96% for FLX 2550 
(Table E.S2).  2551 
 2552 
5.4.2. tPODs of EE2 across species 2553 
Features with BMCs after early-life exposure to EE2 represented 75, 84, and 53% of all 2554 
features with fitted models for WS, RBT, and FHM, respectively (Table 5.2). These relatively low 2555 
ratios may have been due to the wide confidence intervals of some geneBMC estimates, estimates 2556 
greater than the highest dose, and expression values that did not exceed the BMR (National 2557 
Toxicology Program, 2018). Indeed, FHM had over 600 features with geneBMCs higher than the 2558 
highest tested concentration, which were excluded in downstream analyses, and which were likely 2559 
to have moved the second mode further to the right of the x-axis if higher concentrations were 2560 
tested, suggesting lesser transcriptional sensitivity of FHM to EE2, overall. Nonetheless, the 2561 
bimodal distribution patterns of geneBMCs for EE2 across the three species were comparable, 2562 
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with two peaks each. A notable similarity between the distribution patterns of RBT and WS can 2563 
be observed (Figure 5.1), characterized by a high first peak at low concentrations and a relatively 2564 
flatter second peak. The similarity across response patterns may be rooted in the largely conserved 2565 
immunological and endocrine functions in ray-finned fish (Bury, 2017), which are the primary 2566 
targets of EE2. Downstream biochemical and physiological bimodal responses have also been 2567 
observed by other authors in response to exposure of fishes to xenoestrogens (Anderson et al., 2568 
2020; Pawlowski et al., 2004), which could have been driven by a variety of molecular 2569 
perturbations occurring across concentrations. RBT geneBMCs formed a narrow peak at very low 2570 
concentrations, with an omicBMCmode of 4.38 ng/L, compared to 16.51 and 24.93 ng/L for WS 2571 
and FHM, respectively, both of which have relatively broader and lower first peaks, suggesting a 2572 
relatively simultaneous transcriptional perturbations in a smaller window of concentrations. A 2573 
second and wider mode above 80 ng/L can be observed for FHM, suggesting that most of the 2574 
active genes deviated from the control treatment responses at higher concentrations compared to 2575 
RBT and a lesser extent to WS. The second mode is interpreted as the secondary onset of cellular 2576 
processes, which represents general stress response and disruption of molecular machinery. 2577 
Nevertheless, the values for omicBMCmode derived across the three species in this study were 2578 
within the same range of some less sensitive apical BMCs for EE2 reported previously; for 2579 
instance, GSI, condition factor, the number of batches of eggs, and fertilization rates in FHM 2580 
significantly decreased when exposed to 10-100 ng/L EE2 (Pawlowski et al., 2004). Similarly, 2581 
reduction in testis mass, number of eggs attaining the eyed stage of embryonic development, and 2582 
plasma 11-ketotestosterone were observed in RBT exposed to 10-100 ng/L EE2 (Schultz et al., 2583 
2003).  2584 
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OmicBMC10th were 7.98, 1.44, and 27.82 ng/L for WS, RBT, and FHM, respectively, all 2585 
of which were within the tested concentrations for all species. On the other hand, omicBMC20 were 2586 
0.06, 0.12, and 2.39 ng/L for WS, RBT and FHM, respectively, which were the most sensitive 2587 
tPOD estimate in all species. Only the estimate for FHM fell within the tested concentrations, 2588 
although estimates for RBT and WS were still within 10% of the lowest tested concentrations. 2589 
Pathway-level BMC for RBT was 1.68 ng/L with 5 genes contributing to fatty acid biosynthesis 2590 
pathway, while carbon metabolism pathway had the greatest number of genes, with 46, and a 2591 
pathBMC of 4.64. PathBMC for FHM was 45.61 ng/L for olfactory transduction, with 3 active 2592 
genes, while neuroactive ligand interaction pathway had the greatest number of active genes of 17. 2593 
Most, if not all geneBMCs contributing to the most sensitive pathBMC of RBT were within the 2594 
first mode, while that of the FHM were in the second mode, suggesting a more relevant first mode 2595 
for RBT but second mode for FHM, in terms of estimating pathBMC. 2596 
There have been no studies that directly compared the apical effects of EE2 among WS, 2597 
RBT, and FHM. A previous report showed that a distant relative of WS, the Siberian sturgeon, 2598 
appeared to be more sensitive in vivo against the phytoestrogen genistein in terms of hepatocyte 2599 
Vitellogenin (Vtg) protein abundance, relative to RBT (Latonnelle et al., 2002). Vtg is the classic 2600 
biomarker for the exposure of fish to estrogens, such as EE2 (Jones et al., 2000). Similarly, there 2601 
have been no direct comparisons of the apical effects of EE2 between FHM and RBT, but previous 2602 
reports suggest a relatively greater sensitivity of FHM compared to RBT based on a range of apical 2603 
outcomes such as plasma Vtg and other reproductive parameters (Caldwell et al., 2012), although 2604 
endpoints and experimental parameters were not necessarily identical, and therefore, should be 2605 
interpreted with caution.  In the literature, the consensus apical EE2 lowest observed effect 2606 
concentration (LOEC) was between sub- to low- ng/L concentrations, such as those that caused 2607 
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disruption of egg production and quality in FHM (Jobling et al., 2004; Parrott and Blunt, 2005; 2608 
Runnalls et al., 2015), and a predicted no-effect concentration (PNEC) of  0.10 and 0.35 ng/L, 2609 
respectively (Caldwell et al., 2012, 2008). The estimate for omicBMC20 for RBT and WS closely 2610 
approximated the PNEC and were well protective of the apical thresholds that caused adverse 2611 
effects. In contrast, the omicBMC20 for FHM differed by approximately one order of magnitude.2612 
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Table 5.2. Summary of tPODs across species. Datasets were fitted using the models Exp2, Exp3, 2613 
Exp4, Exp5, Linear, Poly2, Hill, and Power, with a threshold lack-of-fit p-value > 0.1 and a 2614 
benchmark-response (BMR) factor = 1. 2615 
 FLX (µg/L) EE2 (ng/L) 
 WS RBT FHM WS RBT FHM 
Features with 
fitted model 
1715 1378 2300 2957 2326 1367 
Features with 
BMC 
1222 1110 2154 2219 1957 724 
omicBMC20 0.02 0.02 0.56 0.06 0.12 2.39 
omicBMC10th 0.64 0.32 5.0 7.98 1.44 27.82 
omicBMCmode 2.08 5.01 7.43 16.51 4.38 24.93 
pathBMC - 0.19 5.66 - 1.68 45.61 
omicBMC20 = median of the 20 most sensitive geneBMCs 2616 
omicBMC10th = tenth percentile of all geneBMCs  2617 
omicBMCmode = mode of the first peak of all gene BMCs 2618 
pathBMC = most sensitive pathway BMC, with at least 3 geneBMCs, based on bootstrapped median of constitutive geneBMCs 2619 




Figure 5.1. Transcriptome-wide points-of-departure derived from embryonic exposures to EE2 2622 
across three freshwater fish species. Distribution patterns of geneBMCs were depicted with the 2623 
density plots; broken lines showing the mode of the first peak of all geneBMCs within a species 2624 
(omicBMCmode); solid black lines show the 10th percentile of all geneBMCs (omicBMC10th); 2625 
straight line showing the 10th percentile.      ⃝ RBT; □ FHM; Δ WS. X-axis – EE2 benchmark 2626 
response (BMC; in ng/L); Y-axis – cumulative percentile of geneBMCs. Rug – individual 2627 
geneBMCs. Inset: Scaled figure highlighting (arrows) omicBMC20. RBT – rainbow trout; FHM – 2628 
fathead minnow; WS – white sturgeon; omicBMC10th – the 10
th percentile of all geneBMCs; 2629 
omicBMC20 – median of the 20 most sensitive geneBMCs; omicBMCmode – mode of the first peak 2630 
of all geneBMCs. Note: Density plots were used to assess distribution patterns/modes and were 2631 
not scaled to the Y-axis.  2632 
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5.4.3. tPODs of FLX across species 2633 
Features with BMCs represented 71, 81, and 94% of features with fitted models for WS, 2634 
RBT, and FHM, respectively (Table 5.2). Distribution patterns showed WS geneBMCs with a 2635 
prominent single peak at very low concentrations, FHM with two well defined peaks, and RBT 2636 
with two low peaks at the lower and upper end of the tested concentrations with geneBMCs well 2637 
distributed across the tested concentration range (Figure 5.2A). The bimodal tPOD response 2638 
patterns observed in the two teleosts may be one of the causes of a wide range of measured 2639 
biological potencies of FLX that have been reported in the literature (Bidel et al., 2016; Cunha et 2640 
al., 2018; de Farias et al., 2019). On the other hand, there have been no reports on the apical 2641 
responses of WS to FLX; hence, there were no information to validate or explain the single 2642 
peak/mode of geneBMC distribution observed. Perhaps the difference in response patterns 2643 
between the teleosts and the sturgeon may be one of the evolutionary implications that could be 2644 
attributed to the teleost-specific whole genome duplication events, which occurred after the 2645 
phylogenetic divergence of the Acipenseriformes lineage from the actinopterygian stem (Glasauer 2646 
and Neuhauss, 2014). However, it is yet to be investigated how the conservation of molecular 2647 
targets of FLX in ray-finned fishes were affected by these evolutionary events, although 2648 
serotonergic mechanisms and FLX metabolism were reported to be relatively conserved across 2649 
vertebrates (Beulig and Fowler, 2008; Margiotta-Casaluci et al., 2014b). A dose-dependent rapid 2650 
development and hyperactive behaviour were qualitatively observed in WS relative to controls, 2651 
although this observation must be validated with an experiment specifically designed to evaluate 2652 
this endpoint. In contrast, accelerated development (degree days to swim up; Figure E.S1), 2653 
concentration-dependent mortalities (Figure E.S2), and concentration-dependent hyperactivity 2654 
(qualitatively observed; data not shown) were observed in RBT at later life stages. These 2655 
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observations were not apparent at all in FHM even at 28 dph. These observations may suggest 2656 
greater potency of FLX in WS, which may be due to coincident perturbations in multiple genes 2657 
and pathways at low concentrations as it appeared in the geneBMC distribution, although these 2658 
observations have to be further validated.  OmicBMCmode were 2.08, 5.01, and 7.43 µg/L for WS, 2659 
RBT, and FHM, respectively. These tight estimates across species were within the range of 2660 
concentrations reported to cause adverse apical effects in FHM (Weinberger and Klaper, 2014), 2661 
although extremely high and extremely low concentrations (sub-µg/L to mg/L) of FLX have also 2662 
been reported to cause changes in behaviour and locomotor response in other fish (Kohlert et al., 2663 
2012; Martin et al., 2019). OmicBMC10th were 0.64, 0.32, and 5.0 µg/L for WS, RBT, and FHM, 2664 
respectively (Figure 5.2B), and were within the tested concentrations. OmicBMC20 were 0.02, 2665 
0.02, and 0.56 µg/L for WS, RBT, and FHM, respectively (Figure 5.2C & 5.2D), and although 2666 
only the estimate for FHM was within the tested concentrations, both estimates for WS and RBT 2667 
were within 10% of the lowest tested concentrations. These sub- to low-µg/L omicBMC10th and 2668 
omicBMC20 tPOD estimates for FLX were protective of some of the most sensitive responses 2669 
observed in the literature such as that of multigenerational hypocortisolism and behavioral 2670 
disruption in zebrafish exposed to 0.54 µg/L FLX (Vera-Chang et al., 2018).  2671 
The pathBMC of the most sensitive pathway for RBT was 0.19 µg/L for hippo signaling 2672 
pathway with 3 constitutive geneBMCs while the pathway with the greatest number (28) of 2673 
constitutive geneBMC was lysosome pathway with pathBMC of 89.9 ug/L. For FHM, the 2674 
pathBMC of 5.66 ug/L for vasopressin-regulated water reabsorption was the most sensitive 2675 
pathBMC with 9 geneBMCs and PI3K-Akt signaling pathway had the greatest number of 2676 
constitutive geneBMCs (43) with pathBMC of 8.98 µg/L. These pathways are generally involved 2677 
in the regulation of cellular homeostasis, cell proliferation, and homeostasis, but a deeper dive into 2678 
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specific functions would be necessary to elucidate the specific MOA of the compounds tested.  No 2679 
pathBMD could be calculated for WS for the reasons specified above.   2680 
There have been no studies directly comparing the apical responses of the three tested 2681 
species towards FLX. Observed apical responses such as histological, behavioral, and 2682 
physiological responses in fish occurred at a wide range of concentrations, ranging from sub-µg/L 2683 
to mg/L (Brooks, 2014; Stanley et al., 2007). All estimated tPODs in this study were within the 2684 
lower spectrum of concentrations that have been reported to result to these apical responses, with 2685 
omicBMD20 from WS and RBT being the most protective and within the same range of the most 2686 




Figure 5.2. Transcriptome-wide points-of-departure after embryonic exposures to FLX across 2689 
three fish species. (A) Distribution patterns of geneBMCs with density plots showing the mode of 2690 
the first peak of all geneBMCs within a species (omicBMCmode); Rug – individual geneBMCs. (B) 2691 
the 10th percentile of all geneBMCs (omicBMC10th); straight line showing the 10
th percentile. (C) 2692 
and (D) median of the 20 most sensitive geneBMCs (omicBMC20).     ⃝ RBT; □ FHM; Δ WS. RBT 2693 
– rainbow trout; FHM – fathead minnow; WS – white sturgeon. X-axis – FLX benchmark 2694 
concentration (in µg/L). Y-axis – cumulative percentile of geneBMCs. X- and Y-axes were scaled 2695 
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to highlight tPODs. Note: Density plots were used to assess distribution patterns/modes and were 2696 
not scaled to the Y-axis  2697 
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5.4.4. Insights from EE2 and FLX tPODs in embryonic fish  2698 
This study demonstrated that whole embryo-alevin/larval tPOD estimates were comparable 2699 
to empirically derived apical PODs in the literature, with omicBMC20 and omicBMC10th exhibiting 2700 
sensitive and reasonable estimates that were protective of even some of the most sensitive apical 2701 
PODs reported in the literature (de Farias et al., 2020; Parrott and Blunt, 2005). The omicBMCmode 2702 
were relatively less sensitive.  As this estimate reflects changes in specific molecular targets 2703 
(Judson et al., 2016), the modes of the geneBMC distribution can potentially be used as a guide to 2704 
elucidate the modes-of-action of the compound given that it is formed by a collective set of genes 2705 
with expression values departing from the control-level expression (Chauhan et al., 2016). 2706 
However, the elucidation of specific mechanisms of toxic action of chemicals based on geneBMC 2707 
distribution modes was beyond the scope of this study but is an important theme in future research.  2708 
Generally, RBT embryos were the most sensitive in terms of all tPOD estimates and that 2709 
derived tPODs were protective across species both for FLX and EE2, whereas FHM appeared to 2710 
be the least sensitive despite the longer exposure duration of FHM (from ~6 hrs post-fertilization 2711 
(hpf) to 4 dph; approximately 7 days total).  The tPOD estimates of WS and RBT were more 2712 
comparable to each other than those obtained for FHM.  Furthermore, BMC distribution patterns, 2713 
specifically for EE2, were more similar between RBT and WS than between either of these species 2714 
and FHM. This observation is interesting because cyprinids are phylogenetically closer to 2715 
salmonids than sturgeons, and therefore, the responses were expected to be more similar between 2716 
the two teleost species. One explanation for these differences may be the length of exposure and 2717 
developmental times. FHM were exposed earlier and for a longer time than the other two fishes 2718 
(from 6hpf); hence, compensatory and downstream physiological responses may have taken place 2719 
and manifested feedback responses to the toxic insults; the shorter exposure time for WS and RBT 2720 
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(from hatch to 4 dph) may not have been sufficient time for these compensatory feedbacks to 2721 
manifest yet. A time-course study on transcriptional responses may help elucidate this hypothesis. 2722 
Typically, cyprinids such as FHM and zebrafish are the choices for many ecotoxicological studies 2723 
due their relatively ease of husbandry, small size, and short breeding cycle, among others (Ankley 2724 
and Villeneuve, 2006; Dai et al., 2014). However, salmonids, including RBT, have been reported 2725 
to be among the most sensitive commonly tested freshwater fish, while cyprinids appeared to be 2726 
the least sensitive, and which was demonstrated in a study that evaluated a suite of 190 chemicals 2727 
(Teather and Parrott, 2006). In contrast, apical PODs for WS were not available for comparison 2728 
due to limitations in its use in toxicological studies because of the conservation status of several 2729 
of its populations in North America, as well as its long life-cycle. It should be noted that the WS 2730 
dataset may not necessarily be directly comparable to those of the two teleosts at it was analyzed 2731 
at the transcript level using a de novo assembled transcriptome, while RBT and FHM were 2732 
summarized into gene-level responses. This means that there are possible redundancies in the 2733 
reference transcriptome of WS that could result in a shift of the distribution peak when summarized 2734 
into gene levels. However, this may not be ascertained unless a fully assembled genome or 2735 
transcriptome is available for WS. Nevertheless, estimated tPODs from WS were within the range 2736 
of those of the two teleost species assessed in this study, and therefore, we argue that tPODs from 2737 
teleosts, specifically from RBT, could be protective towards adverse apical effects to WS. Of 2738 
course, additional studies with a wider range of diverse chemical contaminants are needed to 2739 
confirm this hypothesis. 2740 
A fundamental limitation of estimated protective tPODs in this study, specifically 2741 
omicBMC20 and omicBMC10th, was the lack of definitive biological interpretation typically 2742 
inferred from the identity of the active genes and gene sets. PathBMC is typically the choice for 2743 
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tPOD estimation as it can be anchored to biological inference from gene set information, and 2744 
therefore, aid in informing possible mechanisms of action and characterization of plausible links 2745 
to the etiology of biological responses (Dean et al., 2017; Farmahin et al., 2017; National 2746 
Toxicology Program, 2018); however, this strategy is highly influenced by the annotation of the 2747 
genome or transcriptome of the species under study, which is a significant limitation in 2748 
nonstandard organisms. It is notable that pathway-based tPODs (pathBMC) were not the most 2749 
protective estimates in this study, which has also been observed previously (Pagé-Larivière et al., 2750 
2019). In fact, only ~35-45% of the active genes of the three tested species were annotated with 2751 
KEGG orthologs, and therefore, limited the downstream gene set enrichment analyses. 2752 
Annotations are typically biased towards more studied biomolecular processes that are relevant 2753 
especially for human health, and thus, may not be a robust representation of environmentally 2754 
relevant concerns. Until functional databases improve and develop focused annotations for non-2755 
human/non-mammalian species, it remains difficult to reliably conduct such analyses. Currently, 2756 
the implications of the results would be limited to those associated with human functions, unless 2757 
the mechanisms are conserved across vertebrates. 2758 
Another limitation may be the use of embryo-larval/alevin stage that could affect the 2759 
identification of gene targets specific to certain tissues or organs as these may get diluted in the 2760 
analyses of whole embryo transcriptomes, which adds to the difficulty of MOA characterization.  2761 
Also, artifacts of molecular processes related to an organism’s active development at this life stage 2762 
might interfere in the mechanistic characterization of the MOA of a chemical at later life stages. 2763 
On the other hand, effects on developmental processes may represent unique and highly sensitive 2764 
endpoints indicative of apical effects at this often most sensitive life stage. Nevertheless, it should 2765 
be noted that the primary purpose of deriving tPODs is to quickly and cost-effectively identify the 2766 
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concentration or dose that would closely approximate toxicity thresholds and that mechanistic 2767 
hazard identification is secondary; thus, direct mechanistic linkage to adverse effects is not critical 2768 
at this point. Still, it is acknowledged that mechanistic linkage of molecular perturbations to 2769 
adverse outcomes will be necessary for regulatory acceptance in chemical hazard assessment.  2770 
This study clearly demonstrated the potential for embryonic stage-derived tPODs to aid in 2771 
chemical hazard assessment; however, much work is needed for the regulatory acceptance of this 2772 
strategy in deriving toxicity thresholds. In particular, there is a need to establish a more robust non-2773 
mammalian databases for the interpretation and linkage of molecular perturbations with biological 2774 
functions and processes.  In particular, more extensive genome assemblies and curation of 2775 
annotations of species of interest are needed, as well as improvement of databases such as KEGG 2776 
to include molecular interactions and processes for species other than humans to reflect biological 2777 
processes that are unique to oviparous (e.g. reproduction) or aquatic vertebrates. Specific studies 2778 
addressing reproducibility of results are also crucial, such as the number of reasonable replications, 2779 
exposure windows and timing, sequencing depth, the number and range of concentrations to test, 2780 
and curve fitting strategies, among others. Recommendations from the NTP genomic dose-2781 
response modelling may serve as a guide in establishing guidelines in the standardization of 2782 
procedures in deriving tPODs from embryonic fish studies. Lastly, studies utilizing other fish 2783 
species and compounds acting on diverse mechanisms should be conducted to validate the 2784 
effectivity of this strategy in deriving robust tPODs that are protective of apical PODs across 2785 
species.    2786 
  2787 
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CHAPTER 6: GENERAL DISCUSSION2824 
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6.1. Introduction 2825 
The increasing number of chemicals that require toxicity testing, which is hampered by 2826 
high costs, low throughput, and significant ethical concerns, prompted a growing interest in the 2827 
development of new approach methodologies (NAMs) that can replace, reduce, and refine (3R) 2828 
the use of live animals (Kavlock et al., 2018; Krewski et al., 2020). While in vitro and 2829 
computational methods hold promise as alternatives to live animal tests, many of these models are 2830 
limited with regards to quantitatively predicting adverse outcomes and their corresponding toxicity 2831 
thresholds as these models do not represent the entirety of an organism. Recent developments 2832 
suggest that early-life stages (ELS) of fish are sensitive surrogates of adult fish (Wheeler et al., 2833 
2014) while not being considered as live animals in many jurisdictions (Canadian Council on 2834 
Animal Care, 2005; European Union, 2010; UK, 1993). Similarly, advancements in omics 2835 
technologies now allow the interrogation of full suites of molecular families without a priori 2836 
knowledge of the modes of action (MOA) of a compound, and can provide a snapshot of molecular 2837 
perturbations before long-term apical effects are observed (Garcia-Reyero and Perkins, 2011; 2838 
Schirmer et al., 2010; Zhang et al., 2018). Together, (molecular) mechanistic information in ELS 2839 
assays present a compelling strategy for the development of NAMs that may aid in regulatory 2840 
decision-making as they are more likely to gain regulatory acceptance than tissue-/cell-based in 2841 
vitro assay and in silico models (Basu et al., 2019). Thus, this dissertation aimed to develop short-2842 
term ELS assays for evolutionary diverse species of fish for the derivation of transcriptomic points-2843 
of-departure (tPODs), particularly for chemical testing prioritization, in support of environmental 2844 
risk assessment (ERA). Specifically, fathead minnow (FHM), rainbow trout (RBT), and white 2845 
sturgeon (WS) were exposed at the embryonic stage to graded concentrations of two contaminants 2846 
of concern (CECs), 17α-ethinylestradiol (EE2) and fluoxetine (FLX). Whole body tissues were 2847 
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collected for transcriptomic and proteomic analyses at 4-days post-hatch (dph). The remaining 2848 
larvae/alevins were continuously exposed to CECs until 28 dph (FHM) and 60 dph (RBT) for 2849 
histological investigations, biometric measurements, and survival analysis. Construction of 2850 
toxicity pathway models was attempted to link molecular pathways with downstream effects and 2851 
apical outcomes. Transcriptomic points-of-departure (tPODs) were calculated and compared to 2852 
concentrations that caused apical chronic effects in studies conducted here and in the literature. 2853 
Lastly, tPODs of EE2 and FLX were compared across species.  2854 
 2855 
6.2. Toxicity pathway models at early-life stages of fish 2856 
It is commonly accepted that establishing a toxicity pathway model is a tedious and 2857 
comprehensive process and requires a suite of studies including those that interrogate molecular, 2858 
physiological, histological and apical responses (Andersen et al., 2015). Perhaps the most 2859 
compelling result in this dissertation with regards to deriving mechanistic toxicity pathways using 2860 
fish ELS are those from Chapter 2, which demonstrated that molecular analyses of EE2-exposed 2861 
embryo-larval FHM at 4 dph revealed core responses that are indicative of apical outcomes 2862 
(Alcaraz et al., 2021b). Genes coding for specific biomarkers associated with EE2 were highly 2863 
dysregulated in a concentration-dependent manner, such as vitellogenin (vtg), aromatase 2864 
(cyp19a1b), and estrogen receptor 1 (esr1) with their corresponding protein products showing 2865 
similar dysregulation patterns. Likewise, overrepresented gene sets from both omic levels showed 2866 
significant perturbations along the estrogen signalling pathway. Histological observations, as well 2867 
as length and weight analyses, showed responses that were in accordance with these molecular 2868 
responses. Similarly, Chapter 3 demonstrated that apical responses at 60 dph in EE2-exposed RBT 2869 
were linked to transcriptomic responses at 4 dph (Alcaraz et al., 2021a).  However, in certain cases 2870 
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the assembly of toxicity pathway models may require examination of specific molecular signals 2871 
from target organs and tissues (e.g. selective serotonin reuptake inhibitors (SSRIs) specifically 2872 
affect particular regions of the brain; low molecular weight hydrocarbons (LMWHCs) affect 2873 
cardiovascular functions), among others. This may be one of the main limitations of whole-body 2874 
omics analyses with ELS as certain tissue-specific signals may be diluted and lost, and it may be 2875 
challenging to attribute certain signals to specific tissues/cells where the greatest toxicological 2876 
insults occurred. For instance, Chapter 4 revealed that most of the common FLX-target genes 2877 
and/or proteins were not significantly dysregulated in 4 dph FHM, which could be an artifact of 2878 
signal dilution in whole body tissue analyses given that these features are known to be specifically 2879 
expressed in certain regions of the central nervous system (CNS). Even so, functional analyses 2880 
integrating whole-body transcriptomics and proteomics with downstream results and information 2881 
from the literature may provide additional evidence that can be used to build informed putative 2882 
toxicity pathway models. In Chapter 3, proteomic profiles at 4 dph provided limited mechanistic 2883 
evidence with regards to the classic estrogenic endpoints such as overproduction of Vtg protein, 2884 
which could have been due to several factors, including the presence of prominent yolk sac biasing 2885 
assessment, among others. Nevertheless, histological observations and previous studies (Alcaraz 2886 
et al., 2021a; Tompsett et al., 2012) presented overwhelming evidence of the presence of this 2887 
protein in fish and frogs exposed to EE2. In Chapter 4, FLX-induced transcriptomic and proteomic 2888 
perturbations at 4 dph in FHM were complementary, providing more comprehensive and 2889 
informative insights into the mechanism of toxicity of this chemical than when analyzed 2890 
independently, and offered information that can be linked to apical outcomes. Overall, while the 2891 
putative models developed here were not complete, they provided support and weight-of-evidence 2892 
regarding the link between molecular signals and apical outcomes.  2893 
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In general, concordances of transcript-protein pairs were weak in all the studies conducted 2894 
as part of this thesis (Chapters 2-4), observations that were not unexpected as similar observations 2895 
were made in many other studies. It was hypothesized that these inconsistencies are primarily due 2896 
to the many post-translational factors influencing the synthesis of the resulting protein products 2897 
(Liu et al., 2016; Maier et al., 2009; Vogel and Marcotte, 2012; Wu et al., 2013). In fish, very 2898 
limited concordance between transcriptomic and proteomic responses was previously observed in 2899 
EE2-exposed zebrafish (De Wit et al., 2010), which was in accordance with the limited 2900 
concordance observed in FHM and RBT in this thesis (Alcaraz et al., 2021b, 2021a; Chapters 2-2901 
4).  For instance, in Chapter 2, 22 features were significantly dysregulated in both the transcriptome 2902 
and proteome level of EE2-exposed FHM, including multiple variants of the estrogenicity 2903 
biomarker vtg, but the overall concordance of transcript abundance ratios and protein abundance 2904 
ratios was very weak (Pearson’s ρ = 0.130). Regardless, important signalling pathways were 2905 
typically present at both omic levels. In Chapters 2 and 4, combined network analyses of 2906 
differentially expressed transcripts and differentially abundant proteins were complementary with 2907 
regards to the characterization of overrepresented terms and pathways that could have been missed 2908 
if analyzed separately, suggesting that there were interactions and feedback loops among these 2909 
features at different molecular levels. This observation highlights the value of comparing and 2910 
integrating multiple molecular features from different omics streams in identifying relevant 2911 
molecular processes associated with an external stimulus.  2912 
Notable inconsistencies were observed in the proteomic profiles across the conducted 2913 
experiments, and how these profiles could inform the toxicity pathway models developed. In 2914 
Chapter 2, proteomics showed direct translation of several important transcripts to protein products 2915 
when FHM was exposed to EE2. In contrast, exposure to FLX showed proteomics results that were 2916 
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not the products of immediate translation from significantly dysregulated transcripts but were 2917 
complementary to the transcriptomic profiles at a functional level (Chapter 4). In RBT, proteomic 2918 
profiles had a less clear link with the transcriptomic profiles. In addition to the intrinsic properties 2919 
of genomic translation noted above, several extrinsic factors may have also contributed to these 2920 
inconsistent observations:  2921 
(1) Co-incident sampling for transcriptomics and proteomics. Much remains to be resolved 2922 
regarding the dynamics (how much and how quickly) of gene product formation and the 2923 
interactions of biomolecules at different biological levels, which drives their abundances and 2924 
activities (Liu et al., 2016; Maier et al., 2009). mRNA molecules can be simultaneously transcribed 2925 
and translated, and post-transcriptional regulation plays an important role in the control of the 2926 
abundances of gene products. Despite increased transcriptional activities of CEC-responsive 2927 
genes, the level of synthesized gene products may not necessarily be observed at the proteome 2928 
level at the same instant as at the transcriptome level. In Chapter 3, multiple variants of vtg were 2929 
significantly dysregulated at the transcriptomic level, but were not differentially abundant at the 2930 
proteome level, both of which were processed from samples at 4 dph. However, histological 2931 
observations at later life stages showed overwhelming evidence of the presence of this protein 2932 
(Alcaraz et al., 2021a). 2933 
(2) Localization of target proteins in certain regions of the organ/tissue. Proteins exhibit 2934 
spatial localization among tissues, which is tightly linked to protein functions (Digre and Lindskog, 2935 
2021). For instance, tissue-elevated expression of glial fibrillary acidic protein is observed in the 2936 
brain, follicle stimulating hormone beta subunit in the endocrine tissues, insulin in the pancreas, 2937 
and fatty acid binding protein 4 in the adipose and soft tissues (www.proteinatlas.org). Thus, the 2938 
abundance of proteins in small tissues or in specific regions of an organ may become diluted 2939 
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relative to the summation of the whole-body protein, rendering its presence below detectable 2940 
levels. In Chapter 4, common FLX-target neuropeptides were not differentially abundant which 2941 
could be because these peptides are typically found in specific regions of the CNS; thus, their 2942 
abundance might have been significantly diluted by those of other proteins expressed throughout 2943 
other tissues present in whole body samples. 2944 
(3) Short exposure times limiting the synthesis of protein products and associated 2945 
detectable abundance differences. Estrogen-responsive proteins exhibited high spectral intensities 2946 
in Chapters 2 and 3; however, detectable protein abundance differences were only observed in 2947 
FHM exposed to EE2 for 7 days to EE2 (Chapter 2) and not in RBT exposed to EE2 for 4 days 2948 
(Chapter 3), even though exposure concentrations were similar. The reason for this difference may 2949 
be due to FHM having been exposed for 3 additional days, and hence may have had enough time 2950 
to synthesize gene products in response to the toxic insult, as well as manifestation of feedback 2951 
responses. In addition to exposure times, these observations may have been affected by differences 2952 
in developmental time between the two species and (4). 2953 
(4) Presence of significant concentrations of maternally transferred proteins in RBT that 2954 
may have masked changes in protein abundance ratios. At the time of sampling (4 dph) rainbow 2955 
trout had still prominent yolk sacks compared to FHM that were approaching swim-up and 2956 
independent feeding.  As yolk consists predominantly of Vtg and closely related proteins, any 2957 
potential differences in yolk protein production in these fish may have been diluted as corroborated 2958 
by very high spectral intensities of yolk proteins in RBT in treated and untreated groups (Chapter 2959 
3).  2960 
Despite these shortcomings of the proteomics studies conducted as part of this dissertation, 2961 
good concordance between downstream responses and transcriptomics was observed, which 2962 
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supports the construction of a toxicity pathway model. For instance, histological observations in 2963 
EE2-exposed FHM and RBT showed evidences of proteinaceous fluids in the liver, kidneys, and 2964 
coelom (Alcaraz et al., 2021a, 2021b; Chapters 2 & 3), suggesting EE2-induced overproduction 2965 
of estrogen-associated proteins such as Vtg and coagulation factors, among others (Tompsett et 2966 
al., 2012; Weber et al., 2003; Wolf and Wheeler, 2018). Behavioral responses were altered in 2967 
FLX-exposed FHM, which were corroborated by combined transcriptomics and proteomics 2968 
overrepresentation analyses (Chapter 4) and by reports in the literature (Brooks, 2014; Mole and 2969 
Brooks, 2019). Thus, downstream responses observed in the studies done here and those found in 2970 
the literature tend to supplement/complement the linkage across biological levels. More 2971 
importantly in the context of chemical hazard assessment, evidence of the transcriptomics-apical 2972 
response linkages instilled confidence in the connection between changes in gene expression and 2973 
apical outcomes, which paved the way for exploring derivation of tPODs discussed in the next 2974 
section. tPODs are based on the hypothesis that genomic dose response studies (GDRS) provide a 2975 
good approximation of the toxicological potencies of chemicals observed under apical chronic 2976 
scenarios (Thomas et al., 2013a).  2977 
 2978 
6.3. tPODs from ELS exposures 2979 
 tPODs are concentrations corresponding to whole transcriptome effect levels based on pre-2980 
set benchmark responses (BMRs) that are considered adverse or significant (Ewald et al., 2020; 2981 
National Toxicology Program, 2018; Pagé-Larivière et al., 2019). The National Toxicology 2982 
Program (NTP) recommended the use of a pathway-level benchmark concentration (pathBMC) to 2983 
estimate the tPOD as this approach is based on biologically interpretable sets of genes that may 2984 
produce biological effects such that it may provide indication/evidence of the possible mechanism 2985 
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of action (National Toxicology Program, 2018). However, derivation of pathBMCs is dependent 2986 
on the level of annotation of the genome/transcriptome of the species of interest. This is 2987 
problematic because many ecologically relevant species that are important for ERA lack fully 2988 
assembled and/or have poorly annotated genomes. In recent years, studies have explored other 2989 
statistical approaches to calculate tPODs (Chauhan et al., 2016; Farmahin et al., 2017; Thomas et 2990 
al., 2013b; Webster et al., 2015), but statistical tPODs based on the distribution of gene-level 2991 
benchmark concentrations (geneBMCs) seem to produce the most stable and protective estimates 2992 
(Pagé-Larivière et al., 2019). These tPODs are based on the statistical estimates from benchmark 2993 
concentrations (BMCs) of active features – genes or transcripts that have BMCs - which include 2994 
(1) the median of BMCs of the 20 most sensitive active genes (omicBMC20), (2) the value of the 2995 
BMC of the tenth percentile of all active genes (omicBMC10th), and (3) the mode of the first peak 2996 
of all geneBMCs (omicBMCmode).  2997 
A comprehensive and detailed discussion of cross-species tPODs comparison can be found 2998 
in Chapter 5 of this dissertation. In brief, tPODs across species derived from 4 dph alevins/larvae 2999 
were generally within the range of empirically derived apical PODs reported in this study and in 3000 
the literature (Table 6.1). Overall, omicBMC20s were the most sensitive and protective (lowest 3001 
tPOD value) among all tPOD estimates across species for both EE2 and FLX (Chapter 5). The 3002 
estimated omicBMC20s for EE2 across species were at par with the consensus apical POD of 1 3003 
ng/L, while omicBMC20s for FLX were within the more sensitive/protective range of 3004 
concentrations relative to those reported in the literature (Alcaraz et al., 2021a; Chapters 2-5). 3005 
While protective and sensitive, a major critique with omicBMC20 is that they are purely based on 3006 
statistical and not necessarily biological outcomes. It is acknowledged that the main purpose of 3007 
the derivation of tPODs is to identify the concentration that would significantly perturb biology 3008 
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and would potentially result in a phenotypic outcome (National Toxicology Program, 2018). 3009 
However, the mechanisms associated with or the identification of specific phenotypic outcomes 3010 
may be necessary as weight-of-evidence for regulatory acceptability in chemical hazard 3011 
identification. While the omicBMC20 estimates in this study may be limited to 2 CECs and 3 fish 3012 
species, the high sensitivities and protectiveness of the derived values towards apical chronic 3013 
PODs show significant promise and should be expanded to a broader range of chemical 3014 
contaminants of concern and species of interest in future studies.  3015 
One possible strategy to characterize the link between omicBMC20 and apical outcomes 3016 
could be by manual curation of the annotations of the 20 most sensitive features and placing them 3017 
into gene sets or pathways. Then, interaction networks these genes are involved in can be 3018 
established and used to explain biological and molecular processes that may lead to (an) apical 3019 
outcome(s). This strategy may be a more attractive approach than using pathBMC since operating 3020 
with the 20 most sensitive features with high confidence through manual curation is less tedious 3021 
and relatively more accurate than computationally inferred annotation of the whole 3022 
genome/transcriptome without manual curation for the estimation of pathBMC. This strategy can 3023 
also be extended, at a certain extent, to omicBMC10th, although this is less practical due to possibly 3024 
greater number of genes that need to be curated but at the same time, may yield more information. 3025 
However, it should be noted that the approach that was developed in this dissertation used whole 3026 
body ELS fish, which is limited with regards to characterizing key events and key event 3027 
relationships in toxicity pathways. Specifically, the approach may not be able to discriminate 3028 
tissue-/organ-specific responses or may lack sensitivity for some lowly expressed genes due to 3029 
tissue dilution. Nevertheless, the concept of tPODs was developed as a tool for chemical 3030 
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prioritization to inform more in-depth testing (National Toxicology Program, 2018). It is not yet a 3031 
mature science that can independently characterize MOAs or set toxicological thresholds.  3032 
Overall, RBT appeared to be the most sensitive species based on the derived tPODs closely 3033 
followed by WS, relative to estimates obtained from FHM, both for EE2 and FLX. This 3034 
observation is interesting since RBT and FHM are much closer phylogenetically, although it is 3035 
acknowledged that phylogenetic distance should not be a default basis and explanation for 3036 
similarities and differences in species responses. One possible explanation for these differences 3037 
may be the length of exposure and developmental times. FHM were exposed earlier and for a 3038 
longer time than the other two fishes (summarized in Chapter 5); hence, compensatory and 3039 
downstream physiological responses may have taken place and manifested feedback responses to 3040 
the toxic insults; the shorter exposure time for WS and RBT (from hatch to 4 dph) may not have 3041 
been sufficient time for these compensatory feedbacks to manifest. A time-course study on 3042 
transcriptional responses may help elucidate this hypothesis. In addition, RBT and FHM were 3043 
analyzed (summarized) at gene-level while datasets from WS were analyzed at the transcriptome-3044 
level due to the absence of a fully assembled genome. These differences would render the results 3045 
not directly comparable, but regardless, tPOD estimates across species were within a tight range 3046 
of concentrations despite these 2 major differences in exposure experiments and data analyses. 3047 
Estimates were relatively comparable across species and compared well to empirically-derived 3048 
apical PODs, suggesting that the use of short-term ELS of fish assays in deriving tPODs, even 3049 
with minor variations in the process, hold promise as an effective surrogate for long-term/chronic 3050 
adult exposures. In addition, tPODs derived here were significantly more sensitive relative to cell-3051 
based assays in deriving PODs/BMCs (Caminada, 2008; Pagé-Larivière et al., 2019) and are 3052 
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directly comparable to apical PODs without a need for additional safety factors, further 3053 
highlighting the advantage of the approach being developed in this study.   3054 
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Table 6.1. Summary of tPODs across species. Datasets were fitted using the models Exp2, Exp3, 3055 
Exp4, Exp5, Linear, Poly2, Hill, and Power, with a threshold lack-of-fit p-value > 0.1 and a 3056 
benchmark-response (BMR) factor = 1. 3057 
 FLX (µg/L) EE2 (ng/L) 
tPOD WS RBT FHM WS RBT FHM 
omicBMC20 0.02 0.02 0.56 0.06 0.12 2.39 
omicBMC10th 0.64 0.32 5.0 7.98 1.44 27.82 
omicBMCmode 2.08 5.01 7.43 16.51 4.38 24.93 
pathBMC - 0.19 5.66 - 1.68 45.61 
 3058 
omicBMC20 = median of BMCs of the 20 most sensitive active genes 3059 
omicBMC10th = value of the BMC of the tenth percentile of all active genes  3060 
omicBMCmode = mode of the first peak of all geneBMCs 3061 
pathBMC = most sensitive pathway BMC, with at least 3 geneBMCs, based on bootstrapped median of constitutive geneBMCs 3062 
of that specific pathway 3063 
  3064 
214 
 
6.4. Future work 3065 
The application of tPODs in chemical and environmental risk assessment is a growing 3066 
concept, particularly for chemical testing prioritization. Most often, strategies on deriving tPODs 3067 
were based on rats/mice (Farmahin et al., 2017; Johnson et al., 2014; Thomas et al., 2013b) and 3068 
cell lines (Black et al., 2012; Chauhan et al., 2016). However, these strategies face either 3069 
significant animal ethics issues for the use of live animals or derived threshold concentrations 3070 
require in-vitro-to-in-vivo extrapolation. In this dissertation, we proposed short-term ELS (prior to 3071 
independent exogenous feeding) fish exposures for use in the derivation of tPODs that were 3072 
protective of chronic apical effects while using fish life-stages that are not considered live animals 3073 
under current legislations. Unlike in vitro and in silico NAMs, the approach proposed here is lower 3074 
in throughput and relatively more expensive and tedious, but the estimated tPODs were more 3075 
robust in estimating apical PODs. These aspects have significantly improved relative to current 3076 
chemical hazard testing approaches where live animals are being used, but the methods could still 3077 
be further advanced by streamlining and optimizing several steps. Regardless of its promise, this 3078 
strategy is still at its infancy and much work is needed to gain confidence in the use of ELS-derived 3079 
tPODs in chemical hazard assessment. The following recommendations are based on the 3080 
experience and conduct of this dissertation: 3081 
1. Identify the optimal number of replication with considerations on reasonable experimental 3082 
set-up and cost, as well as the minimum number of dose/concentration/treatment groups 3083 
for the effective derivation of tPODs;  3084 
2. Test and optimize higher-throughput methods in ELS exposures such as petri-dishes and/or 3085 
micro-well plates; 3086 
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3. Determine the ideal sequencing depth such that important molecular responses are within 3087 
detectable levels while reducing sequencing costs; 3088 
4. Assess current statistical strategies in tPOD estimation and identify the best strategies to 3089 
estimate tPODs that are protective of apical POD;  3090 
5. Identify strategies to link statistical tPOD estimates to biological context. The adverse 3091 
outcome pathway (AOP) framework could be a key tool in this exercise; 3092 
6. Conduct similar studies using other species of fish belonging to phylogenetically diverse 3093 
families; 3094 
7. Identify fish species which may potentially serve as an overall standard species for the 3095 
derivation of tPODs; 3096 
8. Use other compounds/mixtures and assess how derived tPODs compare to their 3097 
corresponding apical PODs; 3098 
9. Standardize and develop guidance documents for tPOD derivation from ELS fish. To date, 3099 
the use of omics technologies in ERA and chemical hazard assessment remains to be 3100 
sufficiently validated and trusted by the regulatory community (Sauer et al., 2017). A 3101 
guidance document would allow direct cross-comparison of datasets and standardization 3102 
of dataset generation, processing, and interpretation for regulatory acceptability.  3103 
 3104 
Moreover, additional case studies are needed in establishing the link between tPODs and 3105 
apical effects to gain further confidence in its use in regulatory ecotoxicology. Efforts should also 3106 
be directed towards genome assembly and curation of functional annotations particularly for 3107 
species important to ERA for more accurate prediction of the mechanisms of toxicity. In addition, 3108 
with the vast numbers of compounds that need to be tested, the derivation of tPODs should advance 3109 
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further than simply for the purposes of chemical testing prioritization and should mature such that 3110 
one can derive reference doses and margin of exposure values that are anchored to a biological 3111 
context that is useful for evaluating human and environmental risks. Finally, once proteomics 3112 
techniques and instrumentation mature such that the majority of the proteins in the proteome are 3113 
detected so that a truly global proteomic profile is achieved, it may be of interest to develop 3114 
proteomics-based PODs since proteins are the fundamental effectors of cellular processes and 3115 
therefore are more relevant in downstream biological processes. 3116 
 3117 
6.5. Conclusion 3118 
 In conclusion, this study demonstrated that omics responses can be linked to downstream 3119 
and apical outcomes in diverse fish species. These connections serve as foundations for the use of 3120 
tPODs in estimating apical PODs. Fish ELS-derived tPODs were effective in estimating chronic 3121 
apical PODs, and that tPODs derived using this strategy fall within a tight range of concentrations 3122 
across phylogenetically distant fish species. Therefore, fish ELS-derived tPODs hold promise in 3123 
replacing, reducing, and refinement of the use of live animals in chemical hazard assessment. After 3124 
additional careful calibration and validation, the here proposed ELS tPOD-based hazard 3125 
assessment strategy holds significant promise to replace or minimize current live animal-based 3126 
regulatory testing requirements by enabling accurate prediction of protective toxicity thresholds 3127 
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APPENDIX A 4243 
Table A.S1. CRediT author statement 4244 
Term Definition 
Conceptualization  Ideas; formulation or evolution of overarching research goals and aims  
Methodology  Development or design of methodology; creation of models  
Software  
Programming, software development; designing computer programs; 
implementation of the computer code and supporting algorithms; testing of 
existing code components  
Validation  
Verification, whether as a part of the activity or separate, of the overall 
replication/ reproducibility of results/experiments and other research 
outputs  
Formal analysis  
Application of statistical, mathematical, computational, or other formal 
techniques to analyze or synthesize study data  
Investigation  
Conducting a research and investigation process, specifically performing 
the experiments, or data/evidence collection  
Resources  
Provision of study materials, reagents, materials, patients, laboratory 
samples, animals, instrumentation, computing resources, or other analysis 
tools  
Data Curation  
Management activities to annotate (produce metadata), scrub data and 
maintain research data (including software code, where it is necessary for 
interpreting the data itself) for initial use and later reuse  
Writing - Original 
Draft  
Preparation, creation and/or presentation of the published work, 
specifically writing the initial draft (including substantive translation)  
Writing - Review & 
Editing  
Preparation, creation and/or presentation of the published work by those 
from the original research group, specifically critical review, commentary 
or revision – including pre-or postpublication stages  
Visualization  
Preparation, creation and/or presentation of the published work, 
specifically visualization/ data presentation  
Supervision  
Oversight and leadership responsibility for the research activity planning 
and execution, including mentorship external to the core team  
Project 
administration  
Management and coordination responsibility for the research activity 
planning and execution  
Funding acquisition  
Acquisition of the financial support for the project leading to this 
publication  
 4245 
This table is reprinted from Allen et al., (2019). Copyright (2019), with permission from the 4246 
Association of Learned & Professional Society Publishers (Learned Publishing).  4247 
268 
 
APPENDIX B 4248 
B.1. Chemical analyses 4249 
Water samples from exposure tanks were collected at three time points during the flow-4250 
through exposure experiment (4, 14 and 28dph). Water samples were collected from each replicate 4251 
tank and pooled for analyses at each time point. Concentrations of EE2 in exposure solutions were 4252 
measured at SGS AXYS Analytical Services Ltd, Sidney BC, Canada using a protocol published 4253 
previously (Long et al., 2013). Briefly, water samples were extracted by solid-phase extraction 4254 
and were spiked with d4-17α-ethinylestradiol (d4-EE2; CDN Isotopes, Pointe-Claire QC, Canada; 4255 
Prod# D-4319) for quantification by isotope dilution using a Waters 2690 HPLC or Waters 2795 4256 
HPLC (Waters, Milford MA, USA), equipped with a Waters Xterra MS C18 (10.0 cm length, 2.1 4257 
mm i.d., 3.5 µm particle size; Waters), coupled with a Micromass Quattro Ultima MS/MS (Waters) 4258 
operating in negative ion electrospray mode at unit resolution. A gradient elution using (A) water 4259 
at pH = 10 (adjusted using NH4OH) and (B) 1:1 acetonitrile:methanol was used. A seven-point 4260 
calibration curve ranging from 1.25-780 ng/mL was used for quantitation using 1/x weighted linear 4261 
calibration and response relative to d4-EE2. Measured concentrations were corrected for % 4262 
recovery of d4-EE2. The limit of detection was 6.46 ng/L. 4263 
 4264 
B.2. Transcriptomics 4265 
Since the concentration of EE2 in the low treatment group was below detection limits, only 4266 
the samples from the solvent control, medium, and high treatment groups were used to assess 4267 
transcriptional responses. Total RNA was extracted from pooled whole embryos for each replicate 4268 
using RNEasy Plus Universal Mini Kit (Qiagen, Hilden, Germany; Cat# 73404) following the 4269 
manufacturer’s protocol for whole tissue total RNA extraction. Total RNA concentrations were 4270 
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measured using the QIAxpert (Qiagen) and the RNA Integrity Number (RIN) was assessed with 4271 
an Agilent RNA 6000 Nano kit (Agilent Technologies, Waldbronn, Germany; Part#5067-1511) in 4272 
an Agilent 2100 Bioanalyzer (Agilent Technologies). Samples with RIN > 8 were sent to the 4273 
McGill University and Génome Québec Innovation Centre for 200 base-pairs paired-end (100x2) 4274 
sequencing using a HiSeq 4000 instrument (Illumina Inc, San Diego CA, USA).  4275 
 Raw fastq files were assessed using FastQC(Andrews, n.d.) and trimmed, in pairs, to a 4276 
minimum phred score of 20 and a minimum length of 35 bases per paired read using Trimmomatic 4277 
(Bolger et al., 2014). Reads were aligned against the latest FHM reference genome build  (NCBI 4278 
Acc# WIOS00000000) using HISAT2 (Kim et al., 2015).  StringTie was used to reconstruct the 4279 
transcriptome and to estimate expression levels of transcripts and genes (Pertea et al., 2015). Raw 4280 
counts were filtered to remove features with less than five counts per million in at least five 4281 
samples and were normalized by use of the trimmed mean of M values (TMM) approach 4282 
(Robinson and Oshlack, 2010) using edgeR (McCarthy et al., 2012; Robinson et al., 2010). 4283 
Replicate1 of the solvent control group did not cluster with other replicates within the treatment 4284 
group (Figure B.S5); thus, it was not included in the differential expression analysis. Significance 4285 
of differentially expressed genes (DEG) were assessed using the quasi-likelihood pipeline (Chen 4286 
et al., 2016), and scored with a cut-off false discovery rate (FDR; Benjamini-Hochberg) of ≤ 0.05 4287 
and a minimum effect size threshold fold-change |FC| > 1.5 relative to the solvent control group. 4288 
Default software settings were used for analyses, unless otherwise stated. Raw fastq files are 4289 




B.3. Proteomics 4292 
The transcriptomic analyses showed more pronounced transcriptional perturbations in the 4293 
high treatment group; thus, only the samples from the solvent and high treatment groups were 4294 
selected for non-targeted proteomics analysis. Cell disruption and protein solubilization were done 4295 
using SDT buffer (4% Sodium dodecyl sulfate (SDS; Sigma-Aldrich, St. Louis MO, USA; Cat# 4296 
436143), 0.1 M Dithiothreitol (DTT; Thermo Fisher Scientific, Waltham MA, USA, Cat# R0862), 4297 
0.1 M Tris/HCl (Sigma-Aldrich, Cat# 10812846001; pH = 7.6) lysis buffer in a Thermomixer® 4298 
(Eppendorf, Hamburg, Germany) at 95oC, for 2 hours. Quality of protein extracts was assessed by 4299 
use of 1D SDS-PAGE (12% gels). Protein extracts were then processed following standard 4300 
protocol for filter-aided sample preparation (FASP) (Wiśniewski et al., 2009; Wiśniewski and 4301 
Rakus, 2014). Briefly, proteins were alkylated using 50 mM iodoacetamide (Sigma-Aldrich, Cat# 4302 
I1149) for 20 mins at RT and digested using trypsin (Sequencing grade; Promega, Madison WI, 4303 
USA, Cat# V5111) in 50 mM ammonium bicarbonate at 37oC for 18 hrs, on a 30 kDa membrane 4304 
filter unit. Resulting peptides were eluted with ammonium bicarbonate (AB) buffer and the FASP 4305 
eluates were kept at -80oC until further LC-MS/MS analysis. 4306 
FASP eluates were cleaned using 3 iterations (Yeung and Stanley, 2010) of ethylacetate 4307 
extraction to remove SDS contamination and then were completely dried in a SpeedVac vacuum 4308 
concentrator (Thermo Fisher Scientific, Waltham MA, USA). Cleaned peptides were reconstituted 4309 
by acid extraction using 50 µl of (1:1) 5% formic acid (LC-MS grade, >99% purity; Fisher 4310 
Scientific Cat# A11750) and 100% acetonitrile (HPLC grade, >99.9%; Sigma-Aldrich, Cat# 4311 
34851), with 1.5 µl of 0.01% poly(ethylene glycol) (PEG; Millipore-Sigma, Cat# 95172) to reduce 4312 
sample loses. The final solution was transferred to a TPX (polymethylpentane) vial and vacuum 4313 
concentrated using SpeedVac vacuum concentrator to a final volume of 15 µl.  4314 
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LC-MS/MS analyses were conducted using an Orbitrap Fusion™ Lumos™ Tribrid Mass 4315 
Spectrometer system (Thermo Fisher Scientific) connected online to an Ultimate 3000 RSLCnano 4316 
system (consisted of SRD-3400, NCS-3500RS CAP, WPS-3000 TPL RS; Thermo Fisher 4317 
Scientific). Prior to LC separation, tryptic digests were online concentrated and desalted on a 4318 
cartridge trapping column (300 μm × 5 mm, C18 PepMap100, 5μm particles, 100 A; Thermo 4319 
Fisher Scientific, Cat#160454) using 0.1% formic acid (FA) in water. The peptides were eluted 4320 
from the trapping column onto an Acclaim Pepmap100 C18 analytical column (3 µm particles, 75 4321 
μm × 500 mm; Thermo Fisher Scientific, Cat# 164570) by non-linear gradient (2-35% of mobile 4322 
phase B; mobile phase A: 0.1% FA in water; mobile phase B: 0.1% FA in 80% acetonitrile). The 4323 
analytical column was directly connected to the Digital PicoView® 550 (New Objective, Woburn 4324 
MA, USA) ion source with sheath gas option and SilicaTip emitter (New Objective; P/N: FS360-4325 
20-15-N-20-C12) utilization. Active Background Ion Reduction Device (ABIRD; ESI Source 4326 
Solutions, Woburn MA, USA) was installed to the LC-MS/MS system to isolate the experiment 4327 
from variable background ion interferences. MS data were acquired in a data-dependent 4328 
acquisition strategy, selecting up to top 20 precursors based on precursor abundance in the survey 4329 
scan (350 - 2000 m/z). The resolution of the survey scan was 120,000 (at 200 m/z) with a target 4330 
value of 4×105 ions and maximum injection time of 100 ms. Higher-energy collisional dissociation 4331 
(HCD) MS/MS spectra were acquired with a target value of 5×104 and resolution of 15,000 (at 4332 
200 m/z). The maximum injection time for MS/MS was 22 ms. 4333 
Raw mass spectrometric data files were analyzed using MaxQuant (Cox and Mann, 2008; 4334 
Tyanova et al., 2016) with built-in Andromeda search engine (Cox et al., 2011). Samples were 4335 
mapped against the FHM proteome assembly (NCBI Acc# WIOS00000000), combined with the 4336 
cRAP contaminant database (January 2020; 246 sequences). The reference proteome was cleaned 4337 
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for duplicated and highly similar sequences (>95% similarity; minimum of 35 amino acids; a total 4338 
of 35,108 proteins) prior to analysis. Oxidation (M) and deamidation (N, Q) as optional 4339 
modifications, carbamidomethylation (C) as fixed modification and two enzymes miss-cleavages 4340 
were set for the first and main search. Peptides and proteins with an FDR (q-value) < 1% and at 4341 
least one razor peptide (peptide that has been assigned to the Protein Group with the largest number 4342 
of total identified) (Cox et al., 2009) were selected for downstream analyses. Raw data were 4343 
deposited in the ProteomeXchange Consortium via the Proteomics Identifications (PRIDE) partner 4344 
repository (Accession# PXD021155).  4345 
All downstream differential protein abundance analyses were done in KNIME (Berthold 4346 
et al., 2008) using the OmicsWorkflow pipeline found at the repository 4347 
https://github.com/OmicsWorkflows. Protein groups with missing quantification values on all 4348 
replicates within a treatment group were filtered out. Median normalization strategy was applied 4349 
to all protein group intensities across samples (Figure B.S2). Significance of differentially 4350 
abundant protein (DAP) groups was assessed using limma (Ritchie et al., 2015), with a cut-off 4351 
moderated p-value of ≤ 0.05 and a minimum effect size threshold of |FC| > 1.5 relative to the 4352 
solvent control group. limma estimates moderated p-values by using the whole dataset to shrink 4353 
sample variances towards pooled estimate, which have been shown to be a practical approach in 4354 
detecting DAP with minimal loss from false negatives (Kammers et al., 2015; Pascovici et al., 4355 
2016). Default software settings were used for analyses, unless otherwise stated. 4356 
 4357 
B.4. Statistical Analyses 4358 
 Survival rates of replicate 2 at 28dph showed extreme deviation (high mortality) from the 4359 
rest of the dataset, resulting to relatively higher length and weight due to lesser competition within 4360 
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a tank; thus, this replicate was not included in the statistical analyses of survival rates and 4361 
morphometrics. 4362 
Fulton’s condition factor (Froese, 2006) was calculated using the following equation:  4363 




where: w = weight in mg and l = length in mm.  4365 
Data on growth, condition factor, and survival rates were assessed for significant 4366 
differences across treatment groups using a one-way analysis of variance (ANOVA), followed by 4367 
Tukey’s multiple comparison post-hoc test, with a cut-off p-value < 0.05. Tests for assumptions 4368 
were performed prior to ANOVA. In cases where assumptions of ANOVA were not met, the non-4369 
parametric ANOVA analogue, Kruskal-Wallis test, was performed, followed by Dunn’s multiple 4370 
comparison test with a cut-off p-value < 0.05. Regression analyses were done on all treatment 4371 
groups, excluding the water control group, using ordinary least-squares (OLS) linear regression.  4372 
Opportunistic eye histology was conducted on a randomly selected subset of fish across all 4373 
replicates (solvent control, n=5; high treatment group, n=7). Assessments were made on one eye 4374 
per fish at the widest cross-sectional area. The total cross section area of the eye was measured, as 4375 
well as the total retina thickness and thickness of 3 individual retina layers: the photoreceptor layer 4376 
(PRL), outer plexiform layer (OPL), and inner plexiform layer (IPL). Eye Index (EI) was 4377 
calculated as: EI = [eye area (mm2)/fish length (mm)]*100 (modified from Hyeon et al., 2019)). 4378 
All non-omics statistical analyses were carried out in GraphPad Prism. 4379 
  4380 
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Table B.S1. List of software used in Chapter 2. 4381 
Software Versions Use 
FastQC v0.11.9 
Quality control of raw 
reads 
Trimmomatic v0.38 
Trimming of low quality 
and short reads ( < 35 bp) 
HISAT2 v2.1.0 
Alignment of reads to the 
reference genome 





Data manipulation of 
aligned reads 
Cytoscape v3.7.1 
Platform for downstream 
network analysis 
g:Profiler 
Ensembl 98, Ensembl 
Genomes 45 (rev 4d9abf6, 




Construction of PPI 
network 
NetworkAnalyzer v4.4.5 
Docked in Cytoscape; 
Assessment of topological 
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parameters of the PPI 
network 
Galaxy Europe  




protein pair concordance 
MaxQuant v.1.6.10.43 
Quantitative proteomics 
software to identify 






GraphPad Prism v8.4.2 




  4383 
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Table B.S2. Nominal and measured concentrations of EE2 in exposure tanks. Concentrations were 4384 
based on percent (%) recovery of standard d4-EE2 spiked to the samples. Water samples were 4385 
collected prior to (t = 4dph), during (t = 14 dph), and immediately after (t = 28dph) flow-through 4386 








@ t = 4dph 
Measured 
concentration 
@ t = 14dph 
Measured 
concentration 




Water Control 0 ND ND ND ND 
Solvent 
Control 
0 ND ND ND ND 
Low dose 4 ND ND ND ND 
Medium dose 20 30.69 25.05 14.65 23.46 ± 8.13 





Table B.S3. Average physico-chemical characteristics of exposure solutions measured daily 4390 
(temperature, pH, conductivity and dissolved oxygen) and weekly (ammonia, nitrates, nitrite, 4391 
hardness and alkalinity). 4392 
Parameters Values 
Temperature 23.12 ± 0.77 oC 
pH 8.28 ± 0.09 
Conductivity 486.6 ± 12.5 µS/cm 
Dissolved oxygen (DO) 104.4 ± 2.6 % 
Ammonia ≤ 0.25 mg/L 
Nitrates 0.68 ± 0.35 mg/L 
Nitrite ≤ 0.05 mg/L 
Hardness 175.43 ± 15.53 mg CaCO3/L 





Table B.S4. Incidence of pathological features in control and exposed larval FHM. 4395 
FHM ELS 









Gonad Differentiation (ovaries vs. testes) 6M : 9F 14 ?* : 1 F 14 ?* : 1 F 
      
Kidney Tubules distorted / enlarged 0 6 15 
 Tubule lumens dilated 0 1 13 
 Tubule lumens contain eosinophilic fluid 0 1 13 
 
Epithelial cells hypertrophied / vacuolated / 
swollen 
0 6 15 
 Glomeruli - increased # and size 0 9 14 
      
Liver Hepatocyte basophilia 0 15 15 
 Hepatocyte glycogen accumulation 12 4 0 
 Hepatocyte lipid accumulation 0 0 0 
 
Eosinophilic intravascular fluid 
accumulation 
0 15 15 
      
Coelom Eosinophilic fluid accumulation 0 6 14 
*Gonad was either not detected, or was undifferentiated/poorly developed. 4396 
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M – male 4397 




Figure B.S.1. Study design. Exposures were initiated at <6 hpf, between late cleavage and high 4400 
blastula developmental stages. Samples for omics analyses were collected at 4dph. Exposure was 4401 
terminated at 28dph, when measurements for lengths and weights of individual fish were taken 4402 



















GO:MF sequence-specific DNA binding GO:0043565 1400 23956 0.0005628 61 15 
GO:MF 
DNA-binding transcription factor activity, 
RNA polymerase II-specific GO:0000981 612 23956 0.008051161 61 9 
GO:MF DNA binding GO:0003677 2532 23956 0.013323067 61 18 
GO:MF transcription regulator activity GO:0140110 1459 23956 0.021982549 61 13 
GO:MF lipid transporter activity GO:0005319 149 23956 0.039864457 3 2 
GO:BP cellular response to estrogen stimulus GO:0071391 49 21726 3.14E-09 8 5 
GO:BP response to estrogen GO:0043627 52 21726 4.27E-09 8 5 
GO:BP sensory organ development GO:0007423 673 21726 2.79751E-05 59 13 
GO:BP regulation of transcription, DNA-templated GO:0006355 2348 21726 4.0026E-05 61 23 
GO:BP 
regulation of nucleic acid-templated 
transcription GO:1903506 2387 21726 5.44804E-05 61 23 
GO:BP regulation of RNA biosynthetic process GO:2001141 2388 21726 5.49082E-05 61 23 
GO:BP sensory system development GO:0048880 604 21726 7.72972E-05 59 12 
GO:BP visual system development GO:0150063 498 21726 0.000101471 59 11 
GO:BP eye development GO:0001654 498 21726 0.000101471 59 11 
GO:BP transcription, DNA-templated GO:0006351 2499 21726 0.000127586 61 23 
GO:BP nucleic acid-templated transcription GO:0097659 2536 21726 0.000167206 61 23 
GO:BP RNA biosynthetic process GO:0032774 2542 21726 0.000174618 61 23 
GO:BP 
regulation of cellular macromolecule 
biosynthetic process GO:2000112 2559 21726 0.000197311 61 23 
GO:BP regulation of RNA metabolic process GO:0051252 2575 21726 0.000221145 61 23 
GO:BP 
regulation of macromolecule biosynthetic 
process GO:0010556 2607 21726 0.000277038 61 23 
GO:BP regulation of cellular biosynthetic process GO:0031326 2648 21726 0.000367839 61 23 
GO:BP 
regulation of nucleobase-containing 
compound metabolic process GO:0019219 2663 21726 0.000407454 61 23 
GO:BP regulation of biosynthetic process GO:0009889 2668 21726 0.000421515 61 23 
GO:BP regulation of gene expression GO:0010468 2809 21726 0.001061362 61 23 
GO:BP 
nucleobase-containing compound 
biosynthetic process GO:0034654 2902 21726 0.00188774 61 23 
GO:BP eye morphogenesis GO:0048592 221 21726 0.002656164 59 7 
GO:BP aromatic compound biosynthetic process GO:0019438 2978 21726 0.002967349 61 23 
GO:BP heterocycle biosynthetic process GO:0018130 2988 21726 0.0031456 61 23 
GO:BP central nervous system development GO:0007417 685 21726 0.003348307 61 11 
GO:BP 
organic cyclic compound biosynthetic 
process GO:1901362 3074 21726 0.00513877 61 23 




GO:BP optic nerve development GO:0021554 19 21726 0.010682539 47 3 
GO:BP 
regulation of nitrogen compound metabolic 
process GO:0051171 3726 21726 0.011569677 61 25 
GO:BP sensory organ morphogenesis GO:0090596 289 21726 0.015404875 59 7 
GO:BP regulation of primary metabolic process GO:0080090 3798 21726 0.016327081 61 25 
GO:BP 
cellular nitrogen compound biosynthetic 
process GO:0044271 3542 21726 0.016367354 61 24 
GO:BP nervous system development GO:0007399 1716 21726 0.016918852 61 16 
GO:BP 
regulation of macromolecule metabolic 
process GO:0060255 3878 21726 0.02367494 61 25 
GO:BP regulation of cellular metabolic process GO:0031323 3917 21726 0.028260292 61 25 
GO:BP 
regulation of transcription by RNA 
polymerase II GO:0006357 1426 21726 0.033534025 53 13 
GO:BP epithalamus development GO:0021538 25 21726 0.036134688 53 3 
GO:CC photoreceptor outer segment GO:0001750 45 21269 0.023710041 48 3 
GO:CC photoreceptor cell cilium GO:0097733 54 21269 0.040858593 48 3 
GO:CC 9+0 non-motile cilium GO:0097731 54 21269 0.040858593 48 3 
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peptidase activity, acting on L-amino acid 
peptides GO:0070011 821 23956 0.003372 252 24 
GO:MF peptidase activity GO:0008233 850 23956 0.005988 252 24 
GO:MF cell adhesion molecule binding GO:0050839 129 23956 0.026204 75 5 
GO:MF 
hydrolase activity, acting on acid 
phosphorus-nitrogen bonds GO:0016825 291 23956 0.031913 252 12 
GO:MF serine hydrolase activity GO:0017171 291 23956 0.031913 252 12 
GO:MF serine-type peptidase activity GO:0008236 291 23956 0.031913 252 12 
GO:MF identical protein binding GO:0042802 191 23956 0.04578 132 7 
GO:BP cell-cell junction organization GO:0045216 86 21726 0.031689 90 5 
GO:BP lipid catabolic process GO:0016042 170 21726 0.033548 252 10 
GO:CC vacuole GO:0005773 288 21269 0.000211 270 16 
GO:CC lysosome GO:0005764 204 21269 0.000479 269 13 
GO:CC lytic vacuole GO:0000323 205 21269 0.000506 269 13 
GO:CC tight junction GO:0070160 87 21269 0.007644 90 5 
GO:CC sarcomere GO:0030017 133 21269 0.010018 150 7 
GO:CC cell junction GO:0030054 411 21269 0.011365 35 6 
GO:CC myofibril GO:0030016 137 21269 0.0121 150 7 
GO:CC contractile fiber GO:0043292 138 21269 0.012672 150 7 











Adjusted p-value Query Size 
Intersection 
Size 
GO:MF lipid transporter activity GO:0005319 149 23956 0.045559 3 2 
GO:BP response to estradiol GO:0032355 33 21726 0.002412 3 2 
GO:BP cellular response to estrogen stimulus GO:0071391 49 21726 0.00537 3 2 
GO:BP response to estrogen GO:0043627 52 21726 0.006054 3 2 
 4411 
Figure B.S3. Manhattan plots of significantly enriched pathways from (1) significantly 4412 
upregulated genes from high treatment group, (2) significantly downregulated genes from high 4413 
treatment group, and (3) all significantly dysregulated genes from medium treatment group. 4414 
Enrichment analyses were conducted using g:Profiler with cut-off threshold enrichment p-value < 4415 
0.05. (MF – molecular function; BP – biological process; CC – cellular component; KEGG – 4416 












Adjusted p-value Query Size 
Intersection 
Size 
GO:BP response to estradiol GO:0032355 33 21726 0.049745 7 2 
 4421 
Figure B.S4. Manhattan plot of significantly enriched pathways from all significantly 4422 
differentially abundant Enrichment analyses were conducted using g:Profiler with cut-off 4423 
threshold enrichment p-value < 0.05. (MF – molecular function; BP – biological process; CC – 4424 
cellular component; KEGG – Kyoto Encyclopedia of Genes and Genomes; REAC – Reactome; 4425 




Figure B.S5. PCA plot of RNA-seq samples. Solvent1 was removed in downstream analyses as 4428 
it failed to cluster with other solvent control replicates. 4429 
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APPENDIX C 4430 
C.1. Fish maintenance and exposure conditions 4431 
Eyed-stage RBT embryos (2N) were purchased from Troutlodge, Inc (WA, USA) and were 4432 
kept in McDonald-type hatching jars until first signs of hatchings were observed. Approximately 4433 
100 unhatched eggs were then transferred (Day 0) into each of the hatching cups, which were kept 4434 
in 9-liter tanks containing exposure solutions (3 tanks x 8 treatments). Unhatched eggs were 4435 
removed after 48 hrs.  4436 
Embryos were exposed, in triplicate, to graded concentrations (nominal: water control, 4437 
0.01% DMSO solvent control, 1, 3, 10, 30, 100 and 300 ng/L) of EE2 (>98% purity, Sigma 4438 
Aldrich, MO, USA) under flow-through conditions (at least 50% v/v renewal per day) (Figure 4439 
C.S1). The final concentration of DMSO in all treatment groups was 0.01% v/v, except for the 4440 
water control. These concentrations were selected based on chronic apical endpoints previously 4441 
reported in the literature (Aris et al., 2014). Temperature was maintained at 15 ± 1 oC, under a 4442 
16:8 light:dark cycle. Tanks were monitored daily for temperature, and weekly for pH, 4443 
conductivity, dissolved oxygen, ammonia, nitrates, nitrites, hardness, and alkalinity. Artemia 4444 
nauplii were introduced to alevins at 14 days post hatch (dph), and fish were then transitioned to a 4445 
diet of frozen bloodworms starting 30 dph. 4446 
Three and five alevins were collected and pooled from each tank after 4 dph for 4447 
transcriptomics and proteomics analyses, respectively. These samples were then immediately flash 4448 
frozen in liquid nitrogen and kept at -80oC until further analyses. Swim-up fry were released into 4449 
the tanks outside the hatching cups. At the end of the swim-up stage (~100% swim up in control 4450 
group, 21 dph), fish were culled to 20 individuals per tank to avoid overcrowding, and the rest 4451 
were euthanized using 450 mg/L buffered MS 222 (Sigma Aldrich). In addition, only the water 4452 
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control, solvent control, 30, 100, and 300 ng/L treatment groups were maintained after swim-up 4453 
as mortalities were not expected to occur at lower concentrations. Surviving juveniles were 4454 
euthanized at 60 dph and assessed qualitatively for overt morphological abnormalities. Whenever 4455 
abnormalities were identified, a second person was consulted to confirm the observation. Five 4456 
randomly selected whole fish from each replicate at 60 dph were also fixed in an all-purpose 4457 
fixative for 48 hours, transferred to 70% ethanol, then stored at room temperature until further 4458 
processing for histological assessment. Lastly, length and weight measurements were taken at 4, 4459 
21, and 60 dph by the same person throughout the experiment so as to minimize multiple 4460 
experimenter biases.  However, since significant mortalities occurred at the highest concentrations, 4461 
fish density in the tanks was affected which is therefore not treatment-associated; hence, length, 4462 
weight, and condition factor at 60 dph were not presented here. Survival was also recorded daily. 4463 
The study was approved by the University of Saskatchewan Animal Research Ethics Board 4464 
(Protocol# 20140079). 4465 
 4466 
C.2. Chemical analyses 4467 
Water samples were collected from each tank at 4 and 21 dph. EE2 was captured via 4468 
hydrophobic retention on optimized reverse-phase solid-phase extraction (SPE) sorbent using 100 4469 
mg/6 ml Strata X polymeric cartridges (Phenomenex Inc, CA, USA) under gentle vacuum. 4470 
Cartridges were dried on the manifold, then EE2 was eluted with 100% Methanol (Optima™ for 4471 
HPLC, Fisher Chemical, Hampton NH, USA), followed by solvent evaporation to dryness under 4472 
constant flow of Nitrogen stream. Samples were reconstituted and pre-diluted with 10% Methanol 4473 
to suitable dilutions within the dynamic range of detection of the enzyme-linked immunosorbent 4474 
assay (ELISA) kit (50 – 3000 ng/L). Concentrations of EE2 were measured using EE2-specific 4475 
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competitive ELISA (Ecologiena®, Fukuoka, Japan, purchased from Eurofins Abraxis, PA, USA), 4476 
following the manufacturer’s protocol. The Ecologiena® EE2 ELISA kit is highly specific and has 4477 
previously been used in measurement of EE2 in environmental samples (King et al., 2016). 4478 
Absorbance was read at λ = 450 nm on a Tecan Spark® multimode microplate reader and EE2 4479 
concentrations were quantified against a standard curve using Assayfit Pro v1.3 software (Assay 4480 
Cloud, Nijmegen, The Netherlands).  4481 
 4482 
C.3. Transcriptomics  4483 
Solvent control, 1, 3, 10, 30, and 100 ng/L treatment groups were used for transcriptomics 4484 
analyses. Fish from 300 ng/L treatment group were not used for transcriptomics due to significant 4485 
mortalities as early as swim-up stage, which could have skewed transcriptomic effects towards 4486 
responses associated with non-specific causes of mortality. Total RNA was extracted from each 4487 
replicate of pooled alevins using RNeasy Plus Universal Mini Kit (Qiagen, Germany). Samples 4488 
with RNA integrity number (RIN) ≥8 were sent to Génome Québec Centre d’Expertise et de 4489 
Services for mRNA sequencing (Genome Quebec, Montreal, QB, Canada). Libraries were 4490 
prepared from 250 ng total RNA using NEBNext Ultra Directional kit with poly(A) magnetic 4491 
isolation module (New England Biolabs Ltd, ON, Canada). Total RNA was poly(A)-enriched prior 4492 
to the synthesis of double-stranded DNA. Libraries were quantified using the KAPA Library 4493 
Quantification kit with Revised Primers-SYBR Fast Universal kit (Kapa Biosystems). Average 4494 
size fragment was determined using a LabChip GX (Perkin Elmer, ON, Canada) instrument. A 1% 4495 
PhiX library was spiked into a pool of 225 pM dsDNA, and was loaded onto a NovaSeq 6000 S4 4496 
lane (Illumina, CA, USA)  for a 200 cycles (100 x 2) paired-end mode sequencing.  4497 
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Base calling was performed using RTA v3.4.4 (Illumina). Base calls were then 4498 
demultiplexed and fastq files were generated for each sample using the bcl2fastq2 v2.20 (Illumina) 4499 
software. Reads were assessed for quality using FastQC v 0.72 (Andrews, n.d.), then trimmed to a 4500 
minimum Phred score of 20 and a minimum length of 35 bases using Trimmomatic v.0.38.1 4501 
(Bolger et al., 2014). The abundance of transcripts was estimated using Kallisto (Bray et al., 2016), 4502 
mapped against the reference RBT transcriptome (GenBank Acc# GCA_002163495.1). Only 4503 
features with 5 counts-per-million in at least 3 samples were kept for differential expression 4504 
analysis. Significance of differentially expressed (DE) transcripts was assessed using DESeq2 4505 
(Love et al., 2014), with a minimum effect size threshold of the absolute value of log2 fold-change 4506 
(|log2FC|) ≥ 1 and a false discovery rate (FDR, Benjamini-Hochberg) ≤ 0.05. Default software 4507 
settings were used unless stated otherwise. Raw fastq files are available through the NCBI GEO 4508 
accession# GSE171788. 4509 
 4510 
C.4. Proteomics 4511 
Since the exposure duration was short, only the highest concentrations which may rapidly 4512 
induce responses were analyzed for proteomic alterations. Alevins from the solvent control, 30, 4513 
and 100 ng/L treatment groups were used for non-targeted proteomics analysis, as described in 4514 
Alcaraz et al. (2021) with minor revisions. Briefly, whole body tissues were processed by filter-4515 
aided sample preparation (Wiśniewski et al., 2009; Wiśniewski and Rakus, 2014) using 30 kDa 4516 
Microcon® filters (Merck Millipore, MA, USA), where alkylation was done using iodoacetamide 4517 
and digestion using trypsin. LC-MS/MS analyses of peptide mixtures were conducted using a Q 4518 
Exactive™ HF-X Hybrid Quadrupole-Orbitrap™ mass spectrometer (Thermo Fisher Scientific, 4519 
MA, USA) connected online to an Ultimate 3000 RSLCnano system (consisted of SRD-3400, 4520 
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NCS-3500RS CAP, WPS-3000 TPL RS; Thermo Fisher Scientific). Prior to LC separation, tryptic 4521 
digests were online concentrated and desalted on a cartridge trapping column (300 μm × 5 mm, 4522 
C18 PepMap100, 5μm particles, 100 A; Thermo Fisher Scientific) using 0.1% formic acid (FA) in 4523 
water. The peptides were eluted from the trapping column onto an Acclaim Pepmap100 C18 4524 
analytical column (3 µm particles, 75 µm × 500 mm; Thermo Fisher Scientific) by linear gradient 4525 
(3-35% of mobile phase B; mobile phase A: 0.1% FA in water; mobile phase B: 0.1% FA in 80% 4526 
acetonitrile) over 130 minutes of active gradient and subsequent increase of mobile phase B to 4527 
80% in 5 minutes and 5 minutes column wash with 80% of mobile phase B. The analytical column 4528 
was directly connected to the Digital PicoView® 550 (New Objective, Woburn MA, USA) ion 4529 
source with sheath gas option and SilicaTip emitter (New Objective; P/N: FS360-20-15-N-20-4530 
C12) utilization.  4531 
Analysis of mass spectrometric data was carried out using MaxQuant v1.6.14 (Tyanova et 4532 
al., 2016). MS/MS ion searches were done using the MaxQuant contaminant database (247 protein 4533 
sequences) and the RBT reference proteome (GenBank Acc# GCA_002163495.1; 71,233 protein 4534 
sequences). Carbamidomethyl (C) was set for fixed modification while Oxidation (M), 4535 
Deamidation (NQ), Oxidation (P), and Acetyl (Protein N-term) were set as variable modifications, 4536 
with a maximum of 2 missed cleavages allowed for first and main search. Peptides and proteins 4537 
with an FDR (q-value) < 1% and at least one razor peptide were selected for downstream analyses. 4538 
Changes in the abundance of proteins were assessed in KNIME v.4.2.3 (Berthold et al., 2008). 4539 
Data were filtered to keep protein groups with 2 or more peptides, and at least two measured 4540 
intensity values in both experimental groups being compared. Log2-transformed protein group 4541 
intensities were loess-normalized.  Significance of differentially abundant protein (DAP) groups 4542 
was assessed using limma with a cut-off moderated p-value ≤ 0.05 and a minimum effect size 4543 
292 
 
threshold |log2FC| ≥ 1 relative to the solvent control group.  Limma estimates moderated p-values 4544 
by using the whole dataset to shrink sample variances towards pooled estimate, which have been 4545 
shown to be a practical approach in detecting DAP with minimal loss from false negatives 4546 
(Kammers et al., 2015; Pascovici et al., 2016). Proteomic spectral datasets were deposited in the 4547 
ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al., 2019) partner repository with 4548 
dataset identifier PXD025251. DAP analysis workflow template can be found in 4549 
https://github.com/OmicsWorkflows. 4550 
 4551 
C.5. Histological assessments 4552 
 At 60 dph, 5 fish per replicate from each treatment were randomly selected for histology. 4553 
Individuals were fixed whole in HealthCare™ PROTOCOL™ SafeFix™ II All-Purpose Fixative 4554 
(Fisher Scientific, MA, USA) for 48 hours, and then transferred to 70% ethanol for storage.  The 4555 
ethanol was decanted and replaced twice to remove excess fixative from the tissues prior to further 4556 
processing. A subset of individuals from the solvent control and 100 ng/L treatment groups (3-4 4557 
individuals per replicate) were selected for processing. The samples were trimmed (i.e., head and 4558 
tail removed) and then dehydrated in graded alcohols, cleared in xylene, and infiltrated with molten 4559 
paraffin using a Belair RVG/1 Vacuum Tissue Processor (University of Saskatchewan, Histology 4560 
Core Facility). The samples were then embedded in paraffin blocks for longitudinal step-sectioning 4561 
in frontal plane (5 mm thick). For each individual, representative sections were taken at a minimum 4562 
of nine different levels through the body cavity at approximately 100 mm intervals, mounted on 4563 
glass slides, and stained with Harris’ hematoxylin and eosin.  4564 
Liver sections were assessed for the presence/absence of glycogen-type and lipid-type 4565 
vacuolation  and the overall staining (eosinophilic or basophilic) of the hepatocyte parenchyma 4566 
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(Wolf and Wheeler, 2018). All tissue sections were also assessed for the presence of proteinaceous 4567 
fluid within the body cavity. Histological analyses were done qualitatively in support of molecular 4568 
studies, and thus, only the highest concentration with transcriptomic data was assessed and 4569 
histological features were reported as presence/absence in individual fish examined. No statistical 4570 
analysis was done. 4571 
 4572 
C.6. Statistical Analyses 4573 
Apical outcomes (length, weight, condition factor, and survival rates) at 4, 21, and 60 dph 4574 
were assessed for significant differences between treatment groups using one-way analysis of 4575 
variance (ANOVA), followed by Tukey’s multiple comparison post-hoc test, with a cut-off 4576 
adjusted p-value < 0.05. Prior to ANOVA, outliers were identified using ROUT method (Q = 1%) 4577 
and assumptions of ANOVA were tested (normality, homoscedasticity). In cases where 4578 
assumptions of ANOVA were not met, the non-parametric ANOVA analogue, Kruskal-Wallis test, 4579 
was performed, followed by Dunn’s multiple comparison test with a cut-off p-value < 0.05. All 4580 
non-omics statistical analyses were carried out in GraphPad Prism v.9.0.2. 4581 
  4582 
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Table C.S1. Nominal and measured concentrations of EE2 in exposure tanks based on EE2-4583 
specific competitive ELISA measurements. 4584 
Treatment Group 
(Nominal 
concentration in ng/L) 
Measured Concentration (ng/L) 
(mean ± standard deviation) 
% Nominal 
Water Control < 0.01  




1 ng/L 1.13 ± 0.10 113 
3 ng/L 1.57 ± 0.33  52 
10 ng/L 6.22 ± 1.16 62 
30 ng/L 16.34 ± 2.45 54 
100 ng/L 55.10 ± 9.46 55 




Table C.S2. Average physico-chemical characteristics of exposure solutions measured daily 4586 
(temperature) and weekly (pH, conductivity and dissolved oxygen, ammonia, nitrates, nitrite, 4587 
hardness and alkalinity). Values are expressed as mean ± standard deviation. 4588 
Parameters Values 
Temperature 14.96 ± 0.52 oC 
pH 7.99 ± 0.19 
Conductivity 247.51 ± 34.26 µS/cm 
Dissolved oxygen (DO) 97.83 ± 5.73 % 
Ammonia ≤ 0.25 mg/L* 
Nitrates ≤ 0.5 mg/L*  
Nitrite ≤ 0.05 mg/L*  
Hardness 110.86 ± 16.85 mg CaCO3/L 
Alkalinity 84.58 ± 13.65 mg CaCO3/L 
*during rare occasions of detectable levels of ammonia, nitrates, and/or nitrites during random 4589 




Table C.S3. Percent overlap of dysregulated transcripts. Left columns are the number of 4592 
overlapping transcripts. Right columns highlighted in yellow are the percent overlap between the 4593 
two groups being compared, where percent overlap equals the number of overlapping transcripts 4594 
over the number of dysregulated transcripts in a given concentration (#dysreg; column values). 4595 
# dysreg 930 688 210 281 331 
  1.13 ng/L 1.57 ng/L 6.22 ng/L 16.3 ng/L 55.1 ng/L 
1.13 ng/L X         
1.57 ng/L 450 48.39 X       
6.22 ng/L 81 8.71 80 11.63 X     
16.3 ng/L 133 14.30 137 19.91 91 43.33 X   
55.1 ng/L 118 12.69 104 15.12 96 45.71 136 48.40 X 
 4596 
   4597 
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Table C.S4. Summary of incidences of pathologic features observed in 60 dph RBT exposed to 4598 
EE2. 4599 






Liver Hepatocyte basophilia 0 9 
 
Hepatocyte glycogen vacuolation 10 0 
 
Hepatocyte lipid vacuolation 0 7 
 
Eosinophilic intravascular fluid accumulation 1 9 
Coelom Eosinophilic fluid accumulation 0 9 
*where n is the number of individual fish examined and does not correspond to biological 4600 
replicates. At least 3 fish per replicate tank were examined for pathological features. 4601 
  4602 
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Figure C.S1. Study design. Exposures were initiated at hatch (Day 0). Three replicates each of 4607 
~100 embryos were exposed to water, solvent control (0.01% DMSO), 1, 3, 10, 30, 100, and 300 4608 
ng/L nominal concentrations of EE2. Samples for omics analyses were collected at 4 dph. Fish 4609 
were culled to 20 individuals at swim-up (21 dph) to prevent overcrowding. Exposure was 4610 
terminated at 60 dph where samples for histology were collected. Weight and length measurements 4611 















Figure C.S2. Truncated overview heatmap profiles across concentrations based on DE transcripts 4613 




Figure C.S3. UpSetR plot of intersecting overrepresented terms and pathways based on 4616 











































































































Figure C.S4. Morphometric measurements at (A) 4 dph and (B) swim-up stage (21 dph) (DataSet 4619 
4, Tabs B1-B3 and C1-C3). Top = length (mm); Middle = weight (mg), Bottom = condition factor, 4620 








Figure C.S6. Transcriptomic BMD probability distribution (normal scale). Yellow line indicated 4625 
the first mode of the geneBMD distribution (omicBMDmode). Note that the plot is a smoothed 4626 
probability distribution which would spill to the left of zero concentration and should therefore 4627 
be interpreted with caution since the area at the left of zero is an artifact of curve smoothing and 4628 
that there was no geneBMD below zero. The area below zero has been truncated. 4629 
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APPENDIX D 4630 
D.1. Chemical analyses 4631 
Concentrations of FLX in solution were measured at SGS AXYS Analytical Services Ltd 4632 
(BC, Canada).  Reference fluoxetine (FLX) was obtained from Millipore Sigma (ON, Canada) 4633 
while d5-Fluoxetine (d5-FLX) was obtained from CDN Isotopes (QB, Canada).  FLX was 4634 
quantified following the method previously described (Long et al., 2013), with minor revisions.  4635 
Briefly, FLX from water samples was extracted by solid phase extraction/isotope-dilution prior to 4636 
LC-MS/MS analysis. An appropriate aliquot based on expected exposure concentrations was 4637 
spiked with d5-FLX, diluted to 500 mL in reagent water, and buffered to a pH of 3.8 using a sodium 4638 
acetate:acetic acid buffer. Samples were then loaded on a 1g Oasis-HLB cartridge (Waters, MA, 4639 
USA) and eluted using 12 mL of methanol and 6 ml of 1:1 acetone:methanol. Sample extracts 4640 
were evaporated to dryness under a stream of N2 and reconstituted in 2 mL of methanol with 0.1% 4641 
formic acid solution. FLX was quantitated using a Waters 2690 HPLC, equipped with Xterra MS 4642 
C18 (Waters; 10.0 cm, 2.1 mm i.d., 3.5 µm particle size), coupled with Micromass Quattro Ultima 4643 
MS/MS (Waters) operating in positive ion electrospray mode at unit resolution. Transitions used 4644 
for FLX and d5-FLX were 310 ⟶ 148 and 315 ⟶ 153, respectively. The flow rate varied from 4645 
0.15-0.3 mL/min. The column was maintained at 40°C. A gradient elution using mobile phases 4646 
0.1% formic acid buffer (A) and 1:1 acetonitrile:methanol (B) was used. The LC gradient program 4647 
was as follows (time, %A): 0.0, 95%, 4.0, 95%, 22.5, 12%, 23.0, 0%, 26.0, 0%, 26.5, 95%, and 4648 
33.0, 95%. Source temperature was 120°C and the desolvation temperature was 350°C. A seven-4649 
point calibration curve ranging from 0.375-1250 ng/mL was used for quantitation using 1/x 4650 
weighted linear calibration and response relative to d5-FLX. Concentrations are expressed as µg/L 4651 
FLX. For exposures in petri dishes only (0.44 and 112 µg/L FLX), since the working solutions 4652 
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were from serially diluted stock solutions for all treatments, concentrations were based on the 4653 
average % nominal of treatments with measured concentrations. This was done because the 4654 
volumes used in petri dishes were too low for analytical testing. 4655 
 4656 
D.2. Proteomics 4657 
To assure that proteomic responses were not due to non-specific toxic responses, 7 µg/L 4658 
FLX treatment group was selected based on the NOEC of an in-house a priori early-life stage 4659 
rainbow trout sub-chronic survival assay (data not shown; SuppMat Figure File RBT).  4660 
Proteomics was conducted following Alcaraz et al. (submitted). Cell disruption and protein 4661 
solubilization were done using SDT lysis buffer (4% Sodium dodecyl sulfate (SDS; Sigma-4662 
Aldrich), 0.1 M Dithiothreitol (DTT; Thermo Fisher Scientific, MA, USA), 0.1 M Tris/HCl 4663 
(Sigma-Aldrich; pH = 7.6) in a Thermomixer® (Eppendorf, Hamburg, Germany) at 95oC, for 2 4664 
hours. Quality of protein extracts was assessed by use of 1-D SDS-PAGE (12% gels). Protein 4665 
extracts were then processed by filter-aided sample preparation (FASP) (Wiśniewski et al., 2009; 4666 
Wiśniewski and Rakus, 2014). Briefly, proteins were alkylated using 50 mM iodoacetamide 4667 
(Sigma-Aldrich) for 20 mins at RT and digested using trypsin (Sequencing grade; Promega, WI, 4668 
USA) in 50 mM ammonium bicarbonate at 37oC for 18 hrs, on a 30 kDa membrane filter unit. 4669 
Resulting peptides were eluted with ammonium bicarbonate (AB) buffer and the FASP eluates 4670 
were kept at -80oC until further LC-MS/MS analysis. 4671 
FASP eluates were cleaned using 3 iterations (Yeung and Stanley, 2010) of ethylacetate 4672 
extraction to remove SDS contamination, then completely dried in a SpeedVac vacuum 4673 
concentrator (Thermo Fisher Scientific). Cleaned peptides were reconstituted by acid extraction 4674 
using 50 µl of (1:1) 5% formic acid (LC-MS grade, >99% purity; Fisher Scientific) and 100% 4675 
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acetonitrile (HPLC grade, >99.9%; Sigma-Aldrich), with 1.5 µl of 0.01% poly(ethylene glycol) 4676 
(PEG; Millipore-Sigma) to reduce sample loses. The final solution was transferred to a TPX 4677 
(polymethylpentane) vial and vacuum concentrated in SpeedVac vacuum concentrator to a final 4678 
volume of 15 µl.  4679 
LC-MS/MS analyses were conducted using a Q Exactive™ HF-X Hybrid Quadrupole-4680 
Orbitrap™ mass spectrometer (Thermo Fisher Scientific, MA, USA) connected online to an 4681 
Ultimate 3000 RSLCnano system (consisted of SRD-3400, NCS-3500RS CAP, WPS-3000 TPL 4682 
RS; Thermo Fisher Scientific). Prior to chromatographic separation, tryptic digests were online 4683 
concentrated and desalted on a cartridge trapping column (300 μm × 5 mm, C18 PepMap100, 5μm 4684 
particles, 100 A; Thermo Fisher Scientific) using 0.1% formic acid (FA) in water. The peptides 4685 
were eluted from the trapping column onto an Acclaim Pepmap100 C18 analytical column (3 µm 4686 
particles, 75 μm × 500 mm; Thermo Fisher Scientific) by non-linear gradient (2-35% of mobile 4687 
phase B; mobile phase A: 0.1% FA in water; mobile phase B: 0.1% FA in 80% acetonitrile). The 4688 
analytical column was directly connected to the Digital PicoView® 550 (New Objective, Woburn 4689 
MA, USA) ion source with sheath gas option and SilicaTip emitter (New Objective; P/N: FS360-4690 
20-15-N-20-C12) utilization. Active Background Ion Reduction Device (ABIRD; ESI Source 4691 
Solutions, Woburn MA, USA) was installed to the LC-MS/MS system to isolate the experiment 4692 
from variable background ion interferences. MS data were acquired in a data-dependent 4693 
acquisition strategy, selecting up to top 20 precursors based on precursor abundance in the survey 4694 
scan (350 - 2000 m/z). The resolution of the survey scan was 120,000 (at 200 m/z) with a target 4695 
value of 4×105 ions and maximum injection time of 100 ms. Higher-energy collisional dissociation 4696 
(HCD) MS/MS spectra were acquired with a target value of 5×104 and resolution of 15,000 (at 4697 
200 m/z). The maximum injection time for MS/MS was 22 ms. 4698 
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Raw mass spectrometric data files were analyzed using MaxQuant v.1.6.15 (Cox and 4699 
Mann, 2008; Tyanova et al., 2016) with built-in Andromeda search engine (Cox et al., 2011). 4700 
Samples were mapped against the FHM reference proteome (NCBI Acc# GCA_016745375.1; 4701 
48,456 sequences; Martinson et al., n.d.), combined with the cRAP contaminant database (April 4702 
2021; 246 sequences). Acetyl (protein N-term), oxidation (M), oxidation (P) and deamidation (N, 4703 
Q) as optional modifications, carbamidomethylation (C) as fixed modification and maximum of 4704 
two enzymes miss-cleavages were set for the first and main search. Peptide identification was set 4705 
to match between runs at 0.7 min match time window. Peptides and proteins with an FDR (q-4706 
value) < 1% and at least one razor peptide were selected for differential abundance analyses. Raw 4707 
data were deposited in the ProteomeXchange Consortium via the Proteomics Identifications 4708 
(PRIDE) (Perez-Riverol et al., 2019) partner repository under accession# PXD027024.  4709 
All downstream differential protein abundance analyses were done in KNIME (Berthold 4710 
et al., 2008). Datasets were filtered to keep protein groups with 2 or more peptides, and at least 4711 
two measured intensity values in both experimental groups being compared. Log2-transformed 4712 
protein group intensities were quantile-normalized.  Protein groups with missing quantification 4713 
values on all replicates within a treatment group were filtered out. Missing values were imputed 4714 
by global minimum strategy. Significance of differentially abundant  (DA) protein groups was 4715 
assessed using limma (Ritchie et al., 2015) with a cut-off moderated p-value of ≤ 0.05 and a 4716 
minimum effect size threshold of |FC| > 1.5 relative to the water control group. limma estimates 4717 
moderated p-values by using the whole dataset to shrink sample variances towards pooled 4718 
estimate, which have been shown to be a practical approach in detecting DA proteins with minimal 4719 
loss from false negatives (Kammers et al., 2015; Pascovici et al., 2016). Default software settings 4720 
were used for analyses, unless otherwise stated. 4721 
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All significant DA proteins with at least 2 peptides identified were used in the 4722 
overrepresentation analyses as previously described (Sec. 4.4.3). 4723 








Figure D.S2. Photomicrographs of livers from FLX-exposed early-life stage (32 dpf) fathead 4728 
minnows (Hematoxylin and Eosin stain).  (A) Water control and (B) 10.2 µg/L FLX treatment 4729 




Figure D.S3. Overrepresentation analyses of significantly dysregulated transcripts from all FLX 4732 
treatment groups using gene ontologies (GO: molecular function, biological process, cellular 4733 
component) from D. rerio as reference set. Statistical test was done using two-sided 4734 
hypergeometric test with p-value cut off <0.05 followed Benjamini-Hochberg correction for 4735 
multiple testing and a kappa score = 0.04. (A) Overrepresentation network. GO parent-child terms 4736 
based on similar associated genes were fused (GO Fusion). Nodes were set with a minimum of 3 4737 
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genes or 4% of genes in a term. Size of the nodes reflects the statistical significance of the terms. 4738 
Clustering reflects the relationships between the terms based on the similarity of their associated 4739 
genes. Group leading term is the most significant term of the cluster. (B) Relative number of 4740 




Figure D.S4. Overrepresentation analyses of significantly dysregulated proteins from the 3.38 4743 
µg/L treatment group using gene ontologies (GO: molecular function, biological process, cellular 4744 
component) from D. rerio as reference set. Statistical test was done using two-sided 4745 
hypergeometric test with p-value cut off <0.05 followed Benjamini-Hochberg correction for 4746 
multiple testing and a kappa score = 0.04. (A) Overrepresentation network. GO parent-child 4747 
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terms based on similar associated genes were fused (GO Fusion). Nodes were set with a 4748 
minimum of 3 genes or 4% of genes in a term. Size of the nodes reflects the statistical 4749 
significance of the terms. Clustering reflects the relationships between the terms based on the 4750 
similarity of their associated genes. Group leading term is the most significant term of the 4751 




Figure D.S5. Frequency of statistical models among best fit curves based on the lowest AIC.  4754 
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Table D.S1. Nominal and measured concentrations of fluoxetine in exposure solutions. Water 4755 
samples were collected at 3 time-points (Day 4, 10 and 28). 4756 











1.75 0.74 0.08 42.41 
7 3.38 0.56 48.35 




†average % nominal from measured concentrations 4757 
*estimated based on average % nominal 4758 
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Table D.S2. Physico-chemical characteristics of exposure solutions. Water replacements were ~ 4759 
3x the volume of each tank per day. 4760 
Parameters Values (mean ± stdev) 
Temperature 22.43 ± 0.65 oC 
pH 8.24 ± 0.08 
Conductivity 451.77 ± 45.97 µS/cm 
Dissolved oxygen (DO) 87.82 ± 1.75 % 
Ammonia ≤ 0.25 mg/L* 
Nitrates ≤ 1 mg/L*  
Nitrite ≤ 0.1 mg/L*  
Hardness 190.52 ± 6.51 mg CaCO3/L 
Alkalinity 132.92 ± 5.93 mg CaCO3/L 
* whenever measured NH4, NO3, or NO2 were above detection limits, tanks were drained to 4761 




Table D.S3. List of common dysregulated features from differentially expressed genes and 4764 
differentially abundant proteins (based on gene symbols). 4765 






















APPENDIX E 4767 



























Figure E.S1. Degree days to 50% swim up of RBT exposed to FLX. 4769 
 4770 


















4dph swim up early fry (60dph)
 4771 
Figure E.S2. Survival rates of RBT at different life stages after continuous exposure to FLX. 4772 
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en
t 
d
et
ec
ti
o
n
 o
r 
(2
) 
w
at
er
 s
am
p
le
s 
(i
n
 p
et
ri
 d
is
h
es
) 
w
er
e 
n
o
t 
en
o
u
g
h
 f
o
r 
an
al
y
ti
ca
l 
m
ea
su
re
m
en
ts
. 
∂
 6
0
 d
p
h
 m
ax
im
u
m
 f
o
r 
co
n
tr
o
l 
an
d
 t
h
e 
h
ig
h
es
t 
co
n
ce
n
tr
at
io
n
 o
n
ly
. 
D
u
e 
to
 t
h
e 
li
m
it
ed
 s
p
ac
e 
in
 t
h
e 
fi
sh
 q
u
ar
an
ti
n
e 
fa
ci
li
ty
, 
m
o
st
 o
f 
th
e 
la
rv
a 
h
ad
 t
o
 b
e 
cu
ll
ed
 a
t 
v
er
y
 e
ar
ly
 l
if
e 
st
ag
es
. 
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